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Our research group’s interest in the “Ming Decoction of 21 Tonics for Kidney” 
arose from treatment in a patient with lupus nephritis and chronic nephritic 
syndrome, in whom clinical remission started after ingestion of this Chinese 
herbal decoction (CM).  Preliminary studies have demonstrated the 
immunosuppressive potency of both the crude decoction CM, as well as the 
active fraction CMX-13, a derivative of the herb Rubia cordifolia, on in-vitro T-
lymphocyte proliferation, as well as B-cell secretion of immunoglobulins in both 
normal individuals as well as patients with SLE.  In addition, we have shown 
the efficacy of CMX-13 on preventing acute rejection in a rat lung transplant 
model of hyperacute allograft rejection.  This thesis utilizes the MRL-lpr/lpr 
murine model of lupus nephritis to study the mechanism of the 
immunosuppressive action of CMX-13 and its derivatives. 
 
In the first part of this thesis, work was performed to characterize CMX-13, 
which is the fraction which contains the active component(s) of the herb Rubia 
cordifolia, following separation by liquid chromatography using spectroscopic 
and chemical methods.  RP-HPLC revealed that CMX-13 contained a mixture 
of possibly 8 or more compounds. Two RP-HPLC fractions of CMX-13, namely 
CMX-13-1 and CMX-13-5 had 100% immunosuppressive properties.  The RP-
HPLC fraction CMX-13-5 contained fewer impurities than CMX-13-1 as 
illustrated by their respective RP-HPLC profiles. Therefore we attempted to 
elucidate the structure of CMX-13-5 by 1H-NMR and LC-Mass spectrometry.  
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The LC chromatogram of CMX-13-5 showed a single peak, suggesting either a 
single molecule with a weight of 807.5 or two molecules with a weight of 270 
and 537.5.  1H-NMR spectrum of CMX-13-5 was shown to resemble the 1H-
NMR spectra of a bicyclic hexapeptide isolated by the group of Itokawa and co-
workers [Itokawa et al., 1992; Itokawa et al., 1993].  Subsequent to our work, 
our collaborators were able to analyze the structure of the purified bioactive 
compound in CMX-13’ (using material from the same source) and showed that 
the bioactive compound in CMX-13’ was identical to a compound previously 
identified by Itokawa and co-workers, namely, RA-VII. 
 
In the second part of the thesis examined the effect of CMX-13 on both cell 
cycle progression and the apoptotic events in peripheral blood mononuclear 
cells (PBMC) isolated from normal controls and patients with SLE, as well as 
Jurkat cells, a human T-cell line.  In addition to its suppressive effect on PHA-
stimulated PBMC proliferation, CMX-13 was also shown to significantly inhibit 
spontaneous Jurkat cell proliferation by >99% even at low concentrations of 1 
µg/ml.  The inhibitory effect of CMX-13 on Jurkat cell proliferation was not due 
to inhibition of cell-cycle progression, but rather by the induction of 
spontaneous apoptosis in cells in the G0/G1 phase.  This effect of CMX-13 on 
apoptosis in Jurkat cells was confirmed by DNA fragmentation analysis and 
Annexin-V staining.  Apoptosis was induced at a very early phase, as was 
demonstrated by the “sub-G1” or apoptotic peaks appearing in the cell-cycle 
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analysis.  This mechanism of action was different from drugs such as 
cyclohexmide, which induces apoptosis related to a G0/G1 cell-cycle arrest.    
 
In SLE, one of the hypothesis is that dysregulation of apoptosis might be 
responsible for the induction of anti-nuclear antibodies, pathognomonic of the 
disease.  In some patients, decreased apoptosis in SLE appears to be 
associated with increased production of a soluble form of the Fas molecule that 
is capable of inhibiting apoptosis after a stimulus to proliferate [Cheng et al., 
1994], whereas other studies reported accelerated apoptosis of lymphocytes in 
SLE patients [Emlen et al., 1992; Lorenz et al., 1998].  Similarly, in our SLE 
patients, the percentage of apoptotic cells was increased with increasing 
activity of the disease as measured by the SLICC score.  Hence the 
immunosuppressive mechanism of CMX-13 could be partly related to its effect 
on apoptosis, especially in the context of suppression of SLE activity, where 
increased apoptosis has been demonstrated.   
  
In the third part of this thesis, we examined the effect of CMX-13 on the 
development of lupus nephritis in the MRL-lpr/lpr mouse model of autoimmune 
disease.  MRL-lpr/lpr mice spontaneously develop an autoimmune disorder 
with pathological features similar to human SLE, including vasculitis, 
generalized lymphadenopathy, arthritis and a severe immune complex 
glomerulonephritis, resulting in increased mortality, with the majority of mice 
dying of renal failure at 16-24 weeks of age.  In our experiments, these clinical 
features, accompanied by elevation of serum anti-dsDNA antibody levels, were 
 XV
seen in the untreated MRL-lpr/lpr mice and the control group treated with the 
solvent DMSO.  The severity of the autoimmune disease increased with the 
age of the mice, with the majority of the untreated and DMSO control mice 
dying of renal failure at 16-24 weeks of age. Treatment of the MRL-lpr/lpr mice 
with CMX-13 and dexamethasone (DEX) resulted in delay by at least 4 weeks 
in the development of lymphadenopathy, which was also less severe than in 
the control groups.  All of the mice developed anti-dsDNA antibodies from the 
age of 8 weeks, with the untreated and DMSO control mice having the highest 
level of rise in antibody concentrations by 16 weeks of age, whereas both the 
CMX-13 and DEX-treated groups had significantly lower anti-dsDNA antibody 
levels.  CMX-13 was also able to improve survival of the MRL-lpr/lpr mice 
compared to the untreated or DMSO controls, where 48% of the mice treated 
with CMX-13 were still alive at 22 weeks of age, whereas only 4.5% of the 
untreated controls and 24% of the DMSO controls survived.   Moreover, CMX-
13 treatment of MRL-lpr/lpr mice with progressive lupus nephritis resulted in 
decrease in the degree of proteinuria and improvement in renal histological 
indices.   Hence CMX-13 appeared to be effective in attenuating the clinical 
and histological disease activity in the MRL-lpr/lpr mouse model of SLE.  
 
In the final part of the thesis, we examined the effect of CMX-13 on cytokine 
gene expression in PBMCs (in particular CD4+ and CD8+ T-cells), liver and 
glomeruli of the autoimmune MRL-lpr/lpr mouse.  The mice were treated with 
either DMSO (solvent control), CMX-13 or DEX, from the age of 12 weeks, and 
real-time RT-PCR was used to examine IL-2, IL-6, IL-10 and IFN-γ mRNA 
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expression levels in PBMCs isolated at 16 weeks of age, and subsequently in 
tissues and lymphocyte subsets from each of the groups of MRL-lpr/lpr mice 
that were sacrificed at 23 weeks.  Our studies showed that diseased MRL-
lpr/lpr mice which did not receive any treatment had decreased CD4+ and CD8+ 
IL-2/IFN-γ mRNA ratio at the age of 23 weeks, as well as upregulation of CD4+ 
IL-10 mRNA expression, similar to other reports in the literature.  In addition, 
glomerular mRNA expression of IFN-γ, IL-6 and IL-10 were also increased.  On 
the other hand, the CMX-13 treated group showed significantly higher CD4+ 
and CD8+ IL-2/IFN-γ mRNA ratio, and this was associated with improved 
clinical, serological and histopathological parameters, including survival.  
However, CMX-13 treatment did not improve the abnormality in glomerular 
IFN-γ, IL-6 and IL-10 gene expression.   
 
In conclusion, one possible mechanism by which CMX-13 acts an 
immunosuppressive agent in the treatment of lupus nephritis in the 
autoimmune MRL-lpr/lpr mouse model is through the induction of apoptosis of 
autoreactive lymphocytes.  Auto-aggressive CD4+CD8- αβT-cells have been 
postulated to be the driving force for autoreactive B-cells in SLE resulting in 
abnormalities in cytokine production, and suppression of these autoreactive 
lymphocytes could result in inhibition of autoantibody production, thus retarding 
the progression of lupus nephritis.   
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Further investigations into the apoptotic mechanisms are required to examine 
the transcription of apoptotic and cell-cycle genes, so that the exact molecular 
targets of CMX-13 or its purified molecule, RA-VII can be identified. 
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CHAPTER 1  INTRODUCTION 
 
The first drugs used by human beings were plant extracts [Schultes, 1972]. 
Currently, 70% of the world population depends on remedies for diseases 
through the use of medicinal plants [Latiff, 1991]. About 80% of the population 
in developing countries depends entirely on higher plants as the main source of 
healing remedies, simply because of their availability [Farnsworth, 1990].   
  
The plants employed in traditional medical practice have been included in 
traditional medicinal systems by trial and error, a development that took several 
centuries. The search for effective natural compounds for medicinal purposes is 
fraught with difficulties. Screening criteria and factors like time and money are 
crucial [Farnsworth, 1990]. The National Cancer Institute in the USA screened 
32,000 plants at random over a period of 30 years, for their ability to inhibit 
tumors.  Only 7% were found to be effective, however even these products 
could not be marketed because none of them were sufficient or consistent in 
their bioactivity [Farnsworth, 1990].  Approximately 119 pharmaceutical agents 
are currently derived from higher plants, of which 74% were discovered by 
chemists who were trying to identify the bioactive compound of therapeutic 
traditional medicines1 [Farnsworth, 1990]. These Figures show that traditional 
medicine can serve as a great source for the development of new therapeutic 
agents.  
                                                 
1 Traditional Medicine is according to the World Health Organization (WHO), a term to 
distinguish ancient and culture-bond health care practices which existed before the application 
of science to health matters in official modern scientific medicine or allopathy [Farnsworth, 
1990]. 
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1.1  TRADITIONAL CHINESE MEDICINE AS 
IMMUNOSUPPRESSIVE AGENTS 
 
Traditional Chinese Medicine (TCM) are derivatives of natural products that 
have been used for centuries in China to treat a variety of human diseases, 
including immune-mediated diseases [Chen and Chen, 1989]. The 
development of immunosuppressive agents with high efficacy and minimal 
toxicities has been the focus of novel drug research. Current 
immunosuppressive drugs include corticosteroids, with their side-effect on 
growth in children, cataract formation, increased risk of unusual infections, 
hypertension and osteoporosis; alkylating agents such as cyclophosphamide, 
chlorambucil or azathioprine, with dose and time-dependent adverse effects on 
bone marrow, liver and the gonads, as well as a risk of malignancy [Donadio 
and Galssock, 1993] and more recently, Cyclosporin A (CsA) and tacrolimus 
with the potential for nephrotoxicity and neurotoxicity [Sewing et al, 1990; 
Bennett, 1995; Bennett et al., 1996; Tezcan  et al, 1998].  Although TCM have 
been shown to be effective in various clinical studies, the mechanism of action 
has been less understood.  
 
Systemic Lupus Erythematosus (SLE) is an autoimmune disease, which affects 
multiple organ systems. There have been several clinical studies on the use of 
TCM with and without conventional immunosuppressants for treatment of SLE 
[Ruan and Ye, 1994; Wang, 1989].  In one clinical trial whereby investigations 
were conducted upon the effect of a combination of TCM with steroids and 
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cyclophosphamide, the authors showed that this combination resulted in 
increased therapeutic efficacy in 41 active SLE patients, as compared to the 
control group of 35 patients treated only with steroids and cyclophosphamide 
[Ruan and Ye, 1994]. In another study an “anti-lupus pill” comprising of a 
decoction of 17 herbs was shown to improve the activity status of SLE patients, 
defined by an improvement in the skin manifestations, oral ulcers and arthritis, 
and a decrease in the anti-nuclear antibody titres [Wang, 1989]. Use of this 
“anti-lupus pill” in combination of steroids was effective in 92% of the 230 
patients studied, and in another 76 patients treated with the “anti-lupus pill” 
alone, its efficacy was 85%.  
 
The “thunder god” vine, Tripterium wilfordii Hook F (TWHf), has been 
extensively used in China for the treatment of SLE [Qin et al., 1981; Wang and 
Yuan, 1989] and rheumatoid arthritis [Yu, 1983; Li and Weir, 1990]. Ingestion of 
TWHf in conjunction with steroids has been associated with induction of 
remission in a patient with severe lupus nephritis [Kao et al., 1993]. Moreover 
its benefit has also been demonstrated in unblinded studies [Qin et al., 1981; 
Wang and Yuan 1989]. Another study using the Gentian macrophylla complex 
tablet together with prednisolone (PNL) in 62 patients with SLE was able to 
demonstrate a 86% remission rate as compared to 32% in the control group of 
19 patients treated with PNL alone [Yuan and Feng, 1989]. This herbal 
complex appeared to improve erythema, arthritis, nephropathy and serological 
abnormalities such as serum complements.  
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Unfortunately, there are currently no reported well-controlled randomized 
clinical trials with TCM in the treatment of SLE. However, several experimental 
studies examining the effect of TCM on lymphocyte activation and function in 
SLE patients, as well as animal models of lupus nephritis have been described. 
Studies conducted on (New Zealand black x New Zealand white) F1 
([NZBxNZW] F1) mice with Codonopsis pilosula and Cordyceps sinensis was 
able to prolong the life span of these mice, which develop spontaneous SLE, 
as well as to inhibit anti-DNA antibody production. Yang and co-workers were 
able to extract H1-A a pure compound from Cordyceps sinensis and tested it 
on the MRL-lpr/lpr mice. They showed that H1-A prolonged life-span and 
normalized biochemical factors [Yang et al., 1999]. Refined extracts from the 
root xylem of TWHf have been shown to be effective in the treatment of lupus 
nephritis and arthritis in MRL-lpr/lpr mice [Zhang et al., 1992; Gu et al., 1992]. 
TWHf was able to decrease the amount proteinuria in this spontaneous lupus 
nephritis mouse model, as well as to improve survival. However no effect was 
demonstrated in the histopathology of lupus nephritis. Another herb, stragalin, 
was shown to inhibit deposition of intracellular adhesion molecule –1 (ICAM-1), 
immunoglubulins and C3 in the glomerular capillary walls of MRL-lpr/lpr mice 
[Chen et al., 1995].  
 
The development of new immunosuppressive agents with a high therapeutic 
index for solid organ transplantation remains a priority. As an extension of their 
use in autoimmune diseases, TCM with immunosuppressive properties have 
been tested in animal models of organ transplantation.   
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Berbamine, an alkoloid from the plant, Berberis juliane, has been demonstrated 
to have anti-hypertensive, anti-arrthymic and immunosuppressive properties [Li 
et al., 1989]. Luo and colleagues [Luo et al., 1995] demonstrated that 
berbamine was able to inhibit the lymphoproliferate response to Concavalin A 
(Con-A) and Lypopolysaccharide (LPS), decrease the plaque-forming colonies 
to T-dependent antigens, as well as the CD4+/CD8+ ratio. Moreover, berbamine 
not only suppressed the mixed lymphocyte reaction (MLR) and delayed-type 
hypersensitivity reaction, but was also able to prevent rejection of skin grafts in 
mice [Luo et al., 1998].  
 
TWHf has also been studied for its use in organ transplantation [Li et al., 1990]. 
Demethylzelasteral, a triterpenoid isolated from the root cortex of TWHf, was 
shown to inhibit the MLR in mice splenic cells [Tamaki et al., 1996]. Studies on 
heart allograft transplant in Lewis rats demonstrated that a combination of 
demethylzelasteral at 10 mg/kg/day with CsA A increased allograft survival to 
15.0±1.2 days, whereas single drug treatment with demethylzelasteral also 
improved survival to 17.4±2.9 days. On the other hand, untreated control rats 
rejected their heart allograft after 6 days.  
 
Although the Chinese philosophy of medical treatments is based on achieving 
a “perfect balance between the Yin and Yang”, in recent years, the use of TCM 
as immunosuppressive agents has been studied in-vitro and in-vivo in various 
experimental animal models of autoimmune diseases and allograft transplant. 
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Moreover, experimental studies based on active extracts of several different 
herbs commonly used as immunosuppressants, have identified a few extracts 
active in other cytokine-mediated diseases such as mesangial proliferative 
glomerulonephritis [Kuo et al., 1998]. There are very few well-designed 
randomized placebo-controlled clinical trials demonstrating their use in various 
diseases [Sheehan et al., 1992; Sheehan and Atherton, 1992]. In conclusion 
there is both laboratory and clinical evidence that the derivative of many of 
these herbs have significant beneficial immunosuppressive effects, however, 
concerns such as toxicity and dosage must be addressed [Harper, 1994]. This 
is especially true as the pot-pouri of chemicals produced by these plants are 
extremely variable, and may be affected by seasonal changes, agricultural 
conditions, to name a few.  Hence exact dosing of the active components is 











1.2          BACKGROUND 
 
Our research group’s interest in the “Ming Decoction of 21 Tonics for Kidney” 
arose from treatment of a patient with lupus nephritis and chronic nephrotic 
syndrome, in whom clinical remission started after ingestion of this Chinese 
medicinal decoction (CM) [Yap et al, 1999].  This medicinal decoction included 
the following genera Prubella, Lycium, Bletilla. Ligustrum, Dianthus, Myrrha, 
Eucommia, Rehmannia, Rosa, Rubia, Imperata, Curculigo, Panax, Astragalus, 




A 16-year-old Chinese girl presented with features of SLE at the age of 7 years. Her initial 
manifestations were prolonged pyrexia for 1 month, arthralgia, and erythematosus rash over 
the malar region. She had oral ulcerations and hepatosplenomegaly. Her blood pressure was 
within normal limits at 120/80 mm Hg. Laboratory findings included hemoglobin of 120 g/L, 
white blood cell count of 5.6X109/L. The erythrocyte sedimentation rate was 110 mm/hr: results 
of direct Coomb test, positive; serum total hemolytic complement (CH50) level, 13 U (normal 
range 20-50 U); anti-nuclear antibody titer, 1:1280 (homogenous pattern); and anti-double 
stranded DNA antibody, greater than 15 mg/L (normal, <5 mg/L). Results of urinalysis did not 
reveal any microscopic hematuria, but proteinuria was present (1+). High-dose PNL therapy at 
60 mg/day was started until the fever and anthralgia resolved. The PNL therapy was then 
slowly tapered to a maintenance dosage of 10 mg/day. 
 
At the age of 12 years, she developed the nephrotic syndrome, with generalized edema, 
urinary total protein excretion of 1.7 g/day per 1.73m2, and low serum albumin level of 25 g/L. 
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Her renal function was normal. She refused a renal biopsy, as well as increase in her dose of 
PNL, or additional cytotoxic drugs such as azathioprine or cyclophosphamide. During the next 
4 years, her nephrotic state worsened, with an increase in the urinary protein excretion to 13.4 
g/day per 1.73m2 and a decrease in serum albumin level to 11 g/L. Hypertension subsequently 
developed, with a blood pressure of 160/110 mm Hg and a rise in serum creatinine level to 132 
µmol/L. She also had serological markers of active lupus, with an erythrocyte sedimentation 
rate of 108 mm/hr, C3 level of 58.5 mg/L (normal range, 83-177 mg/L), C4 level of 15 mg/L 
(normal range, 15-45 mg/L), and anti-double stranded DNA antibody level of greater than 15 
mg/L. She again refused a renal biopsy and any increase in her immunosuppressive therapy. 
Instead, she took CM twice daily, together with PNL at the maintenance dose of 10 mg/day. 
 
After 4 months of CM therapy, when the patient returned for follow-up (Figure 1.2.1), she was 
noted to be edema free, with blood pressure at 120/75 mm Hg (within normal limits). Her 
laboratory features continued to improve during the next few months with a urinary protein 
excretion of 1.3 g/d per 1.73 m2, serum albumin level of 30 g/L, serum creatinine level of 61 
µmol/L, erythrocyte sedimentation rate of 25 mm/hr, C3 level of 100 mg/L, ad C4 level of 24.7 
mg/L (Figure 1.2.2). Her anti-double stranded DNA antibody level decreased to 11 mg/L. 
Subsequently her PNL dosage could be tapered to 5 mg/d, without any increase in the lupus 
activity. No adverse effects were noted with the use of CM. 
 
The SLE patient had long-standing nephrotic syndrome with severe proteinuria 
of 13.4 g/day per 1.73 m2. Although results of renal histological studies were 
not available, development of hypertension and a rising serum creatinine level 
accompanied with by low serum complement levels were harbingers of 
progressive lupus activity. The patient’s clinical and serological features 
improved dramatically after starting on CM. At this time, the patient only 
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received 10 mg/day of maintenance PNL. As the PNL dose was not increased 
during this period, it could not account entirely for the significant improvement 
in the nephrotic state of the patient. Although it is conceivable that the lupus 
nephritis went into spontaneous remission, this was unlikely in view of the 
chronicity of the nephrotic syndrome before the ingestion of CM. CM may have 
a synergistic action with PNL, inducing clinical improvement of the nephrotic 
state and the lupus activity.  
 
 
Figure 1.2.1  Treatment of a SLE patients with CM. Normalization of diastolic 
blood pressure (DBP), serum creatinine (Cr), albumin (Alb) and total urinary 



























































Figure 1.2.2  Effect of CM on serum complement (C) levels in a patient with 
lupus nephritis. PNL indicates prednisolone in milligrams per day. Complement 
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1.3       EFFECT OF CM ON BIOLOGICAL PROCESSES in-vitro   
 
Preliminary studies done in our laboratory confirmed the in-vitro 
immunosuppressive activity of CM:  
 
1. CM at a concentration of 440 µg/ml significantly inhibited normal 
lymphoproliferative response to phytohemaglutunin (PHA) in 5 normal subjects 
(C1, C2, C3, C4, C5), as measured by incorporation of 3[H]-Thymidine in 
counts per minute (cpm) (Figure 1.3.1).  Cell viability was greater than 90% as 
assessed by the trypan blue method. 
 
Figure 1.3.1 Effect of CM on PHA-stimulated lymphoproliferation as measured 























2. CM significantly inhibited the expression of CD25 and Human Leucocyte 
antigen-DR (HLA-DR) on CD3+ cells, markers of T-cell activation (Figure 
1.3.2). 
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3. CM significantly inhibited the pokeweed mitogen (PWM)-stimulated 
lymphocyte production of immunoglobulins (Figure 1.3.3). 
 
Figure 1.3.3  Effect of CM on PWM-stimulated Peripheral Blood Mononuclear 




Additionally, our laboratory has examined the effect of the hydrophobic ethyl 
acetate extract (EX) of CM on PWM-stimulated immunoglobulin G (IgG) 
production by PBMCs from patients with active SLE.  Previous in-vitro studies 
have shown that in patients with active SLE, spontaneous IgG production by 
PBMC was increased [Wigfall et al., 1988].   Our study confirmed that children 
with SLE had increased in-vitro spontaneous PBMC production of IgG 
(210±110 µg/ml) compared to normal controls (64±20 µg/ml) [Yap et al, 1999].  





Ig (ηg/ml) MEDIA CM 220 µg/ml CM 440 µg/ml 
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PBMCs from 10 SLE patients were subsequently cultured with the hydrophobic 
extract, EX.  Significant suppression of IgG (96±52 ηg/ml) was observed in the 
group of the SLE patients when the PBMCs were cultured with CM (p<0.005) 
(Figure 1.3.4). 
 










SLE  Ethanol CM EX
p<0.0005p<0.0005
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4. CM was also able to act in synergism with CsA to inhibit the 
lymphoproliferative response to both PHA and the anti-human CD3 T-cell 
antibody (OKT3) with a dose reduction index of 7.06 (Figure 1.3.5). 
 
Figure 1.3.5 Drug interactions of CM with CsA and dexamethasone (DEX):  



























5. CM was able to inhibit both T-cell colony formation (Table 1.3.1) and 
bone marrow cultures (Table 1.3.2).  Colony-forming units were significantly 
decreased in cultures when CM was added, indicating a mode of action at an 
early phase of cell proliferation, rather than on mature T-cells. 
 
Table 1.3.1 Effect of CM on T-cell colony formation 
 Plate 1# Plate 2# Mean# 
Control 92 91 91.5 
CM 220 µg/ml 49 65 57 
CM 440 µg/ml 15 11 13 
# colonies/105 cells plated 
 
Table 1.3.2 Effect of CM on bone marrow cultures (colony forming units or 
CFU-C) 
 




D7 234 53 3 
D14 158 114 6 






1.4    PURIFICATION OF CMX-13 FROM CM  
 
The “Ming Decoction of 21 Tonics for Kidney” crude CM preparation contained 
extracts from 21 Chinese herbs, which included the following genera Prubella, 
Lycium, Bletilla. Ligustrum, Dianthus, Myrrha, Eucommia, Rehmannia, Rosa, 
Rubia, Imperata, Curculigo, Panax, Astragalus, Codonopsis, Dioscorea, 
Nelumbo, Boswellia, Polygonum. Citrus, and Glycyyrrhiza.    Identification of 
the bioactive components in this decoction (CM) was performed using a 
bioassay based on the ability of the components to suppress 
lymphoproliferation following stimulation with PHA, and measured by 3[H]-
Thymidine incorporation.  Preliminary extraction processes involved first 
refluxing with methanol, followed by partitioning the methanol extract between 
ethyl acetate and water. The active components of CM in terms of 
immunosuppressive properties, were found in the organic layer (EX) (Figure 
1.4.1).  Further evaluation of various combinations of the herbs contained in 
CM showed that the extract of the herb Rubia cordifolia (RC) contained the 
most active components.  Following ethyl acetate (EtOAc) extraction by the 
Soxhlet method, the EtOAc extract of RC, CMX, was again subjected to solvent 
extraction with n-Hexane (Hex) and 90% methanol (MeOH)/H2O. The 90% 
MeOH/H2O fraction was mixed with dichloromethane (CH2Cl2) and made up to 
50%MeOH/H2O.  The CH2Cl2 fraction was found to have the highest 
immunosuppressive activity, and was subsequently subjected to purification by 
flash column chromatography. Fourteen fractions were obtained, of which 
fraction 13 was the most active and was labelled CMX-13.  CMX-13 was shown 
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to be at least 1000 times more potent in terms of inhibition of PHA-stimulated 
lymphocyte proliferation, as compared to the original medicinal decoction CM.   
 
Figure 1.4.1 Comparison of the inhibitory effect of the various extracts of CM  



























1.5   PRELIMINARY STUDIES OF CMX-13 ON A RAT LUNG 
ALLOGRAFT MODEL OF ACUTE REJECTION  
 
A pilot study was performed to test the efficacy of CMX-13 in the Brown-
Norway→Lewis rat lung transplant model.  This is a model of aggressive and 
rapid allograft rejection with all grafts completely destroyed by day 6 post-
transplant.  In this model, acute rejection (AR) was graded using a pathologic 
intensity score (stages I to IV), based on perivascular and peribronchial 
mononuclear cell infiltrates, oedema, vasculitis, necrosis, and intra-alveolar 
haemorrhage [Kondo et al, 1991].  CMX-13 given at 5 mg/day IV to 5 rats daily 
for 3 days, resulted in a significant inhibition of the acute rejection response, 
with treated animals showing no necrosis, oedema, intra-alveolar haemorrhage 
or vasculitis (Figure 1.5.1).  This effect was similar to that seen with a single 
high dose CsA given at 25 mg/kg (Yap et al, 1998; Zuo et al, 2000). 
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Figure 1.5.1 The effect of CMX-13 and CsA on acute rejection in the Brown 
NorwayÆLewis rat lung transplant model.  The stages of AR was graded by a 
pathologic intensity score (stages I to IV), based on perivascular 
andperibronchial mononuclear cell infiltrates, oedema, vasculitis, necrosis, and 
intra-alveolar haemorrhage. The rats treated with 5mg/kg CMX-13 had similar 





The effect of CMX-13 on Con-A stimulated proliferation of isolated spleen cells 
from the Lewis rat showed that CMX-13 at 0.25 µg/ml and 1 µg/ml was able to 
suppress cell proliferation in a dose-dependent manner, similar to the effect of  




































Figure 1.5.2 Comparison of CMX-13 with CsA on rat splenic cell proliferation 
following Con-A stimulation. 
 
 
The effect of CMX-13 on the Th1 cytokines, interleukin (IL)-2 and interferon 
(IFN)-γ gene expression in Con-A stimulated rat spleen cells has also been 
examined. Rat splenic cells were stimulated with 5.0 µg/ml Con-A and cultured 
either with or without CMX-13 or CsA.   CsA showed significant inhibition of IL-
2 messenger RNA (mRNA) expression at 6, 24 and 40 hours following Con-A 
stimulation.  CsA also significantly inhibited IFN-γ mRNA expression at 6 hours 
following Con-A stimulation.  In contrast, CMX-13 did not have any significant 
effect on both IL-2 and IFN-γ mRNA expression at all the time points tested 
[Zuo et al, 2000].  These findings suggested that the immunosuppressive 
effects of CMX-13 were possibly post-transcriptional and antiproliferative.   
 


































1.6  SLE: CLINICAL SYNDROME  
 
SLE is considered to be the prototypic systemic autoimmune disease, in which 
autoantibodies have the potential to damage diverse organs. The 
immunopathogenesis of SLE is complicated, involving genetic susceptibility 
elements, poorly defined cellular immune mechanisms, and mostly unknown 
triggering agents. SLE predominantly affects women at any age (~ 90%), but 
women at childbearing age are primarily affected [Gaffney et al.,1998; Kotzin, 
1996].  The female to male ratio is maximum (>8:1) for patients between 15-50 
years and the ratio decreases to 2:1 for disease that develops during childhood 
or after menopause. A role for estrogens contributing to the development of 
SLE and androgens protecting against disease development have thus been 
postulated [Kotzin, 1996]. The overall prevalence of SLE (~1 in 2000) is about 
the same as multiple sclerosis and about 5-to 10-fold less than type 1 diabetes 
mellitus and rheumatoid arthritis [Lindqvist and Alarcon-Riquelme, 1999]. SLE 
is more prevalent in certain ethnic groups when compared to Caucasians 
[Kotzin, 1996]. 
 
The clinical presentation and progression of disease are extremely varied 
[Vyse and Kotzin, 1998; Kotzin, 1996]. Individual patients exhibit striking 
variability in their clinical symptoms and laboratory findings. For example, some 
patients go into spontaneous remission, while others present predominantly 
with skin rashes and joint pains requiring little medication, and yet others 
develop severe and progressive organ involvement such as lupus nephritis, 
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requiring therapy with high doses of steroids and cytotoxic drugs such as 
cyclophosphamide. Due to the variability in clinical presentation and clinical 
course, criteria for the classification of SLE have been established to facilitate 
the uniform reporting of SLE cases in epidemiological and research studies 
(Table 1.6.1) [Tan et al., 1982].   
 
The modified American Rheumatological Association (ARA) classification is 
based on 11 criteria. For the purpose of identifying patients in clinical studies, a 
person is diagnosed to have SLE if any 4 or more of the 11 criteria are present, 
serially or simultaneously, during any interval of observation [Tan et al., 1982]. 
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1 Malar Rash Fixed erythema, flat or raised, over the malar eminences, 
tending to spare the nasolabial folds 
2 Discoid lesions Erythematous raised patches with adherent keratotic scaling  
and follicar plugging 
3 Photosensitivity Skin rash as a result of unusual reaction to sunlight, 
documented by patient history or physician observation 
4 Oral ulcers Oral or nasopharyngeal ulceration, usually painless, observed 
by a physician 
5 Arthritis Nonerosive arthritis involving 2 or more peripheral joints, 
characterized by tenderness, swelling, or effusion 
6 Serositis a) pleuritis (a convincing history of pleuritic pain or rub or 
evidence of pleural effusion)  
b) pericarditis (documented by electrocardiogram, or evidence 
of pericardial effusion) 
7 Nephropathy a) persistent proteinuria> 0.5 g/day or >3+ if quantitation not  
performed  
b) cellular casts (may be red cell, hemoglobin,  granular, tubular, 
or mixed)  
c) otherwise unexplained elevation of serum creatinine >75 
µmol/L 
8 Neurological   
Involvement 
a) Seizures in the absence of offending drugs or known  
metabolic derangements, e.g., uremia, ketoacidosis, or 
electrolyte imbalance 
b) Psychosis in the absence of offending drugs or known  




a) Hemolyitc anemia with reticulocytosis  
b) Leukopenia:< 4000/µl total on two or more occasions or 
c) Lymphopenia: < 1500/µl on two or more occasions or 




a) Positive LE cell preparation or 
b) Anti-DNA:antibody to native DNA in abnormal titer  
c) Anti-Sm: presence of antibody to SM nuclear antigen  
d) False-positive serological test for syphilis known to be 
positive for at least 6 months and confirmed by TPI or FTA-ABS 
11 Antinuclear 
Antibody 
An abnormal titer of ANA by immunofluorescence or an 
equivalent assay at any point in time and in the absence of 






1.7     PATHOGENESIS OF SLE 
 
SLE is an immune-mediated disorder characterized by autoantibody formation. 
The major hallmark of this disease is the elevated serum levels of antibodies to 
nuclear constituents (i.e., anti-nuclear antibodies), the principal targets include 
protein-nucleic acid complexes, notably chromatin, the U1 and Sm small 
nuclear ribonucleoprotein (snRNP) particles, and the Ro/SSA and La/SSB RNP 
complexes [Tan, 1989; Kotzin and O’ Dell, 1995].  In contrast to other 
autoimmune diseases, T-cells do not appear to play a direct role in tissue 
damage in SLE, but are indirectly involved in the production of IgG 
autoantibody production. The mechanism by which many autoantibodies 
mediate SLE pathology remains unclear.  IgG autoantibodies to double-
stranded DNA appear to play a prominent role in the genesis of lupus nephritis 
[Lindqvist and Alarcon-Riquelme, 1999; Vyse and Kotzin, 1998].  Deposition of 
immune complexes containing these antibodies does not appear to mediate 
renal damage.  The proposed mechanisms for lupus nephritis include in-situ 
immune complex formation following binding of DNA to the glomerulus, and 
cross-reactive anti-DNA antibodies to non-DNA glomerular structures 
[Bernstein et al., 1995].  Immune complexes may also be responsible for other 
disease manifestations such as arthritis, rashes, serositis, and vasculitis, 
whereas a separate group of autoantibodies that are directed to cell surface 
determinants may cause problems such as hemolytic anemia, 
thrombocytopenia, and central nervous system damage [Vyse and Kotzin., 
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1998]. Thus, the development of disease in SLE appears to involve the 
development of both autoreactive T-cells and B-cells. 
 
Evidence from several studies strongly supports the hypothesis that pathogenic 
IgG autoantibody production in SLE is selective for only certain self-antigens, 
and that autoreactive B-cells are driven by self-antigens.  In SLE and lupus 
mice, studies have shown that a subset of anti-DNA antibody-producing B-cells 
are clonally expanded [Radic et al., 1993].  Experiments with transgenic mice 
encoding self-reactive antibodies have demonstrated that B-cell development 
involves a process of tolerance that deletes or functionally inactivates 
autoreactive cells.   Hence SLE could be considered a disease syndrome 
involving loss of self-tolerance [Steinberg, 1994].  Tolerance to self could 
involve intrathymic deletion, peripheral deletion, and peripheral tolerization 
without deletion.  A loss of any of these processes could result in disease.   
 
Genes encoding for the major histocompatilibility complex (MHC) Class II 
antigens seem to play a pivotal role in the development of SLE [Vyse and 
Kotzin, 1998; Lindqvist and Alarcon-Riquelme, 1999; Drake et al., 1995].   MHC 
Class II proteins bind to T cell receptor (TCR) of the CD4+CD8- αβ-T-cells in the 
thymus thus preparing them for positive selection [Nikolic-Zugic et al., 1991; 
Rothenberg, 1990; Sha et al., 1988].  Autoreactive T-cells that escape negative 
selection have a low affinity for the MHC Class II proteins, and populate the 
periphery [Guerder and Flavell, 1996].  Studies have shown that these genes 
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may be involved in the development of auto-aggressive CD4+CD8- αβ T-cells 
and lupus nephritis [Jevnikar et al., 1994].  The role of the auto-aggressive 
CD4+CD8- αβ T-cells is further demonstrated in SLE murine lupus models 
where they are found to be related to autoantibody production [Peng et al., 
1996, Peng et al., 1998; Seery et al., 1999; Koh et al., 1995]. Moreover, the 
central role of these cells in murine lupus is further supported by the 
demonstration that the elimination or down-regulation of these cells result in 
significant disease amelioration [Jevnikar et al, 1994; Steinberg et al, 1978; 
Yamamoto et al, 1990; Koh et al, 1995].   
 
CD4+ T-cell dependence of autoantibody production has been demonstrated in 
studies where blocking of T-cell activation or T- and B-cell interactions 
prevented autoantibody production and the development of murine lupus [Finck 
et al., 1994a; Mohan et al., 1993; Mohan and Datta, 1995]. Additionally, 
treatment with anti-CD4 antibodies ameliorated IgG autoantibody production 
and disease [Kotzin, 1996]. The CD4+ T-cells play an important role in Kotzin’s 
hypothesis for immunopathogenic events that contributes to the development of 
SLE. According to this hypothesis auto-aggressive CD4+CD8- αβT-cells are 
generated through genetic susceptibility and environmental triggers. They act 
as a driving force for autoreactive B-cells, which become hyperreactive and 
produce autoantibodies. The hypothetical model for the development of SLE is 
depicted in Figure 1.7.1.  
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Figure 1.7.1  Hypothetical model for immunopathogenic events in the  
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1.8     MRL-lpr/lpr AUTOIMMUNE MOUSE MODEL 
 
MRL-lpr/lpr mice represent an excellent model to study the pathogenesis of 
lupus nephritis [Theofilopoulos and Dixon, 1985].  These mice spontaneously 
develop a generalized autoimmune disease, including vasculitis, generalized 
lymphadenopathy, arthritis and a severe immune complex glomerulonephritis, 
dying of renal failure between 5 to 8 months of age [Andrews et al, 1978].  
These mice also produce autoantibodies such as anti-double-stranded DNA 
antibodies and anti-IgG (rheumatoid factor). Moreover, MRL-lpr/lpr mice display 
proinflammatory alterations in the intrarenal cytokine network [Boswell et al, 
1988a; Boswell et al, 1988b; Fan et al, 1997].   Alterations in the cytokine 
network are characteristic of many immune-mediated disorders.  Cytokines 
produced by Th1 type lymphocytes, such as Tumor necrosis factor (TNF)-α 
and IFN-γ, may play a major role in the pathogenesis of autoimmune diseases.   
 
The role of MHC Class II proteins in the genesis of SLE has also been 
demonstrated in gene knockout models of murine lupus. The development of 
SLE was inhibited in lupus-susceptible mice in which the genes encoding for 
the MHC Class II proteins were deleted [Ibnou-Zekri et al., 1997].  MRL-lpr/lpr 
mice which were rendered MHC Class II-deficient, did not exhibit any 
autoantibody production [Anderson et al., 1993].  Moreover, these mice had a 
reduced level of total serum immunoglobulin, implying defective polyclonal 
regulation of B cells by T-cells [Anderson et al., 1997].  
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Apoptosis genes are another set of candidate genes, which are involved in the 
development of SLE.  Mutations in the lymphoproliferative (lpr) Fas gene and in 
the gld or Fas ligand (FasL) gene result in the development of an autoimmune 
illness resembling SLE in mice. The Fas and FasL genes are involved in 
programmed cell death through apoptosis [van Houten and Budd, 1994].  
Complete development of SLE in the MRL-lpr/lpr mouse is dependent on the 
presence of homozygous mutations of the Fas and the FasL gene. The exact 
mechanism by which these mutations result in disease in MRL-lpr/pr mouse 
model is unknown.  A hypothesis which is widely accepted is that self-reactive 
T- and B-cells are generated when they fail to undergo apoptosis. Studies have 
shown that Fas (CD95) is not essential in intrathymic tolerance during T-cell 
development, and that peripheral T-cell tolerance mechanisms are affected by 
the lpr mutation [Singer and Abbas, 1994; Herron et al., 1993].  Defective 
transcription of the apoptosis gene encoding Fas causes massive 
lymphoproliferation of double-negative (CD4-CD8-) T-cells [Watanabe et al., 
1992; Adachi et al., 1993].  These CD4-CD8- T-cells are a rich source of 
proinflammatory cytokines including TNF-α and IFN-γ [Murray et al., 1990; 
Murray and Martens, 1990].    
 
Only two mutations in the Fas gene [Rieux-Laucat et al., 1995; Fisher et al., 
1995] and the FasL gene [Wu et al., 1994] have been reported in humans, 
these were patients with autoimmune lymphoproliferative syndrome. However 
no mutations in the Fas or FasL genes have been found in SLE patients. 
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Hence there may be other genes or pathways related to apoptosis which may 
be involved in the generation of autoreactive lymphocytes.  In the sera of SLE 
patients high expression levels of a soluble form of the Fas (sFas) molecule 
have been identified. Studies have shown that sFas inhibits apoptosis in 
lymphocytes [Cheng et al., 1996] and may consequently lead to the 












1.9     SCOPE OF THE THESIS  
 
Preliminary studies have demonstrated the immunosuppressive potency of 
both the crude decoction CM, as well as the active fraction CMX-13 on in-vitro 
T-lymphocyte proliferation, as well as B-cell secretion of immunoglobulins in 
both normal individuals as well as patients with SLE.  In addition, we have 
shown the efficacy of CMX-13 on preventing acute rejection in a rat lung 
transplant model of hyperacute allograft rejection.  This thesis utilizes the MRL-
lpr/lpr murine model of lupus nephritis to study the mechanism of the 
immunosuppressive action of CMX-13 and its derivatives.  
 
Objective 1: 
To characterize CMX-13, which is the fraction which contains the active 
component(s) of the herb RC. following separation by liquid chromatography) 
using spectroscopic and chemical methods. 
 
Objective 2: 
To explore the molecular mechanisms of action of CMX-13 in-vitro. 
 
The molecular basis for the immunosuppressive effects of CMX-13 remains to 
be elucidated. We have previously shown that CMX-13 was able to suppress 
mitogen-stimulated lymphoproliferative responses and immunoglobulin 
production, as well as inhibit T-cell colony formation.  In our earlier studies on 
the possible mechanisms of action, CMX-13 did not show any inhibitory effects 
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on IL-2 and IFN-γ mRNA expression, suggesting that its mechanism of action is 
different from that of CsA [Zuo et al., 2000].   As there is strong evidence that 
dysregulation of apoptosis in the immune regulatory cells could have a role in 
the genesis of SLE, this part of the thesis will examine the effect of CMX-13 on: 
(1) Cell cycle progression in PBMC isolated from normal controls and 
patients with SLE, as well as Jurkat cells, a human T-cell line  
(2) Apoptotic events.   
 
Objective 3: 
To study the effect of CMX-13 in a mouse model of generalized autoimmune 
disease, which resembles human SLE (MLR-lpr/lpr mice).   
 
The MRL-lpr/lpr mouse strain has a mutation in the fas gene, which leads to 
the development of SLE in these mice. Significant similarities exist with the 
human form of SLE and the MRL-lpr/lpr mouse model. Studies have shown 
that CD4+ T-cells are responsible for the development of SLE in these mice. 
Our earlier studies have shown that CMX-13 had immunosuppressive effects 
on stimulated lymphocytes, therefore the aims of this section of the thesis are 
to study the effect of CMX-13 on the following parameters in the MRL-lpr/lpr 
mouse strain: 
1. Development of clinical disease, as assessed by degree of 
lymphadenopathy, articular swelling and proteinuria, including survival 
analysis 
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2. Development of autoantibodies, namely, anti-double stranded DNA 
antibodies and anti-IgG (rheumatoid factor) 
3. Histolopathological evidence of glomerulonephritis 
4. Dysregulation of cytokines, especially IL-2, IFN-γ, IL-6 and IL-10, 





























CHAPTER 2     MATERIALS AND METHODS 
 
 
2.1          BIOASSAY GUIDED ISOLATION AND PURIFICATION 
OF BIOACTIVE COMPOUNDS 
 
2.1.1   Soxhlet Extraction 
 
The roots of RC. used in this experiment were purchased from local Chinese 
Traditional Medicine shops in Singapore. The crude roots were grounded (45 
grams each time) and extracted with 500 ml EtOAc using a Soxhlet apparatus 
for 5-8 hours. The EtOAc extract was then lypholized under reduced pressure 
and tested for its immunosuppressive properties. 
 
2.1.2  Solvent Partition 
 
The bioactive EtOAc extract was dissolved in MeOH followed by addition of 
water to MeOH a ratio of 9:1. The 90% MeOH aqueous solution was partitioned 
three times with Hex in a separation funnel. The organic phase (Hex) was 
collected and evaporated, which produced the Hex extract. Water was added 
to the 90% MeOH aqueous extract phase until the MeOH:H2O ratio was 1:1. 
The 50% MeOH/H2O solution was then partitioned three times with CH2Cl2. 
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2.1.3   Isolation of CMX-13 from EtOAc extract by Flash Column 
Chromatography and Reverse Phase-Thin Layer 
Chromatography 
 
Approximately 4.2 g of CH2Cl2 extract was subjected to flash chromatography 
(column diameter 8 cm, 60A silica gel (Kieselgel 60 with a mesh range 230-400 
ASTM from Merck) 25 cm high, 100% Hex wet packed. The CH2Cl2 extract was   
eluted with Hex, followed by a Hex-EtAOc solvent system, and subsequently by 
an EtOAc-MeOH solvent system. Sixteen fractions were isolated by Reverse 
Phase-Thin Layer Chromatography (RP-TLC). RP-TLC on Flash Column 
Fractions. RP-TLC was carried out on silica gel pre-coated glass plates (Merck, 
Kieselgel 60F254, 250 µm layer thickness). Solvent system: 90% EtOAc/MeOH. 
The Rf value defined as the distance moved by the spot relative to that moved 
by the solvent front. Two samples that have similar compounds will have an 
identical Rf value. The solvent systems for the Flash Column Chromatography 














Solvent Volume in ml 
1 100% Hex 250 
2 80% Hex/20% EtOAc 300 
3 60% Hex/40% EtOAc 300 
4 50% Hex/50% EtOAc 300 
5 40% Hex/60% EtOAc 300 
6 20% Hex/80% EtOAc 300 
7 0% Hex/100% EtOAc 300 
8 100% EtOAc 300 
9 80% EtOAc/ 20%MeOH 300 
10 60 % EtOAc/ 40%MeOH 300 
11 50 % EtOAc/ 50%MeOH 300 
12 20 % EtOAc/ 80%MeOH 300 
13 100% MeOH 400 
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2.1.4     Purification of CMX-13 fractions by Reverse Phase- High 
Performance Liquid Chromatography (RP-HPLC) 
 
RP-HPLC conditions were optimized and were as follows, Column: Nova-pack 
C18 Column, pore size 4 µm, 3.9 x 300 mm from WATERS; Mobile phase 100% 
water/acetonitrile:  water/100% acetonitrile in a gradient program; flow rate: 0.6 
ml/min; detection: Ultra Violet 254 nm or PDA detection varying from 200-600 nm; 
performed on a Waters 600E system; software: Millenium from Waters; injection 
volume of 50 µl at a concentration of 5.0 mg/ml dissolved in 50% 
MeOH/Acetonitrile. The complete RP-HPLC program is shown in Table: 2.1.4.1.  
Table 2.1.4.1  RP-HPLC conditions for CMX-13. Stationary Phase: C18 Reverse 













0 0.6 0 100 
15 0.6 50 50 
25 0.6 65 35 
40 0.6 100 0 








2.1.5   Nuclear Magnetic Resonance (NMR) 
 
The proton spectra were recorded on a Bruker Spectrometer (AM 500) and 
processed on a Bruker data station.  CMX-13-5 purified from RP-HPLC was 
dissolved in 0.5 ml deuteriated MeOH in a 5 mm tube. 
 
2.1.6  Liquid Chromatography- Mass Spectrometry (LC-MS) 
 
Mass spectral analysis was conducted on a Finnigan Thermo-Quest LCQ triple 
quadrupole mass spectrometer using FAB mode of ionization while scanning in 
alternating positive full-scan mode. Mass spectrometer was coupled to a Hewlett-
Packard 1090A HPLC and chromatographic analyses were conducted by 
reversed-phase on a Nova-pack C18 Column, pore size 4 µm, 3.9 x 300 mm from 
WATERS with UV detection at 254 nm. Solvents for elution consisted of 100% 
water/acetonitrile to water/100% acetonitrile in a gradient program at a flow rate of 
0.6ml/min. 
 
2.1.7   Bioassay Based On Inhibition of Cellular Proliferation 
 
PBMCs were isolated from Heparinized blood using standard Ficoll-Hypaque 
(Amersham Pharmacia Biotech AB, Uppsala Sweden) density-gradient 
centrifugation at 2000 rpm for 30 minutes. The mononuclear cell interface was 
collected and washed twice in RPMI 1640. The Jurkat cells and PBMCs were 
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maintained in complete media RPMI 1640 (Gibco, Life Technologies, Grand 
Island NY, USA), supplemented with 10% fetal calf serum (FCS) (Gibco, Life 
Technologies, Grand Island NY, USA), 100 U/ml penicillin, 100 µg/ml 
streptomycin (Gibco, Life Technologies, Grand Island NY, USA) and 1 mM of  
L-glutamine (Sigma Chemicals, USA).  
 
Jurkat cells or PBMCs were cultured in flat-bottomed microtitre plates (200 µl/well) 
in triplicates at a concentration of 1x106 cells/ml in RPMI 1640, supplemented with 
10% FCS, 100 U/ml penicillin, 100 µg/ml streptomycin and 1 mM of L-glutamine. 
The PBMCs were stimulated with 0.75 µg/ml PHA for cell proliferation.  The Jurkat 
cells and PHA-stimulated PBMCs were incubated for 24 hours and 72 hours 
respectively with or without treatment, after which the cells were pulsed with 3[H]-
Thymidine (New England Nuclear, Boston, MA) at 2 µCi/well.  The cells were 
harvested after 16 hours, following which the incorporated radioactivity was 
measured in a liquid scintillation counter (Beckman Instruments, CA, USA). Cells 
treated with 0.004% Dimethylsulfoxide (DMSO), the solvent for CMX-13, served 
as the DMSO control. 
 
Inhibition of cell proliferation was calculated as follows:    
Percent Inhibition = [1-(cpm of treated cells)/(cpm of untreated cells)]*100  
 
Cell viability was assessed by the Trypan Blue exclusion method, and only those  
experiments where the cell viability was >90% were included in the results. 
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2.2 STUDIES ON CELL CYCLE PROGRESSION AND  
APOPTOSIS 
 
2.2.1  Patients and Controls 
 
The study population consisted of 20 patients who fulfilled the modified ARA 
criteria for SLE [Tan et al, 1982].  The patients were recruited from the 
Departments of Medicine and Pediatrics outpatient clinics at the National 
University Hospital.  The normal controls for the study included 20 healthy age-
sex matched individuals.   
 
SLE disease activity in the patients was defined using 2 different scoring systems: 
University of Toronto SLE-Disease Activity Index (SLEDAI) [Tan et al, 1982; 
Arnett et al., 1988; Bombardier et al., 1992; Hochberg, 1997] and the Systemic 
Lupus International Collaborating Clinics (SLICC) Damage Index [Stoll et al.,1996; 
Gladman et al.,1997].  The SLEDAI measures disease activity in the various 
organs, whereas the SLICC Damage index measures accumulated organ 
damage that has occurred since the onset of SLE, resulting from the disease 
process, and include descriptors in the different organ systems. The SLEDAI 
(Appendix 4.2) and SLICC Damage Index (Appendix 4.3) were able to 
discriminate single disease activity states among subjects better than other 
scoring systems.  Each patient was scored according to the clinical descriptor(s) 
present at the time of blood sampling, and the total score for each Index was then 
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computed as a measured of disease activity. The scoring systems for the SLEDAI 
and SLICC methods are shown in Table 2.2.1.1 and Table 2.2.1.2, respectively.  
Informed consent was obtained prior to blood sampling.   
 





Retinal change OR Optic atrophy 
 
0 1 
0          1 
Neuropshychiatric 
Cognitive impairment 
OR Major psychosis 
Seizures requiring therapy for 6 months 
Cerebral vascular accident ever (score 2 if > 1), resection not for 
malignancy 




0   1 
0 1 
0 1    2 
0 1   
0           1     
Renal 
Estimated or measured GFR < 50% 
Proteinuria 24 h, > 3.5 g 
OR 
End-stage renal disease (regardless of dialysis or transplantation) 
    
0          1  
0  1   
 
 
3    
Pulmonary 
Pulmonary hypertension (right ventricular prominence, or loud P2) 
Pulmonary fibrosis (physical and X-ray) 
Shrinking lung (X-ray) 
Pleural fibrosis 
Pulmonary infarction (X-ray) OR resection not for malignancy 
  
     0          1      
 
0          1 
0          1 
0          1 
0          1  
Cardiovascular 
Angina OR coronary artery bypass 
Myocardial infarction ever (Score 2 if > 1) 
Cardiomyopathy (ventricular dysfunction) 
Valvular disease (diastolic murmur, or a systolic murmur >3/6) 
Pericarditis x 6 months or pericardiectomy 
      
0   1 
0            1   2 
1            1 
0            1 
0            1 
Peripheral Vascular 
Claudication x 6 months 
Minor tissue loss (pulp space) 
Significant tissue loss ever (eg. loss of digit or limb, resction) (Score 
2 if > 1) 
Venous trombosis with swelling, ulceration, OR venous stasis 
 
0              1 
0 1 
0 1   2 
 










Infarction or resection of bowel (bowel duodenum) , spleen, liver or 
gall bladder ever (Score 2 if > 1) 
Mesenteric insufficiency 
Chronic peritonitis 
Stricture OR upper gastrointestinal tract surgery 








0               1 
Musculoskeletal 
Atrophy or weakness 
Deforming of erosive arthritis (including reducible defomrmities, 
excluding avascular necrosis) 
Osteoporosis with fracture or vertebral collapse (excluding avascular 
necrosis) 











0             1 
Skin 
Alopecia 
Extensive scarring or panniculum other than scalp and pulp space 
 
0 1 
0            1 
Premature Gonadal Failure      0            1 
Diabetes (regardless of treatment)      0            1 























Table 2.2.1.2 (I): SLEDAI scoring system  
 
 
Weight Descriptor Definition 
8 Seizure Recent onset. Exclude metabolic, 
infectious, or drug causes 
8 Psychosis Altered ability to function in normal activity 
due to severe disturbance in the 
perception of reality. Include hallucinations, 
incoherence marked loose associations, 
impoverished thought content,marked 
illogical thinking, nizarre disorganized, or 
catatonic behavior. Exclude uremia and 
drug causes 
8 Organic brain syndrome Altered mental function with impaired 
orientation, memor,orother intellectual 
function, with rapid onset and fluctuating 
clinical features. Include clouding of 
consciousness with reduced capacity to 
focus, and inability to sustain attention to 
environment, plus at least 2 of the 
following: perceptual disturbance, 
incoherent speech, insomnia or daytime 
metabolic, infectious, or drug causes. 
8 Visual disturbance Retinal changes of SLE. Include cytoid 
bodies, retinal hemorrhages, serous 
exudates or hemorrhages in the choroids, 
or optic neuritis. Exclude metabolic, 
infectious, or drug causes. 
8 Cranial nerve disorder New onset of sensory or motor neuropathy 
involving cranial nerves 
8 Lupus headache Severe, persistent headache: may be 
migrainous, but must be nonresponsive to 
narcotic analgesia 
8 CVA  New onset of cerebrovascular accident (s). 
Exclude arteriosclerosis. 
8 Vasculitis Ulceration, gangrene, tender finger 
nodules, periungual infarction, splinter 
hemorrhages, or biopsy or angiogram 
proof of vasculitis 
4 Arthritis More than 2 joints with pain and signs of 
inflammation (i.e. tenderness, swelling or 
effusion) 
4 Myositis Proximal muscle aching/weakness, 
associated with elevated creatine 
phosphokinase/aldolase or electromygram 
changes or a biopsy showing mysitis. 
4 Urinary casts Heme-granular or ed blood cell casts 
4 Hematuria > 5 red blood cell/high power field. Exclude 
stone, infection, or other cause. 
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Table 2.2.1.2 (II): SLEDAI scoring system  
 
 
Weight Descriptor Definition 
4 Proteinuria > 0.5 gm.24 hours. New onset or recent 
increase of more than 0.5 mg/24 hours 
4 Pyuria > 5 white blood cells. Exclude infection.  
4 New rash New onset or recurrence of inflammatory 
type rash 
2 Alopecia New onset or recurrence of abnormal, 
patchy or diffuse loss of hair. 
2 Mucosal ulcers New onset or recurrence of oral or nasal 
ulcerations. 
2 Pleurisy Pleuritic chest pain with pleural rub or 
effusion, or pleural thickening. 
2 Pericarditis Pericardila pain with at least 1 of the 
following: rub, effusion, or 
electrocardiogram or echocardiogram 
confirmation. 
2 Low complement Decrease in CH50, C3, or C4 below the 
low limit of normal for testing laboratory. 
2 Increased DNA binding > 25% binding by Farr assay or above 
normal range for testing laboratory. 
1 Fever >38oC. Exclude infectious cause. 
1 Trombocytopenia <100.000 platelets/mm3 






2.2.2 DEX dose response on PBMCs 
 
A dose response was conducted based on the earlier data published by Seki at 
el., 1998, in which they used PNL. Briefly, PBMCs were isolated from Heparinized 
blood using standard Ficoll-Hypaque (Amersham Pharmacia Biotech AB, Uppsala 
Sweden) density-gradient centrifugation at 2000 rpm for 30 minutes. The 
mononuclear cell interface was collected and washed twice in RPMI 1640. 
PBMCs were maintained in complete media RPMI 1640 (Gibco, Life 
Technologies, Grand Island NY, USA), supplemented with 10% fetal calf serum 
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(FCS) (Gibco, Life Technologies, Grand Island NY, USA), 100 U/ml penicillin, 100 
µg/ml streptomycin (Gibco, Life Technologies, Grand Island NY, USA) and 1 mM 
of L-glutamine (Sigma Chemicals, USA). DEX was diluted at a concentration of 
1000 µg/ml, 500 µg/ml, 100 µg/ml, 5 µg/ml, 1 µg/ml 0.5 µg/ml in culture media. 
Cycloheximide (CH), a protein synthesis inhibitor and apoptosis inducer, was 
used to treat cells as a positive control for apoptosis [Terui et al, 1995; Gong et al, 
1993]. PBMCs were also treated with DMSO, the vehicle for CMX-13 at a 
concentration of 0.008%. The cells were incubated for 24 hrs at a concentration of 
1x106 cells/ml in 5 ml polypropylene round-bottomed tubes in a final volume of 1.0 
ml (Falcon, Becton and Dickinson and Company, Franklin Lakes, NJ). Apoptosis 
was analyzed by Annexin V- Fluorescein-isothiocyanate (FITC) /PI Staining as 
described in section 2.2.5. 
 
 
 2.2.3    Cell-Cycle Progression Analysis 
 
The effect of CMX-13 on cell-cycle progression was studied in Jurkat cells, as well 
as PBMCs stimulated with PHA.  CMX-13 dissolved in DMSO was tested in 
varying concentrations of 1, 2, 4, and 8 µg/ml, with DMSO 0.004% as the negative 
control.  For the Jurkat cell cultures, 1.4 mg/ml CH was used to treat cells as a 
positive control for apoptosis [Terui et al, 1995; Gong et al, 1993], while for 
PBMCs, 2.0 µg/ml CsA  (Sandoz, Switzerland) was the positive control. The cells 
were incubated for 24 hrs at a concentration of 1x106 cells/ml in 5 ml 
polypropylene round-bottomed tubes in a final volume of 1.0 ml (Falcon, Becton 
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and Dickinson and Company, Franklin Lakes, NJ). The cells were harvested by 
centrifugation for 5 minutes at 1500 rpm and washed with 1.0 ml phosphate 
buffered solution (PBS).Cells with an 1N content are considered to be in the 
G0/G1 phase, those with 2N in the G2/M-phase and those with greater than 1N 
and less than 2N in the S-phase. In an untreated normal cell population, most of 
the cells will be in the G0/G1 phase, followed by the S-phase, and finally in the 
G2/M-phase [Bedner et al., 1999]. 
 
During apoptosis, chromatin fragmentation occurs and is considered as a 
hallmark of this process. The nuclei of apoptotic cells take up less PI than the 
nuclei of normal cells, resulting in a decreased fluorescence signal from the 
apoptotic nuclei. As a consequence, apoptotic cells can be identified by PI 
staining. The apoptotic cell population will be observed in the “sub-G1” or the 
hypodiploid area. Nuclei are scored as apoptotic if they demonstrated a decrease 
in PI fluorescence relative to the nuclei of healthy non-apoptotic cells [Caricchio 
and Cohen, 1999]. 
 
Cell-cycle analysis was conducted by staining DNA with Propidium Iodide (PI) 
[Nicoletti et al., 1991; Bedner et al., 1999]. Cell-cycle analysis was performed 
using the CycleTEST™ PLUS DNA Reagent Kit (Becton and Dickinson 
Immunocytometry Systems, San Jose, CA, USA) [Nicoletti et al., 1991; Bedner et 
al., 1999].  Briefly, 5x105 cells were trypsinised using a solution containing trypsin 
and spermine for 10 minutes, treated with RNAse and a trypsin inhibitor for 
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another 10 minutes, and subsequently incubated, on ice, with PI for 30 minutes.  
Samples were then analyzed for total DNA content per cell by flow cytometry 
(FACScan, Becton Dickinson, Mountain View, CA).  Cell death by necrosis results 
in a large decrease in forward scatter (FSC) and sideward scatter (SSC) [Nicoletti 
et al., 1991].  Dead cells and debris were excluded from analysis by selective 
gating for healthy cell populations [Caricchio et al., 1998].  In each experiment 
10,000 events were analyzed. The coefficient of variation of the peaks of the 
control G0/G1 and G2/M phases were less than 3%.  Differential expression of the 
cell-cycle phases was calculated with the ModFit LT Software, (Cell Cycle 
Analysis Software from Verity Software House, Becton Dickinson). The majority of 
cells in a resting population will be in the G0/G1 phase, upon stimulation cells will 
proliferate and will be distributed over the G0/G1, S-phase, and the G2/M-phase 
[Bedner et al., 1999].   
 
2.2.4    Low Molecular DNA Isolation  
 
The DNA ladder that forms during apoptosis results from the activation of an 
endogenous endonuclease that is seen in conjunction with the various structural 
changes described in apoptotic cells [Schwartz et al., 1993].  Briefly, 3 x 1.106 of 
cells (either PBMC’s or Jurkat cells) were fixed in 10 ml of 70% ethanol on ice for 
4 hours. Cells were centrifuged at 1000 g for 5 minutes, and the cell pellet was 
resuspended in 40 µl of phosphate-citric acid buffer (0.2 M disodium hydrogen 
phosphate and 0.1 M citric acid), and incubated for 30 minutes at room 
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temperature.  Following centrifugation at 1500 g for 5 minutes, the supernatant 
was concentrated in a SpeedVac concentrator (Savant Instruments, Inc., 
Farmingdale, NY, USA) and treated with 3 µl (1 mg/ml) RNAse for 30 minutes at 
37oC.  Subsequently, 3 µl proteinase K (1 mg/ml) was added and incubated for 
another 30 minutes at 37oC. DNA in 12 µl loading buffer was then subjected to 
electrophoresis on a 0.8% agarose gel at 2 V/cm for 16-20 hours, and the bands 
were visualized following staining with 5 µg/ml ethidium bromide. 
 
PBMCs from SLE patients and controls were cultured with 0.004% DMSO, 4 
µg/ml CMX-13 and 1.4 mg/ml CH.  CMX-13 at 4 µg/ml was chosen because this 
concentration was previously demonstrated to cause maximal inhibition of PHA-
stimulated lymphocyte proliferation with good cell viability.  Jurkat cells were 
treated in a similarly as the PBMC, but were harvested at different time-points (0, 
4, 6, 8 hrs).   
 
2.2.5   Annexin V- FITC /PI Staining of  Apoptotic Cells 
 
Plasma membrane phospholipids are asymmetrically distributed between the 
inner and outer membrane.  The outer membrane bilayer predominantly contains 
the neutral phospholipids sphingomyelin and phosphaditylcholine, while anionic 
phospholipids, such as phosphaditylserine (PS), are restricted to the inner 
monolayer.  During early apoptosis a breakdown occurs of this asymmetry, and 
PS undergoes translocation to the outer membrane of the plasma membrane 
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[Bedner et al., 1999; Vermes et al., 1995], and becomes exposed on the outer 
membrane.  The PS exposure upon apoptosis is illustrated in Figure 2.2.4.1.  PS 
exposure functions as specific recognition by macrophages and for phagocytosis 
of apoptotic cells [Fadok et al., 1992; Cohen et al., 1993; Savill et al., 1993; van 
Engeland et al., 1998]. 
 
The anticoagulant Annexin-V binds with high affinity to PS, and when conjugated 
to the fluorochrome, FITC, it can be used in flow cytometry analysis to identify 
apoptotic cells.  When cells are stained with a combination of PI and Annexin-V 
conjugated with FITC (Annexin-V-FITC), four different cell populations can be 
distinguished.  Viable cells are Annexin-V-FITC negative and PI negative, early 
apoptotic cells are Annexin-V-FITC positive and PI-negative, while late apoptotic 
cells are Annexin-V FITC positive and PI positive.  Necrotic cells will also be 
Annexin-V FITC positive and PI positive, but these can be excluded through 
gating for the viable cells by FSC and SSC.  [Nicoletti et al., 1991; Bedner et al., 
1999]. 
 
PS exposure on the cell surface membrane was measured using the Annexin V-
FITC Kit1 (PharMingen, CA, USA) [Carricchio et al., 1999]. Briefly, cells were 
resuspended at a concentration of 1x106 cells/ml after centrifugation for 5 minutes 
at 1500 rpm.  One hundred µl (1x105 cells) were double-stained with 5 µl of 
Annexin V-FITC and 2 µl of PI, incubated in the dark at room temperature for 15-
30 minutes.  Flow cytometric analysis was performed on the FACScan, using the 
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CellQuest Software (Becton Dickinson, Mountain View, CA) with windows gated 
on Annexin V-FITC as well as PI positive cells, to include 10,000 events.  Dead 
cells and debris were excluded from analysis by selective gating based on FCS 
and SSC [Lorenz et al., 1997; Emlen et al., 1994]. Data were displayed on a 
logarithmic scale of increasing fluorescence intensity and each histogram plot was 
generated from at least 104 events per sample in all experiments. PBMC from 
controls and SLE patients were treated with 0.004% DMSO (vehicle control), with 
4 µg/ml CMX-13, or 0.5 mg/ml DEX [Seki et al, 1998], and with 1.4 mg/ml CH for 
the duration of 24 hrs.  Jurkat cells were treated for 8 and 24 hrs also with 0.004% 
DMSO, 4 µg/ml of CMX-13, and with 1.4 mg/ml CH (positive control). 
 
Figure 2.2.5.1 PS exposure on apoptotic cells. During apoptosis, PS which is 
located in the inner side on the cell membrane becomes exposed on the outer 

















2.3   CLINICAL AND HISTOLOGICAL STUDIES ON MRL-
lpr/lpr MICE 
 
2.3.1 Breeding Conditions and Examination for Clinical Disease 
 
Fifty-two, 8 week-old female MRL-lpr/lpr mice were purchased from the 
Jackson Laboratory (Bar Harbor, ME), stock number 000482.  Mice were bred 
under normal conditions (room temperature 23.0±2.0oC, ±60% relative 
humidity, and a 12-hours light/dark cycle) in the facilities of the Animal Holding 
Unit of the National University of Singapore.  Mice had free access to pelleted 
laboratory chow and acidified tap water.  Mice were observed for signs of 
autoimmune manifestations, namely hair loss, foot-pad swelling, and 
lymphadenopathy, and their survival was charted over a period of 22 weeks. 
Mouse found to be moribund were euthanized by inhalation of chloroform. 
Each animal was subjected to necropsy, and samples of liver, kidney, and 
spleen were collected and snap-frozen at -70ºC for RNA isolation, as well as 
prepared for histological examination.  
 
 
2.3.2     Treatment Groups 
 
The mice were separated into four groups of 13 mice each. The four groups 
were treated as follows: mice injected with  100 µl PBS were considered as the 
Untreated animals; the second group was treated with 16% v/v DMSO, which 
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served as the vehicle for CMX-13; the third group was treated with 25.0 
mg/kg/day CMX-13: and the fourth group was given 1.0 µg/kg/day DEX.  16% 
v/v DMSO was prepared by dissolving 250 µl DMSO in 1250 µl PBS. CMX-13 
was prepared by dissolving 7.5 mg into 250 µl DMSO followed by resuspension 
in 1250 µl PBS.  DEX was dissolved directly in PBS to a concentration of 1.0 
µg/kg/day.  The mice were treated from the age of 12 weeks to 22 weeks, on 
alternate days by intra-peritoneal injection after filter sterilization (0.20 µm 
syringe filter (Sartorius, Germany) of the diluents.  At the age of 23 weeks, all 
the mice that were still alive were sacrificed. Tissue was collected for 
histological analysis and RNA was isolated for quantitative real-time 
polymerase chain reaction (PCR) of cytokine mRNA transcripts. 
 
2.3.3 Urine Collection  and Proteinuira Measurement 
 
Every single mouse was placed in a clean cage for the collection of urine. They 
were left for approximately 30-60 minutes or until they urinated. Urine was 
collected at 8, 12, 16, 20 and 22 weeks. The urine samples were analyzed by 
colorimetric reaction with urine reagent strips (TECO Diagnostics, URS-2P) 
and were graded semi-quantitatively as follows: 
0 = Negative 
1 = Trace 
2 = 0-30 mg/dl (+) 
3 = 30-100 mg/dl (++) 
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4  = 100- 300 mg/dl (+++) 
5 = > 300 mg/dl (++++) 
 
2.3.4 Sera collection from Mice 
 
Blood was drawn by retro-orbital puncture [Peng et al.; 1996] with a 3mM 
Pasteur pipette at the age of 8, 12, and 16 weeks for sera collection. 
Approximately 200 µl blood was drawn each time, 50 µl was left on the bench 
top for 30 minutes to clot.  Sera were obtained after centrifugation for 10 
minutes at 10,000 rpm. 
 
.2.3.5  Serological  Analysis 
 
Serum samples were obtained from mice at the age of 8, 12 and 16 weeks for 
anti-double stranded DNA (anti-dsDNA) antibody analysis.  Serum levels of 
IgG-specific anti-dsDNA antibody were measured using an enzyme 
immunoassay (ELISA).  Briefly, 96-well plates (Corning, ELISA plate) were 
coated with 100 µl/well of 10 µg/ml bovine serum albumin (BSA).  After 
overnight incubation at 4ºC, plates were washed with PBS-Tween 0.05%.  
Subsequently, 100 µl/well of 2.5 µg/ml calf thymus DNA in 0.1 mmol/l 
phosphate was added.  After another overnight incubation, the plates washed 
three times with PBS-Tween 0.05%, and 200 µl/well of 1.0 mg/ml gelatin was 
added for blocking.  The plates were incubated for 2 hours at 37°C, washed 
with PBS-Tween 0.05% three times.  Serum samples were diluted 1/500 in 
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PBS, and 100 µl was added to each well.  After 1 hour of incubation at room 
temperature, plates were washed, and 100 µl/well affinity-purified goat-anti-
mouse IgG (H+L)-horse-radish peroxidase diluted 1:2000 in PBS was added to 
each well.  After incubation for 1 hour at 37ºC, plates were washed and 100 
µl/well of substrate solution containing o-phenylenediamine (0.4 mg/ml) and 
0.001% hydrogen-peroxide was added.  Following 30 minutes of incubation in 
the dark at room temperature, 50 µl of 10% sodium dodecyl sulfate was added 
to stop the reaction.  Absorbance was determined at 405nm.  All samples were 
assayed in triplicates on the same day. 
 
Serum creatinine was measured by the alkaline picrate method. A standard 
curve was created using the Sigma creatinine Standards Cat # 925-11. Briefly, 
50 µl serum was mixed with 50 µl H2O, 50 µl Na. Tungstate (5%) and 50 µl 
sulphuric acid and left on room temp for 10 minutes. The samples were spun 
for 10 minutes at 3000 rpm.  The 100 µl supernatant was collected and mixed 
with 20 µl saturated picric acid and 30 µl 1N Sodium hydroxide and left for 20 







2.3.6 Preparation of Kidney Slides and Histological Grading of 
Lupus Nephritis Examination  
 
The surviving mice in all the groups were sacrificed at 23 weeks for histological 
examination.  Mice, which became moribund at the age of 23 weeks were 
sacrificed.  Briefly, the mice were euthanized by chloroform inhalation.  
Kidneys specimens from moribund mice were fixed in 10% neutral buffered 
formalin with phosphate buffer (pH 7.4) for 24 hrs for histological evaluation.  
The samples were dehydrated with an automated processing machine (Leica) 
as follows: 
1) 70% Ethanol for 1 hour 
2) 95% Ethanol for 1 hour 
3) 3 x 100% Ethanol for 2 hours 
4) 2 x Xylene for 2 hours 
The samples were subsequently embedded in paraffin as follows: 
1) Wax for 1 hour 
2)  2x Wax for 2 hours 
 
Each sample was then cut into 4 µm sections using a microtone (Reichert-
Jung).  The sections were dried for 5 minutes, followed by heating on a 80ºC 
hotplate for 10 minutes.Periodic Acid-Schiff (PAS) stain [Bancroft et al, 1990] 
was prepared as follows: 
1) PAS consisted of 1.0 gram periodic acid, 200 ml of distilled water. 
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2) Schiff Reagent was prepared by dissolving 1.0 gram of basic fuchsin in 
200 ml of boiling distilled water.  The solution was cooled to 50°C, and 
2.0 gram of potassium metabisuphite was added and mixed.  After 
cooling to room temperature, 2.0 ml of concentrated hydrochloric acid 
and 2.0 gram of activated charcoal were added.  The solution was left 
overnight in the dark at room temperature.  The solution was then 
filtered through a number 1 Whatman paper and stored until use in a 
dark container at 4°C. 
 
The sections were deparaffinized, treated for 5 minutes with periodic acid and 
washed several times with distilled water.  The sections were then covered with 
Schiff’s solution for 15 minutes and washed in running water.  The nuclei were 
stained with Harris haematoxylin, washed in water and rinsed in absolute 
alcohol.  The sections were subsequently cleansed in xylene. 
 
The kidney sections were graded using a score based on the activity of lupus 
nephritis.  All the mice developed diffuse proliferative lupus nephritis which was 
similar to human Class IV lupus nephritis as defined by the WHO [Peutz-
Kootstra et al, 2001; Appel and Valeri, 1994].  The slides were evaluated by 
two “blinded” observers who were not aware of the experimental groupings.  
Histological grading was based on a continuous grading system from 0 to 3+, 
where 2+ and 3+ were considered severe disease, while 0 and 1+ were 
considered to be mild disease.  The histological features that were graded 
included: 
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1.  glomerular cell proliferation 
2.  leucocyte exudation 
3.  karyorrhexis and fibrinoid necrosis 
4.  cellular crescents 
5.  hyaline deposits 
6. interstitial inflammation.  
A minimum of 20 glomeruli/slide were assessed and scored.  In calculating the 
activity index, fibrinoid necrosis and cellular crescents were weighted by a 
factor of 2.  The activity index for lupus nephritis was defined as the sum of 
individual scores [Austin et al, 1984], and the maximum activity index was 24 
points.  As some mice died before 23 weeks, an overall histological index for 
each kidney was obtained by a score/age ratio to compensate for the effect of 











2.4                      CYTOKINE GENE EXPRESSION STUDIES IN   THE MRL  
   lpr/lpr MICE     
 
2.4.1  Isolation of Murine Splenic CD4+ and CD8+ T-Cells 
 
The spleens were excised using and ruptured in a petri-dish containing 5 ml 
HBSS.  Debris of the tissue was separated using a 70.0 µm cell strainer 
(Becton and Dickinson, USA). Lymphocytes were isolated using the Ficoll-
Hypaque centrifugation method.  The isolated cells were washed and the 
supernatant was removed completely. The cells were resuspended in 90  µl of 
buffer (PBS + 2mM EDTA + 0.5% BSA) per 107 cells and incubated with 10 µl 
of MACS CD4 (L3T4) Microbeads (Miltenyi Biotech, Germany) per 107 total 
cells, for 15 minutes at 6 -12°C. The cells were then washed with 10-20x 
labeling volume of PBS supplemented with 2 mM EDTA and 0.5% BSA 
(Sigma) (PBS/BSA/EDTA) and centrifuged at a speed of 300 x g for 10 
minutes.  The cell pellet was resuspended in  0.5 ml PBS/BSA/EDTA per 108 
total cells.  The LS+ Magnetic Separation columns with positive selection 
(Miltenyi Biotec, cat no. 130-042-401) were attached to the magnetic separator.  
The column was prepared by washing with 5 ml PBS/BSA/EDTA.  The cell 
suspension was applied onto the column. The column was then washed with 
3x 3 ml of PBS/BSA/EDTA.  The effluent was collected as the negative fraction.  
The column was removed from the separator and placed under a new 
collection tube and finally 5 ml of PBS/BSA/EDTA was applied to the reservoir 
of the LS+ column and the cells were flushed out.  The cells were then 
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harvested by centrifugation at 1500 rpm for 5 minutes.  The supernatant was 
discarded and the pellet was resuspended in 1 ml of TRIZol (Gibco BRL) for 
RNA isolation. 
 
CD4-FITC conjugated antibody and CD8-FITC conjugated antibody were used 
to stain the isolated cells to assess the uniformity of each cell preparation.  
Approximately 0.2 x 106 cells/ml were stained with 1 µl of CD4+/CD8+ antibody 
(Becton and Dickinson, USA) for 20 minutes in 100 µl staining buffer, 
composed of 100 ml RPMI1600, 2.5% FCS, and 50 µl of 20% sodium azide.  
The cells were washed with PBS and spun down for 10 min at 1400 rpm at 
4°C.  The cells were resuspended and stained with 5 µl of goat antibody and 
100 µl of staining buffer and incubated for 20 min at room temperature.  The 























2.4.2 Isolation of Glomeruli from Cortex of Mouse Kidneys using 
the Graded Sieving Technique 
 
The kidneys were excised using an aseptic technique and transferred to 
Dulbecco’s modification of Minimal Essential Medium (DMEM), the capsules 
were removed, and the cortices were dissected from each kidney [Kreisberg, et 
al 1978].  Glomeruli were isolated from the renal cortex as described by 
Kreisberg with some modifications [Kreisberg, et al 1978].  The cortex were 
sliced into small pieces with a blade and pressed with a spatula through a 
stainless steel screen of 60-mesh (pore size, 250; W.S. Tyler, Inc., Mentor, 
Ohio).  The minced cortices were collected on a petri-dish placed underneath 
the stainless steel screen by washing with DMEM.  The filtrate was then 
passed through a 100 µm nylon cell strainer and again through a 70 µm cell 
strainer (Becton and Dickinson, USA). The glomeruli remained on the 70 µm 
nylon cell strainer, due to their size.  Tubular debris and small fragments were 
removed by washing.  The 70 µm nylon strainers were then placed upside 
down onto a 50 ml culture tube and the isolated glomeruli were collected in the 
culture tube by washing with 10 ml of DMEM. Single isolated glomeruli are 
shown in Figure 2.4.2.1.  The glomeruli were incubated at a concentration of 
0.5 glomeruli/ml for 30 minutes with 1 mg/ml collagenase (Gibco BRL) at 37°C 
[Boswell, et al 1988].  The glomeruli were then harvested by centrifugation at 
600 rpm for 10 minutes.  The supernatant was discarded and the pellet was 
resuspended in 1 ml of TRIZol (Gibco BRL), followed by RNA isolation. 
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2.4.3  RNA  isolation and complementary DNA (cDNA) preparation 
 
 
Total cellular RNA from organs was isolated using TRIZol reagent (Gibco BRL), 
which is a modification of the standard guanidinium-phenol-chloroform 
extraction method [Lemay et al, 1996].  Briefly, 1x106 cells/ml were treated with 
1 ml of TRIZol and subjected to repetitive pipetting. The samples were 
incubated for 5 minutes at room temperature. Two hundred µl of chloroform per 
ml of TRIZol was added and then shaken vigorously for 15 seconds.  The 
samples were incubated for 2-3 minutes at room temperature and then spun at 
12000 rpm for 15 minutes at 4°C.  The colorless phase was obtained and 
placed into di-ethylpyrocarbonate (DEPC)-treated 1.5 ml microcentrifuge tubes.  
Five hundred µl of 100% isopropanol was added and incubated for 10 minutes 
at room temperature, followed by centrifugation at 12000 rpm for 10 minutes at 
4°C.  The supernatant was removed and the pellet was washed with 1.0 ml of 
75% ethanol, and mixed by vortex.  The samples were then centrifuged at 9500 
rpm for 5 minutes at 4°C.  The supernatant was removed and air-dried briefly 
for 5-10 minutes.  The RNA pellet obtained was dissolved in 35 µl DEPC-H2O. 
 
The RNA was subsequently diluted 20x (5 µl RNA+ 95 µl DEPC-H2O) and the 
concentration measured by spectrophotometry using the Ultrospec 2000 
UV/visible spectrophotometer (Pharmacia Biotech) at a wavelength of 260nm 
in a 10mm pathlength cell.  The RNA concentration was calculated as follows: 
[RNA]/(ng/µl) = 40 x A260 x DF 
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Total RNA (ηg) = [RNA] x Vol. of Sample. 
DF = Dilution factor. 
 
Reverse transcription (RT) reactions were carried out in a Hybaid Touchdown 
PCR thermocycler for 1 hour at 37°C followed by 5 minutes at 95°C in 0.6 ml 
thin walled MicroAmp reaction tubes using M-MLV Reverse Transcriptase 
(Promega, USA).  Each reaction contained 200 ηg of total RNA in a volume of 
20 µl containing 1x M-MLV RT reaction buffer, 1 U RNasin Ribonuclease 
Inhibitor, 2.5 µM OligoT20, 0.5 mM dNTP, 20 U M-MLV Reverse Transcriptase. 
The reagents and conditions are summarized in Table 2.4.3.1. 
 
Table 2.4.3.1  Reagents and Enzymes Used in the preparation of cDNA  
 
Reagents Stock Final Volume used 
for 1 reaction 
(µl) 
Reaction Buffer 5 x 1 x 4 
DNTP 25 mM 0.5 mM 0.4 
OligoT20 100 µM 2.5 µM 0.5 
Rnasin 40 U/µl 1 U/µl 0.5 
Reverse Transcriptase 250 U/µl 20 U 0.08 
H2O   9.5 
Total RNA  200 ng 5.0 






2.4.4    Reverse Transcript PCR (RT-PCR) 
 
Optimization of the PCR for each cytokine was performed using freshly 
prepared cDNA following reverse transcription.  The primers for the PCR 
reactions are listed in Table 2.4.4.1.  The PCR reaction was set up as follows: 
10x PCR reaction, 2.5mM MgCl2, 25 mM dNTP, 10 µM primer pairs, 0.5 U of 
Taq polymerase, and buffer with 4µl of cDNA making a final volume of 20.0 µl.  
The reagents are listed in Table 2.4.4.2 (Promega cat. no. M1665).  The PCR 
reactions were run on a HyBaid Touchdown PCR thermocycler using the 
conditions as shown in Table 2.4.4.3. 
 

















Antisense: CTGCGGCATGTTCTGGATTTGACTC 56 168 
IL-6 
(J03783) 
















Table 2.4.4.2  PCR  reagents  
 
 Master mix  Volume for 1 reaction 
ddH2O 7.7 µl 
10x PCR reaction buffer 2.0 µl 
MgCl2, 25mM 2.0 µl 
DNTP, 25mM 0.2 µl 
Forward primer, 10µM 2.0 µl 
Reverse primer, 10µM 2.0 µl 
Taq polymerase, 5U/µl 0.1 µl 
CDNA 4.0 µl 
Total 16 µl 
 
Table 2.4.4.3 PCR amplification conditions   
Steps Temperature (°C) Time No. of cycles 
Denaturation 95 30 sec  
Annealing 54 30 sec 40 
Extension 72 45 sec  
Final extension 72 10 min 1 









2.5  PREPARATION OF STANDARDS FOR QUANTITATIVE 
REAL-TIME PCR  
 
2.5.1 Cloning of Cytokine cDNA into Plasmids for External 
Standard Curves Designated for Quantitative Real-time- PCR  
 
The amplified PCR products were cloned into a plasmid vector using the TOPO 
TA cloning kit (Invitrogen, USA).  The plasmid vector was supplied in linearized 
form with a single 3’-thymidine (T) overhang for TA cloning.  It is important that 
Taq polymerase was used in the above PCR reaction because it has a 
nontemplate-dependent terminal transferase activity that adds a single 
deoxyadenosine (A) to the 3’ends of PCR products.  This allows PCR products 
to insert into the cloning vector efficiently by the principle of TA cloning.  The 
reagents employed in the cloning reactions are listed in Table 2.5.1.1. 
 
The reagents were mixed gently and incubated for 15 minutes at room 
temperature.  Two µl of the cloning reaction mixture were mixed with a vial of 
Escheria coli (E.coli) cells, incubated at room temperature for 15 minutes, and 
subsequently subjected to heat shock treatment at 42°C for 30 seconds.  The 
heat shock- treated cells were mixed with 250.0 µl of LB medium and left in a 
shaker for 1 hour at 37°C.  After incubation, 50µl of the incubation mixture were 
spread onto each of the 2 Luria-Bertani (LB) plates containing X-Galactoside) 
and 50 µg/ml ampicillin. The LB plates were then incubated at 37°C overnight. 
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Positive clones were identified by the principle of blue/white screening. 
Transformed E.coli are ampicillin-resistant because the plasmid vector carries 
the ampicillin-resistant gene.  Therefore, E.coli that are not transformed will not 
survive.  The plasmid vector also carries a LacZα gene, and the protein 
translated by this gene is able to turn X-gal blue.  This function will be lost if the 
PCR products were successfully cloned into the vector.  Ten white colonies 
were chosen from each cloning experiment.  The colonies were cultured in a 
50.0 ml culture tube containing 10ml of LB medium with 50.0 µg/ml of ampicillin 
(Gibco, BRL).  The culture tubes were incubated in a shaker at 37°C overnight. 
 
Table 2.5.1.1  Cloning Reagents  
Reagent Volume 
Fresh PCR product 4.0 µl 
Salt solution 1.0 µl 
TOPO vector 1.0 µl 
Final Volume 6.0 µl 
 
 
Extraction and purification of plasmid DNA were carried out using the QIAprep 
Spin Miniprep kit, cat. no. 27104 (Qiagen, USA).  The QIAprep miniprep 
procedure is based on alkaline lysis of bacterial cells followed by adsorption of 
DNA onto silica in the presence of high salt.  The procedure consists of three 
basic steps: preparation and clearing of the bacterial lysate, adsorption of DNA 
onto the QIAprep membrane, and washing and elution of plasmid DNA.  The 
last 2 steps were performed on a spin column.  
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The concentration of plasmid DNA was measured by spectrophotometry using 
the Ultrospec 2000 UV/visible spectrophotometer (Pharmacia Biotech).  DNA 
concentration was measured by its absorbance at OD260nm since a solution of 
DNA with an optical density of 1.0 (1.0 absorbance unit) has a concentration of 
50 µg/ml respectively, in a 10 mm pathlength cell. The constructs were 
analyzed for insertion by restriction digestion [Blaschke et al, 2000] with EcoRI.  
An EcoRI restriction site is present at the cloning site of the plasmid.  The 
plasmid DNA was treated with 5 µl of EcoRI (10.0 U/µl, Gibco BRL), 2 µl of 
reaction buffer (10x), and 5 µl of plasmid DNA in a final volume of 20 µl for 2 
hours at 37°C.  In Figure 2.5.1.1 the EcoRI digestion of shown of the inserts in 
the plasmid. 
Figure 2.5.1.1 EcoRI restriction digestion of inserts from plasmid. EcoRI 
restriction digestion profile of the clones containing the cytokine cDNA inserts: 
100 bp DNA ladder was used as a size marker; cyclophilin-α (476 bp); IL-2  (165 
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2.5.2 Calculation of Plasmid DNA Copy Number and Dilution of 
 Standards 
 
To determine the absolute copy number of the target transcript, cloned plasmid 
DNA for each cytokine studied was used to generate a standard curve.  The 
plasmid DNA was prepared as described above.  The concentration of the 
plasmid DNA was determined based upon the OD260.  The copy number of 
plasmid DNA template was calculated according to the molecular weight of the 
plasmid (662 x 106 kb-1 average value) and Avogrado’s number (1 mol = 6.022 
x 1023 molecules), using the formula: 
     6.022 x 1023        = 
(plasmid size + size of insert) x (molecular weight of plasmid) 
 
copies per µg of plasmid 
concentration of plasmid DNA 
 
The cloned plasmid DNA were serially diluted from 10-7 to 10-3 in order to 
generate the standard curve. 
 
2.5.3 Quantification of Cytokine mRNA transcripts by Real-time 
PCR   
 
The primers employed for the generation of cytokine cDNA constructs could 
not be used for the quantitative real-time PCR, as they resulted in the formation 
of primer dimers.  New primers within the cloned inserts were designed.  All 
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primers (OPERON), except those for cyclophilin-α, were re-designed using the 
software program from the website: http://www.path.cam.ac.uk/cgi-
bin/primer3.cgi.  Primers for Cyclophilin- α (Gibco BRL) were designed using 
the OLIGO primer design program.  The primers are listed in Table 2.5.3.1. 
 
Table 2.5.3.1  Primers for Real-Time RT-PCR  
 
























4      100 
 
 
Freshly prepared reverse-transcribed total RNA from cells or tissues were 
subjected to real-time PCR analysis.  Reactions were conducted using Roche 
LightCycler DNA Master SYBR Green Kit 1 (Roche Molecular Biochemicals, 
Mannheim, Germany) for the detection of PCR products.  Real-time PCR was 
carried out on the LightCycler (Roche Molecular Biochemicals, Mannheim, 
Germany).  Briefly, the PCR was set up using 5 µl PCR master mix (Light 
Cycler DNA Master SYBR Green Kit 1) supplemented with 3.0 mM MgCl2 and 
 73
custom synthesized primers (Operon).  In order to reduce primer dimer 
formation, the amount of each primer was reduced to 0.25 µM [Dumoulin et al., 
2000].  
 
Optimization was done employing a new set of primers (Table 2.5.3.1), which 
were different from the ones used for cloning.  This optimization was required 
to circumvent primer dimer formation, which interferes with the quantification of 
the absolute copy numbers.  When these new sets of primers were employed, 
no primer dimers were present from analysis of the melting curve.  The PCR 
reagents are listed in Table 2.5.3.2.   
 
Table 2.5.3.2  Real-Time PCR reaction mixture using Roche LightCycler  
DNA Master Kit 1. 
  
 
Master mix Volume (1x) 
ddH2O 2.9 µl 
MgCl2  (25mM) 0.6 µl 
SYBR Green I 0.5 µl 
Forward primer (10µM) 0.25 µl 
Reverse primer (10µM) 0.25 µl 
CDNA 0.5 µl 
Total 5.0  µl 
 
The duration of the amplification reaction was calculated based on the product 
size:  Product size (bp)/25 = seconds for amplification.  The annealing 
temperature was optimized for each cytokine insert. Real-time PCR was 
performed in glass capillaries with an initial denaturation step of 30 seconds at 
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95°C, followed by 40 cycles of denaturation for 10 seconds at 95°C, annealled 
for 5 seconds at the following temperatures:  Cyclophilin-α 60°C; IL-2 64°C; 
IFN-γ 62°C; IL-6 62°C; IL-10 62°C, and extension for (product length (bp)/25) 
seconds at 72°C. At the end of each cycle, the fluorescence emitted by the 
SYBR Green was measured.  After completion of the cycling process, samples 
were subjected to a temperature ramp (from above 5°C annealing temperature 
to 95°C at 2°C/second) with continuous fluorescence detection for melting 
curve analysis.  For each PCR product a single narrow peak was obtained by 
melting curve analysis at the specific melting temperature and only a single 
band of the predicted size was observed by gel electrophoresis [Blaschke et 
al., 2000]. 
 
Quantification in real-time RT-PCR is based on the threshold cycle of 
detectable cDNA molecules.  For each sample, a determination is made of the 
cycle number at which the fluorescence related to the amount of double-
stranded DNA is significantly elevated above background fluorescence. By 
using external standard curves, a calibration curve can be generated and 
samples can be quantified according to their threshold cycle [Heid et al., 1996. 
 
Quantification data was analysed using the LightCycler analysis software.   
Background fluorescence was removed by setting a noise band.  The log-linear 
portion of the standard’s amplification curve was identified and the crossing 
point was the intersection of the best-fit line through the log-linear region and 
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the noise band.  The standard curve is the plot of the crossing point versus the 
log of the copy numbers.  The acquired standard curves, amplification plots 
and melting curves are shown for mouse cyclophilin-α, IL-2, IFN-γ, IL-6, and IL-
10 are shown in Figures 2.5.3.1, 2.5.3.2, 2.5.3.3, 2.5.3.4, and 2.5.3.5 


































Figure 2.5.3.1 Quantification of Mouse Cyclophilin-α mRNA transcripts by 
quantitative real-time PCR. The quantification was based on a standard curve 
which was obtained by analyzing the amplification of a  476 bp mouse 
Cyclophilin-α sequence cloned in a plasmid, in the range from 107 - 103 copies. 
Panel A shows the standard curve; panel B shows the amplification plots of the 
cloned sequence; panel C shows the the melting curves, which signifies product 
specificity.    
 


































Figure2.5.3.2 Quantification of IL-2 mRNA transcripts by quantitative real-time 
PCR. The quantification was based on a standard curve which was obtained by 
analyzing the amplification of a 168bp mouse IL-2 sequence cloned in a plasmid, 
in the range from 107 - 103 copies. Panel A shows the standardcurve; panel B 
shows the amplification plots of the cloned sequence; panel C shows the the 























Y  =3.95x + 42.82 











Figure 2.5.3.3  Quantification of IFN-γ mRNA transcripts by quantitative  
real-time PCR. The quantification was based on a standard curve which was  
obtained by analyzing the amplification of a 155bp mouse IFN-γ sequence  
cloned in a plasmid, in the range from 106 – 102 copies. Panel A shows the  
standard curve; panel B shows the amplification plots of the cloned sequence;  































Y = 2.78x + 38.48 
Error:0.31   
A
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Figure 2.5.3.4  Quantification of IL-6 mRNA transcripts by quantitative real- 
time PCR. The quantification was based on a standard curve which was 
obtained by analyzing the amplification of a 155bp mouse IL-6  sequence 
cloned in aplasmid, in the range from 107 – 103 copies. Panel A shows the 
standard curve;panel B shows the amplification plots of the cloned sequence; 





































Figure 2.5.3.5  Quantification of IL-10 mRNA transcripts by quantitative real-time 
PCR. The quantification was based on a standard curve which was obtained by 
analyzing the amplification of a 231bp mouse IL-10  sequence cloned in a 
plasmid, in the range from 106 – 102 copies. Panel A shows the standard curve; 
panel B shows the amplification plots of the cloned sequence; panel C shows 






























2.5.4     Quantification of cDNA by real-time PCR 
 
Gene expression levels of IL-2, IFN-γ, IL-6, and IL-10 were determined by real-
time PCR using the Roche LightCycler.  Samples (determined in duplicate) 
were quantified using the LightCycler analysis software, version 3.39.  A 
standard curve was generated for each gene targeted as described above.  
The mRNA expression level was quantified based on the external standard 
curve.  cDNA samples from the MRL-lpr/lpr mice were analyzed, and compared 
with those obtained from MRL-wt mice as the normal control.  The 
housekeeping gene, cyclophilin, was used as the common denominator for 
calculation of a cytokine index. 
 
2.5.5 Statistical Analysis 
 
Statistical analysis was performed using SPSS for Windows (version 11.5, 
SPSS Andover, Mass., USA).  The differences between CMX-13 treated 
experimental groups and untreated or DMSO controls were compared using 
the Mann-Whitney rank sum test for non-parametric variables.  Paired data 
were compared using the Wilcoxon signed-rank test.  Spearman’s correlation 
coefficient was used to determine the significance of correlations between non-
parametric variables.  In addition, the effect of CMX-13, compared to the 
untreated and DMSO controls, on the survival of MRL-lpr/lpr mice was 
performed using the Kaplan-Meier analysis, with death before the age of 22 
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weeks as the outcome parameter.  A p-value of less than 0.05 was considered 

























CHAPTER 3  ISOLATION AND STRUCTURE ELUCIDATION OF 
BIOACTIVE COMPOUNDS FROM RC 
 
 
3.1    INTRODUCTION 
 
Natural products are a major source for new medicines. However there are 
various obstacles up to the commercialization process of natural products as 
modern medicines.  Firstly the isolation and purification process from the crude 
herb can be laborious, time-consuming and unreliable. Secondly the production 
of natural products in plants is subjected to many factors like seasonal 
changes, and soil composition [Itokawa et al, 1984] consequently leading to 
inconsistent bioactivity of plant extracts. This inconsistency may cause 
problems regarding toxicity in the case of strong bioactivity or insufficient 
dosage administration when the extract has poor bioactivity. For adequate 
production and commercialization as a reliable product, standardization of the 
production method is essential. Chemical synthesis of plant derived bioactive 
products is a viable alternative. This method creates the possibility to control 
and produce medicines with consistent bioactivity.   
 
Chemical synthesis of a molecule requires the knowledge of the molecular 
structure. Therefore structure elucidation of the bioactive molecule in medicinal 
extract is necessary. However, in the application of traditional medicines a part 
of the plant is used or a combination of several different parts of plants is used, 
resulting in a mixture of many unknown compounds. In many cases only one 
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compound in the whole plant extract is responsible for the therapeutic effect 
and acts as the principle bioactive compound for the whole herbal mixture. It is 
often unknown in these herbal mixtures as to the actual herb, which has the 
actual bioactive effect.  All the herbs have to be tested separately in order to 
identify the sole bioactive herb before isolation of the active compound can 
commence. Here we developed a bioassay-guided fractionation method for the 
isolation of bioactive plant extracts with immunosuppressive properties. We 
employed a bioassay based on the proliferation of PBMCs when stimulated 
with PHA.  An active plant extract when incubated with PHA-stimulated PBMCs 
will result in suppression of PBMC proliferation, i.e., immunosuppression. 
During the bioassay-guided fractionation the plant extracts were tested for their 
immunosuppressive properties after each step of isolation and purification.  
 
 We have shown in our previous work that the roots of RC contain compounds 
that have immunosuppressive properties [Yap et al, 1999]. The bioassay-
guided fractionation procedure depicted in Figure 3.1.1 has been developed 
based on results from our previous studies.  By employing this bioassay we 
were able to purify bioactive fractions from extracts of herbal medicines. The 
extracts with significant immunosuppressive properties are underlined and the 
follow up process indicated with a bold arrow.  
 
In the initial step, the herb was grounded and extracted with EtOAc, followed by 
solvent partition with MeOH, water, Hex and CH2Cl2. The CH2Cl2 extract was 
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found to have immunosuppressive properties and was subjected to flash 
column chromatography. Reverse phase thin-layer chromatography (RP-TLC) 
was employed to distinguish the fractions that were obtained by flash column 
chromatography based on the Rf values. Fourteen flash column 
chromatography fractions were obtained of which fraction 13 (CMX-13) had 
significant immunosuppressive properties.  
 
 In this work we report our approach to further purify the bioactive compound in 
CMX-13 employing a bioassay-guided fractionation strategy using RP-HPLC. 
CMX-13 produced 8 fractions of which CMX-13-5 had significant bioactivity. 
The bioactive RP-HPLC fraction CMX-13-5 was subjected to preliminary 
structure elucidation studies by nuclear magnetic resonance and liquid 
chromatography (LC)-mass spectrometry experiments.  
 
In order to obtain sufficient amounts of CMX-13 for in-vitro and in-vivo 
experiments new batches of RC roots were purchased and subjected to 
bioassay-guided fractionation employing the methods established earlier. From 
these subsequent batches we isolated fraction CMX-13’, (Figure 3.1.2) also a 
flash column chromatography fraction as CMX-13. CMX-13 was used as a 
reference material in the isolation process of CMX-13’. CMX-13’ showed to be 
a more potent immunosuppressant than CMX-13. Further comparison analysis 
of CMX-13’ showed that it is a less complex mixture of compounds than CMX-
13. Both flash column fractions had similar chromatographic profiles when 
subjected to RP-HPLC and RP-TLC. This led us to conclude that CMX-13’ and 
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CMX-13 are flash column fractions with similar properties, with the difference 































Figure 3.1.1 Strategy employed for the isolation of the bioactive compound 
CMX-13 from RC. After each step of purification the compound was subjected to 
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Figure 3.1.2 Strategy employed for the isolation of the bioactive compound 
CMX-13’ from RC. The same bioassay-guided fractionation strategy employed 
for CMX13 was used to isolate CMX-13’. Flash column chromato-graphy of the 
CH2Cl2 fraction produced 16 compounds of which fraction 7 showed was 
bioactive.  Chemical analysis of CMX-13’ and CMX13 revealed that these two 
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3.2         RESULTS 
 
3.2.1              Isolation and Immunosuppressive Bioassay of Commercial 
Crude Herb  
 
PHA stimulates proliferation of PBMCs or the lymphoproliferative response 
(LPR). In the course of cell proliferation DNA is synthesized. When proliferating 
cells are cultured in the presence of 3[H]-Thymidine, incorporation of 3[H]-
Thymidine into DNA occurs. Therefore, cell proliferation can be measured by 
the amount of incorporated 3[H]-Thymidine into the newly synthesized DNA.  
 
The immunosuppressive properties of the herbal roots of RC were tested on 
PBMCs stimulated with PHA (PHA+PBMCs). All experiments were conducted 
in triplicates. In the experimental set up, PHA+PBMCs were cultured with no 
additional treatment (negative control), with DMSO (DMSO-control), or with the 
plant extract. DMSO served as a vehicle for the extracts and therefore was 
used as the solvent control.  The degree of immunosuppression was calculated 
as follows: Percent immunosuppression = [1-(cpm of treated cells)/(cpm of 
untreated cells)]*100  
 
New batches of RC roots were purchased, processed and subjected to 
extraction with EtOAc, as described in section 2.1.1 of Materials and Methods. 
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The EtOAc extracts (EtOAc EXT) were tested for their immunosuppressive 
properties on PHA+PBMCs. Figure 3.2.1.1 shows the results of the 
immunosuppressive bioassay on PHA+PBMCs derived from 3 individuals on 3 
different occasions. 
 
The DMSO-treated PHA+PBMCs showed slight suppression (4.5±4.8%) when 
compared to the untreated PHA+PBMCs, but this was not statistically 
significant.  EtoAC EXT showed a dose-response effect on suppression of 
LPR, with 4 µg/ml EtOAC EXT resulting in 67.6±2.7% immunosuppression 
(p<0.05), while 1.0 µg/ml EtOAc EXT resulting in only 46.3±17.7% suppression 
of the LPR (p=ns) (Table 3.2.1.1 and Figure 3.2.1.1). Hence only the EtOAc 
EXT of RC which had an immunosuppressive effect of 60% or above at a 
concentration of 4 µg/ml were considered suitable for further bioassay-guided 
fractionation. 
 











Unt. PHA+PBMC 93.6±14.3 0  
DMSO  89.4±17.9 4.5±4.8 NS 
1 µg/ml EtOAc EXT 53.2±38.7 46.3±17.7 NS 
2 µg/ml EtOAc EXT 32.6±2.3 64.8±1.9 < 0.05 
4 µg/ml EtOAc EXT 29.8±0.7 67.6±2.7 < 0.05 
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Figure 3.2.1.1 Grounded roots of RC was extracted with EtOAc by Soxhlet 
extraction. The PHA+PBMCs were treated with 1, 2 and 4 µg/ml of EtOAc EXT.  4 




3.2.2 Immunosuppressive Effect of the Extracts Obtained Through 
Solvent Partition 
 
The EtOAc EXT with immunosuppressive properties was subjected to solvent 
partition with 50% MeOH/H2O, Hex and CH2Cl2 as described in section 2.1.2 of 
Materials and Methods. After partition, the 3 solvent extracts were lyophilized 
and tested at a concentration of 4 µg/ml for their immunosuppressive 
properties. Figure 3.2.2.1 shows the results of the immunosuppressive 
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The DMSO-treated PHA+PBMCs showed slight suppression (5.7±4.7%) when 
compared to the untreated PHA+PBMCs, but this was not statistically 
significant. The PHA+PBMCs treated with the CH2Cl2 extract (CH2Cl2 EXT) 
showed significant immunosuppression (71.6±0.8%, p<0.05) (Table 3.2.2.1 and 
Figure 3.2.2.1).  The Hex extract (Hex EXT) and the 50% MeOH/H2O extract 
(50% MeOH/H2O EXT) did not have any immunosuppressive effect on the 
PHA+PBMCs.  The CH2Cl2 EXT was re-tested in 3 further individuals to confirm 
the immunosuppressive effect on PHA+PBMCs.  A similar degree of 
immunosuppression was obtained (72.9±12.9%, p<0.05).  The CH2Cl2 EXT 
was then subjected to flash column chromatography for further purification. 
 
 






in cpm x103 
Immunosuppression 
in %    p value 
Unt.PHA+PBMC 114.2±3.3 0  
DMSO 
107.8±7.0 5.7+ 4.7 NS 
50% MeOH /H2O 
EXT 
99.7±5.0 12.5 ± 9.1 NS 
Hex EXT 114.5±1.9 -0.4 ± 2.8 NS 







Figure 3.2.2.1 Immunosuppressive effect of solvent extracts on PHA+PBMCs. 
The CH2Cl2 extract was shown to significantly suppress the LPR of the 
PHA+PBMCs (71.6 ± 0.8% p<0.05).  No effect was seen with DMSO, Hex EXT, and 






3.2.3     Immunosuppressive Effect of the Fractions Obtained 
Through Flash Column Chromatography  
 
The CH2Cl2 EXT was subjected to flash column chromatography as described 
in Section 2.1.3 (Materials and Methods). The flash column chromatography 
fractions were distinguished from each other based on the retention times (Rf) 
when analyzed by thin layer chromatography. Sixteen flash column 























PHA+PBMCs from one blood donor.  As testing of all 16 fractions involved a 
large amount of blood, this experiment was conducted only once but in a 
triplicate experimental set up. The immunosuppression experiments were 
conducted using concentrations of 4 µg/ml for each fraction. The results are 
shown in Figure 3.2.3.1. Fraction 7 (CMX-13’) had the highest (75%) 
immunosuppressive effect on PHA+PBMCs.  
 
Figure 3.2.3.1 Imunosuppressive properties of flash column chromatography 
fractions. Sixteen fractions were tested at a concentration of 4 µg/ml for their 
immunosuppressive properties. Fraction 7 (F7), showed 75% suppression of the 














To determine the potency of CMX-13’ as compared to the original CMX-13, the 























simultaneously on PBMCs from 3 individual donors in triplicates (Figure 
3.2.3.2). The immunosuppressive effects of CMX-13 and CMX-13’ on 
PHA+PBMCs were 70.9±14.5% and 91.6±7.1% respectively, that is, CMX-13’ 
was at least 20% more potent than CMX-13 at this concentration.  
Approximately 600mg of CMX-13’ was hence obtained and used for further in-
vivo and in-vitro studies. 
 
Figure 3.2.3.2  Comparative bioassay of flash column chromatography fractions 
CMX-13 and CMX-13’. CMX-13 and CMX-13’ were tested for their 
immunosuppressive properties at a concentration of 4 µg/ml.  CMX-13 had an 
inhibitory activity of 70.9±14.5% and CMX-13’ 91.6±7.1% on PHA-stimulated 


























Figure 3.2.3.3 shows a summary of the increase in immunosuppressive activity 
of the extracts after each step of purification. The immunosuppressive activity 
of the extracts ranged from 66.0% for the EtOAc extract of the crude herb to 
92.2 % after further purification by flash column chromatography. Only 600 mg 
(0.4% from the original mass) was obtained with 92.2% immunosuppressive 
bioactivity. The weights of the active extracts and the corresponding 
immunosuppressive potencies (% inhibition of LPR) are shown in Table 
3.2.3.1. 
Figure 3.2.3.3 Immunosuppressive bioactivity in bioassay-guided fractionation 
of CMX-13’.  The extracts were tested at a concentration of 4 µg/ml.  The 


























Table 3.2.3.1  Bioassay-guided fractionation of CMX-13’. The yield obtained from 
the roots after flash column chromatography was only 600 mg, which accounted 
for 0.4% from the total weight. 
 
 





Crude Herb 150   
EtOAc 15 10 66.0±5.5 
CH2Cl2 4.2 2.8 72.9±12.9 
Flash column 
chromatography 
fraction 7 (CMX-13’) 
0.6 0.4 92.2±11.6 
 
 
3.2.4   RP-HPLC and RP-TLC of CMX-13’ 
 
Two chemical experiments were conducted in order to confirm if the flash 
column fraction CMX-13’ and CMX-13 contained similar compounds.  RP-
HPLC and RP-TLC were employed in these comparative studies.  
 
RP-HPLC was conducted with a Nova-pack C18 Column of 4 µm pore size. 
Water and acetonitrile were used as the mobile phase with a flow rate of 0.6 
ml/min. CMX-13’ and CMX-13 were dissolved in 50% MeOH/Acetonitrile at a 
concentration of 5 mg/ml. The injection volume was set to 50 µl. The RP-HPLC 
chromatogram of CMX-13’ is shown in Figure 3.2.4.1. CMX-13’ was subjected 
to RP-HPLC for comparison studies with CMX-13. The compounds in CMX-13’ 
had a retention time from 25-40 minutes. CMX-13 had compounds with similar 
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retention times. The similarities of CMX-13 and CMX13’ were confirmed by the 
retention time of their RP-HPLC profiles.  
 
Figure 3.2.4.1 RP-HPLC Chromatogram of CMX-13’. Conditions; Novapack C18 
Column of 4µm pore size, Gradient: Water-Acetonitrile (100-0% to 0 -100%); Flow 



















3.2.5           Immunosuppressive Bioassay of RP-HPLC Fractions Derived 
From CMX-13  
                     
CMX-13 was subjected to RP-HPLC in order to isolate and purify the bioactive 
compounds for structure elucidation. The RP-HPLC conditions for CMX-13 
were optimized with water and acetonitrile as the mobile phase at a flow rate of 
0.6 ml/min. CMX-13 was dissolved in 50% MeOH/Acetonitrile at a 
concentration of 5.0 mg/ml and injected at a volume of 50 µl on a gradient run 
which lasted 70 minutes. 
 
The RP-HPLC eluents were collected based on the retention time in 8 fractions 
(CMX-13-1 to CMX-13-8). The retention of the fractions times are summarized 
in Table 3.2.5.1 and were collected automatically with a fraction collector. 
These fractions were named in order of appearance and are shown in the 
HPLC Chromatogram in Figure 3.2.5.1. The retention times of the compounds 
are listed in Table 3.2.5.1. Twenty RP-HPLC runs of CMX-13 using a solution 
of 5.0 mg/ml were conducted and the products were collected and freeze-dried. 
The products of the 20 runs were used in the immunosuppressive bioassay. 
 
Each collected fraction was re-analyzed by RP-HPLC. The RP-HPLC 
Chromatograms of the eight fractions obtained from CMX-13 (CMX-13-1 to 
CMX-13-8) are depicted in Figures 3.2.5.3-10. The re-injected fractions 
 100
generally reproduced the original retention time and CMX-13-1 was 
consistently present in all fractions (in small amounts) for some reason.  
 
The CMX-13 RP-HPLC fractions were tested for their immunosuppressive 
activity on PHA+PBMCs. This experiment was conducted in triplicates in one 
experimental set up, due to limited availability of the material. The 
immunosuppressive activity of the CMX-13 fractions is shown in Figure 3.2.5.2. 
CMX-13-1, CMX-13-4, CMX-13-5 and CMX-13-8 had significant 
immunosuppressive activity as shown in Table 3.2.5.2.  The RP-HPLC 
fractions CMX-13-1 and CMX-13-5 showed nearly 100% immunosuppression 
when compared to the DMSO-treated PHA+PBMCs.  
  
The RP-HPLC chromatograms of CMX-13-4 and CMX-13-8 are shown In 
Figures 3.2.5.6 and 3.2.5.10.  These CMX-13 fractions contained peaks with 
shoulders, which are indicative of the presence of more than one compound.  
 
The RP-HPLC chromatogram of CMX-13-1 is shown in Figure 3.2.5.3. CMX-
13-1 consisted of at least 3 different components, which was shown by the 
appearance of two peaks in the 1-5 minutes region and one peak in the 25-27 
minutes region. These 3 peaks implied that CMX-13-1 was a less pure fraction. 
The RP-HPLC chromatogram of CMX-13-5 had two peaks one more 
predominant than the other as shown in Figure 3.2.5.7. This implied that the 
 101
fraction CMX-13-5 was much purer than CMX-13-1. Therefore CMX-13-5 was 
selected for further structure elucidation experiments.   
 
CMX-13-5 was subjected to preliminary structure elucidation by NMR and LC-
Mass Spectrometry experiments. The CMX-13-5 fraction was subjected for a 
second time to RP-HPLC to remove impurities before conducting NMR 
experiments. However some impurities remained in the 1-5 minute region. This 
persistent impurity could be due to the susceptibility to biodegradation.  
 
Figure 3.2.5.1 RP-HPLC Chromatogram of CMX-13. Conditions; Nova-pack C18 
Column with 4µm in pore size, Gradient: Water-Acetonitrile (100-0% to 0-100%); 
Flow rate:0.6 ml/min.   
 


















Table 3.2.5.1 Retention times of RP-HPLC isolates from CMX-13. 
CMX-13 Fractions 
from RP-HPLC 
Retention time  
in minutes 
1 1.0 - 5.0 
2 25.0 – 27.0 
3 27.0 – 29.0 
4 29.0 – 31.0 
5 31.0 – 33.0 
6 33.0 – 35.0 
7 36.0- 37.0 
8 37.0 - 39.0 
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Figure 3.2.5.2 Immunosuppression of PHA+PBMCs by subfractions of CMX-13 
after RP-HPLC. PHA+PBMCs were treated with 4 µg/ml of each fraction. 


















































Table 3.2.5.2 Immunosuppression of PHA+PBMC by CMX-13 fractions isolated 







(cpm x 103) 
Suppression (%) p value 
Unt PHA+PBMC 76.2±8.2 0  
DMSO 75.3±3.5 -1.1± 11.2 NS 
CMX-13 9.3±7.6 99.8±0.2 0.05 
CMX-13-1 0.018±0.9 100.0±0.0 0.05 
CMX-13-2 84.1±5.1 -12.0±19.3 NS 
CMX-13-3 88.2±6.5 -20.0±20.4 NS 
CMX-13-4 24.4±21.4 72.8±23.2 NS 
CMX-13-5 0.021±0.0 100.0±0.0 0.05 
CMX-13-6 67.6±2.2 8.6±12.4 NS 
CMX-13-7 67.3±3.6 9.4± 12.4 0.275 
CMX-13-8 21.2±19.9 76.7±21.7 0.05 
 




































































































































































3.2.6  Reverse Phase Thin Layer Chromatography (RP-TLC) 
 
The 3 bioactive fractions CMX-13’, CMX-13 and CMX-13-5 were subjected to 
RP-TLC. The solvent system used was 90% EtOAc/ MeOH. CMX-13’ produced 
one spot at Rf of 0.40, CMX-13 6 spots, and CMX-13-5 3 spots. The 3 samples 
produced a common spot at Rf = 0.40. The results are listed in Table 3.2.6.1. 
The single spot produced by CMX-13’ by RP-TLC shows that this fraction is the 
least complex mixture of compounds.  





Rf CMX-13 Rf CMX-13-5 Rf CMX-13’ 
1 0.72 0.72  
2 0.64 0.64  
3 0.6   
4 0.55   
5 0.40 0.40 0.40 





3.2.7   NMR Studies of CMX-13-5 
 
The 1H-NMR spectrum for CMX-13-5 and is shown in Figure 3.2.7.1. CMX-13-5 
from all the fractionated collections was dissolved in deuteriated MeOH. 
Impurities remained in the CMX-13-5, and this made data analysis difficult. 
However, the total amount of material was not sufficient for complete spectral 
analysis. The spectrum (Figure 3.2.7.1) bore some resemblance to that of a 
reported peptide RA-VII (Figure 3.3.1).  
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Figure 3.2.7.1 NMR spectrum of CMX-13-5. (A) 500-MHz 1H-NMR  Spectrum  
of CMX-13-5 in deuteriated MeOH.  
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3.2.8       LC-Mass Spectrometry on CMX-13-5 
 
LC-Mass Spectrometry (LC-MS) was performed on CMX-13-5 samples, 
employing similar RP-HPLC settings as was used to purify CMX-13-5 from CMX-
13. Very low concentrations of CMX-13-5 were used for the analyses. The LC 
chromatogram of CMX-13-5 is shown in Figure 3.2.8.1A.  A single peak appeared 
at 27.07 minutes, which was close to the retention time of CMX-13-5. The 
molecules were ionized by Fast Atom Bombardment. The LC-MS analysis in 
Figure 3.2.8.1B shows m/z values of 270.2, 537.5 and 1003.5. 
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Figure 3.2.8.1 LC-Mass Spectrum of CMX-13-5: (A) RP-HPLC \chromatogram; 
(B) LC-Mass spectrum.  The LC-Mass spectrum suggested either a single molecule 
















3.3     DISCUSSION 
 
The extraction and purification of bioactive compounds from herbal medicines is 
laborious and time consuming. In some cases, such as the herb under 
investigation, RC, the bioactivity of the compounds is influenced by factors such 
as soil composition and seasonal changes.  Chemical synthesis allows the 
production of molecules with consistency, facilitating the production process of 
bioactive compounds. By employing chemical synthesis the whole process of 
purification and the problem of inconsistent behaviour of herbal preparations can 
be eliminated.  Hence this chapter focused on the characterization of the 
molecular structure of the active compound(s) extracted from RC. 
 
In our previous work we have shown that CMX-13, a plant-derived compound 
from the roots of RC, has significant immunosuppressive properties.  In the first 
phase of the work in this chapter, we attempted to identify the bioactive 
molecule(s) in CMX-13, and to elucidate the structure(s) of the molecule(s).  In the 
second phase, we isolated sufficient amounts of CMX-13’ following the same 
procedure as for the isolation of CMX-13 for the in-vitro and in-vivo experiments in 
subsequent chapters, and showed that CMX-13’ comprised an active component 
similar to that of CMX-13. 
 
The persistent difficulty in our work was in obtaining sufficient amounts of RC with 
significant bioactivity from one single source.  We found that batches of roots 
possessed immense variability in immunosuppressive properties, ranging from 
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little or no immunosuppressive properties to 30-40% immunosuppression at most. 
The group of Itokawa and co-workers have previously shown that plants produced 
different amounts of compounds depending on factors such as season and soil 
composition [Itokawa et al.,1984]. It was difficult to trace down the geographical 
sources as well as the season the roots of RC was harvested. As several batches 
of RC were tested and shown to have no immunosuppressive bioactivity, one 
reason could be that these batches were not harvested at the right season when 
synthesis of compounds with immunosuppressive activity in the plant was 
occurring. Another second possibility is that the particular batch of herb was 
grown on a soil composition that did not lead to production of the relevant 
compound in the herb. In some cases the batches of RC were a mixture of 
several other different subspecies [Itokawa et al, 1984]. These factors made it 
very difficult to find batches of RC with sufficient immunosuppressive bioactivity. 
 
New batches of RC roots were subjected to similar bioassay-guided fractionation 
as employed for the isolation of CMX-13. CMX-13’ was isolated and purified from 
these new batches, and was shown to have similar immunosuppressive 
properties as CMX-13. CMX-13 and CMX-13’ were both subjected to RP-HPLC 
and RP-TLC.  The RP-HPLC analysis showed that CMX-13 and CMX-13’ 
contained compounds that have similar retention times. The compounds in the 
RP-HPLC chromatograms of CMX-13’ and CMX-13 appeared in the time interval 
of 25-40 minutes, see Figure 3.2.4.1 and Figure 3.2.5.1. The retention time of the 
fraction CMX-13-5 was between 31–33 minutes, which was well within the 25-40 
minutes range, as shown in Figure 3.2.5.7.  RP-TLC studies of CMX-13, CMX-13-
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5 and CMX-13’ showed the presence of one spot with the same Rf value (0.4).  
We concluded from the RP-HPLC, RP-TLC and the immunosuppressive 
bioassays that CMX-13’ and CMX-13 consisted of at least one common 
compound. These results led us to conclude that CMX-13’ and CMX-13 
comprised similar active compounds.  Hence CMX-13’ was subsequently utilized 
for in-vitro and in-vivo experiments.   
 
RP-HPLC revealed that CMX-13 contained a mixture of possibly 8 or more 
compounds. These compounds were isolated (some impurely) and tested for their 
immunosuppressive properties. Each experiment was conducted in triplicates.  
Two RP-HPLC fractions of CMX-13, named CMX-13-1 and CMX-13-5 had 100% 
immunosuppressive properties, as shown in Figure 3.2.5.2.  Our results showed 
that these CMX-13-1 and CMX-13-5 were at least as potent as CMX-13 and 
CMX-13’.  A point to note here was that there was some variability in the PHA-
stimulated lymphoproliferative response of PBMCs from different donors, and this 
probably accounted for the variability in their response to the suppressive effects 
of CMX-13 as seen in the different experiments.  One of the factors which 
influenced the variability in lymphoproliferative response was the age of the 
healthy blood donors, as older donors had poorer response to PHA-stimulation. 
Hence, only those donors who were within the age group of 18-30 years were 
utilized as the lymphoproliferative response was more consistent. 
 
RP-HPLC fraction CMX-13-5 contained fewer impurities than CMX-13-1 as shown 
in the RP-HPLC profiles of CMX-13-1 and CMX-13-5 in Figure 3.2.5.2 and 3.2.5.7 
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respectively. Therefore we attempted to elucidate the structure of CMX-13-5 by 
1H-NMR and LC-Mass spectrometry. The 1H-NMR spectrum of CMX-13-5 was 
shown to resemble the 1H-NMR spectra of a bicyclic hexapeptide isolated by the 
group of Itokawa and co-workers [Itokawa et al., 1992; Itokawa et al., 1993]. 
CMX-13-5 produced 3 spots on RP-TLC analysis, signifying the presence of 
impurities. This has hindered the structure elucidation experiment.  Subsequent to 
our work, our collaborators were able to analyze the structure of the purified 
bioactive compound in CMX-13’ (using material from the same source) and 
showed that the bioactive compound in CMX-13’ was identical to a compound 
previously identified by Itokawa and co-workers, namely, RA-VII (Figure 3.3.1). 
 
We isolated approximately 600mg of CMX-13’ from RC employing the same 
bioassay-guided fractionation procedure for the isolation of CMX-13 (i.e. CMX-13 
and CMX-13’ were both flash column chromatography fractions). However, CMX-
13’ showed an immunosuppressive activity of 91.7±7.1%, which was higher than 
the immunosuppressive effect of CMX-13, (at 70.9±14.5%). Chemical 
experiments revealed that CMX-13’ was a less complex mixture than CMX-13 
(Figures 3.2.4.1. and 3.2.5.1). The presence of fewer impurities may be the 
reason for the apparent higher activity of CMX-13’ as these would have a direct 
effect on the concentration of the bioactive compounds. This observed difference 
in purity was also illustrated by RP-TLC analysis. In the RP-TLC analysis, 6 spots 
appeared in the CMX-13 sample while CMX-13’ produced only 1 spot at Rf=0.4. 
The spot at Rf=0.4 was seen in both the CMX-13 and CMX-13’ samples.  
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Elucidation of the complete molecular structure of the bioactive compound CMX-
13-5 was difficult, mainly because of the complexity of the molecule, persistent 
impurities and the presence of analogs.  We have shown that CMX-13-5 was a 
bicyclic hexapeptide, and our collaborators have shown that this was identical to 
RA-VII as previously identified by Itokawa and co-workers (Figure 3.3.1).  
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Figure 3.3.1  Structure of RA-VII as described by Itokawa and co-workers  
(Itokawa et al, 1993).  
                                                                            













CHAPTER 4 EFFECT OF CMX-13 ON CELL-CYCLE EVENTS AND 
APOPTOSIS 
 
4.1 INTRODUCTION  
 
 
Two distinct mechanisms that direct cell death are known: programmed cell death 
(PCD) and necrosis. The major differences between PCD and necrosis are in the 
morphological changes, the mechanism and the stimuli that trigger these 
processes [Searle et al., 1982; Arends et al., 1990; Wyllie, 1986; Wyllie, 1993; 
Wyllie et al., 1980]. PCD occurs via the apoptotic or paraptotic mechanisms. 
Apoptosis or physiological cell death [Kerr et al., 1972] is only one of the 
mechanisms leading to PCD, though it is often equated with PCD. [Schwartz et 
al., 1993; Sperandio et al., 2000].  
 
Cellular necrosis is a passive process which occurs when cells sustain severe and 
sudden injury and is referred to as accidental cell death [Searle et al., 1982; 
Cohen, 1993]. In contrast, apoptosis is an intrinsically programmed active process 
involving the de novo synthesis of proteins. Morphologically, necrosis involves 
dissolution of DNA (karyolysis), vacuolization and eventual rupture of the plasma 
membrane resulting in cell lysis, and subsequent induction of the inflammatory 
process. Apoptosis, on the other hand, involves nuclear fragmentation via the 
activation of endonucleases secondary to an increase in intracellular calcium, 
without vacuolization of cytoplasm and formation of apoptotic bodies and hence 
absence of release of cellular organelles, or elicitation of an inflammatory 
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process. The distinct morphological changes that occur during necrosis and 
apoptosis are as illustrated in Figure 4.1.1.  
Figure 4.1.1. Morphological changes during apoptosis and necrosis. Shrinkage, 
blebbing, fragmentation and the formation of apoptotic bodies are significant 
characteristics of apoptosis. During necrosis, the cell swells followed by breaking 




































The molecular mechanism of apoptosis is complex, involving different pathways, 
which overlap. The distinct pathways are tissue-specific and dependent on the 
stimulus. Several ligand interactions, hormone stimulation, growth deprivation and 
many other triggers lead to apoptosis [Planey et al., 2000].  Despite the various 
pathways by which apoptosis is stimulated, a common molecular mechanism is 
activated. Upon activation of apoptosis a general process occurs in the following 
sequence: 
1) Receptor activation 
2) Cytochrome c/Apaf-1 complex formation on the mitochondria [Planey et 
al., 2000; Yoshida et al., 1998].  
3) Decreasing mitochondrial potential is the point of no return for the cell 
undergoing apoptosis [Bedner et al., 1999]. 
4) Activation of cysteine proteases that cleave cellular substrates at 
specific aspartate residues, termed caspases [Alnemri et al., 1996], 
leading to cleavage of apoptosis-related proteins [Los et al., 1999]. 
Major differences are found in different cell types and tissues in the 
pathway of caspase activation [Salvesen et al., 1997].  
5) PS exposure due to "flipping" from the inner side of the cell membrane 
to the outer side [Fadok et al., 1992; Savill et al., 1993]. 
6) Morphological changes like blebbing of the cell membrane, cytoplasmic 
compaction, shrinkage of total cellular volume [Bedner et al.,1999].  
7) DNA fragmentation and condensation, one of the major hallmarks of 
apoptosis, is the last process in the apoptotic cells before the 
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membrane starts to bleb and the vesicles are digested by macrophages 
[Cohen 1992; Cohen et al 1993]. 
 
Apoptosis is important in the development and functions of many biological 
systems, including regulated cell death in the developing embryo [Searle et al., 
1982], deletion of autoreactive T-cells clones in the thymus [Shi et al., 1989; 
Mustelin and Altman, 1993] and senescence of neutrophil polymorphs [Savill et 
al., 1993].  Additionally, apoptosis of neutrophil polymorphs occur as a response 
to treatment with physiologically-regulated hormones like glucocorticoids [Wyllie 
and Morris, 1982; Wyllie et al., 1986; Ashwell et al., 2000; Planey et al., 2000] or 
as a cellular response to non-physiological stimuli [Raff, 1992].   
 
Apoptosis is pivotal in tissue homeostasis and serves often as a counterbalance 
to cell proliferation [Los et al., 1999; Piacentini et al., 1993;van Parijs et al., 1998]. 
Genes involved in apoptosis and cell proliferation are closely linked, as illustrated 
by the relationship between proto-oncogenes, oncosuppressor genes and 
caspases [Mountz et al., 1994; Los et al., 2001]. The oncosuppressor gene p53, 
which enhances apoptosis [Talal, 1994; Colombel et al.,1992], operates at 
different points along the pathway leading to apoptosis [Mountz et al., 1994].  One 
role of the oncosuppressor gene p53, may be to initiate apoptosis by causing cell-
cycle arrest at the G1/S phase in cells expressing c-myc [Wyllie, 1993; Yu et al., 
1997; Lane, 1992]. The myc protein, derived from the c-myc gene, can act as a 
bivalent regulator, determining either cell proliferation or apoptosis, depending on 
whether the cell-cycle is supported by growth factors or whether it is limited by 
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growth factor deprivation or treatment with other agents leading to cell-cycle 
blockade [Evan et al., 1992].  In-vivo, c-myc expression has been proposed to be 
associated with a “high turnover” state where both cell proliferation and apoptosis 
co-exist [Wyllie, 1993]. Other oncogenes, such as bcl-2, inhibit apoptosis, 
converting this “high turnover” state into rapid population expansion [Terui et al., 
1995; Reed et al., 1992; Mazel et al., 1996].  Recently, caspases have been 
found to be involved not only in the process of apoptosis itself, but also in the 
control of cell cycle progession [Los et al., 2001].   
 
In the immune system, apoptosis occurs during the development of lymphocytes 
and is also important in the regulation of normal immune responses [van Parijs et 
al., 1998]. Immature T-cells that recognize autoantigens are removed in the 
thymus via two main selective processes, namely negative selection and positive 
selection. Negative selection is an apoptotic process responsible for the 
elimination of CD4-CD8- cells in the mouse thymus [Nikolic-Zugic, 1991; Pircher et 
al., 1989; Shi et al., 1989; Mustelin et al., 1993]. Positive selection of T-cells 
involve the selection of immature T-cells which interact with the MHC expressed 
in the thymus, and only those T-cells which attach to this ligand are selected, and 
survive [Sha et al., 1988]. T-cells that escape negative selection populate the 
periphery. The failure of these T-cells to undergo negative selection and 
consequently apoptosis, may be related to the low affinity for the MHC complex 
[Guerder et al., 1996].  In both humans and animal models of autoimmunity, 
defective apoptotic mechanisms in the immune system may have a role in the 
genesis of disease [Mountz et al., 1994; Emlen et al., 1994].  The oncogenes p53, 
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bcl-2 [Reap et al., 1995] and c-myc have all been found to be abnormally 
expressed in animal models of autoimmunity [Mountz et al., 1994].  
 
Mutations in the Fas cell surface (death) receptor, the FasL [Watanabe et al., 
1992; Reap et al., 1995] and the anti-apoptotic bcl-2 genes [Kroemer, 1997], have 
been linked to the development of lupus-like systemic autoimmune disease in 
mice and some humans. In lymphocytes, Fas, FasL [Sakata, et al 1998a] and bcl-
2 molecules regulate two distinct apoptotic pathways [van Parijs et el, 1998; 
Strasser, 1995].  Fas/APO-1 (CD95) is a cell surface molecule belonging to the 
TNF superfamily and induces apoptosis in several cell lines [Sakata, et al 1998b], 
including lymphocytes [Strasser et al., 1991]. FasL is a type II transmembrane 
protein predominantly expressed on activated CD8 and CD4 Th1 T-cell subsets.  
In normal situations, autoreactive T-cells are eliminated in the germinal centers of 
secondary lymphoid organs via the Fas-FasL apoptotic pathway, resulting in 
immune tolerance [Nagata and Suda, 1995; Singer et al., 1994; van Parijs et al., 
1998].  Defects in either Fas or FasL result in acceleration of murine lupus-like 
diseases.  In humans two mutations in the Fas gene [Fisher et al., 1995; Rieux-
Laucat et al., 1995; Rathmell et al., 1995] and the FasL gene [Wu et al., 
1996;Vaishnaw et al., 1999a; Vaishnaw et al., 1999b] have been found in patients 
with autoimmune lymphoproliferative syndrome, however mutations in Fas or 
FasL have not been found in all patients with SLE, neither has there been any 
consistent finding of a defect in the expression or function of the receptor in most 
patients [Mysler et al., 1994].   
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One of the current hypotheses for the occurrence of SLE in humans is based on 
the finding of high levels of sFas in the serum of SLE patients [Rose et al., 1997; 
van der Linden et al., 2001; Sato et al., 2000].  sFas is a variant of the receptor 
molecule which lacks the transmembrane segment.  Binding of sFas to FasL 
blocks the interaction of FasL with the Fas antigen, inhibiting apoptosis of auto-
reactive lymphocytes [Cheng et al., 1994; Cheng et al., 1996; Papo et al., 1998]. 
The surviving CD4+ lymphocyte subset becomes the driving force for stimulation 
of B-cell hyperreactivity.  These B cells produce IgG autoantibody, leading to 
autoantibody-mediated responses [Kotzin, 1996; Suda and Nagata, 1997]. The 
proposed molecular mechanism is depicted in Figure 4.1.2. 
 
However, this hypothesis is still controversial, as not all studies were able to 
demonstrate the relationship between inhibition of the Fas-FasL pathway and 
apoptosis in patients with SLE [Nozawa et al., 1997; Suda and Nagata, 1997].  In 
fact, several studies have shown that the Fas-FasL pathway of apoptosis was not 
defective in the lymphocytes of SLE patients [McNally et al., 1997; Carrichio et al., 
1999].  On the contrary, accelerated in-vitro apoptosis of SLE lymphocytes have 
been described [Emlen et al., 1994; Lorenz et al., 1997; Perniok et al., 1998; 





Figure 4.1.2.  Blockade of the Fas apoptosis pathway by sFas results in SLE. In  
normal healthy individuals, apoptosis is triggered by binding of FasL to Fas 
antigen. In SLE, the Fas apoptosis pathway is inhibited following binding of sFas 























However, there has not been consistent evidence of upregulation of apoptotic 
genes in PBMCs of SLE patients.  On the other hand, increase in the expression 
of the anti-apoptotic bcl-2 gene has been demonstrated in autoimmune murine 
models [Strasser et al., 1991].  Additionally, increase in lymphocyte Fas and 
intracellular bcl-2 expression, as well as serum sFas have been observed in SLE 
patients [Graninger et al., 2000; Mehrian et al., 1998; Aringer et al., 1994; Lorenz 
et al., 1997], suggesting that there is a block in the apoptotic mechanism in the 
PBMCs of SLE patients.  In fact, current therapy for SLE patients includes the use 
of immunosuppressive drugs that induce apoptosis [Amano et al., 2000; Dooley et 











mechanism in the PBMCs of SLE patients may be effective as a form of therapy 
[Sakata et al., 1998a; Seki et al., 1998].  
 
We have previously shown that CMX-13 was able to suppress PHA-stimulated 
lymphoproliferative responses and immunoglobulin production, inhibit the 
expression of T-cell activation markers CD25 and HLA-DR [Yap et al., 1993], as 
well as inhibit T-cell colony formation [Yap et al., 1998; Yap et al., 1999].  In our 
earlier studies on the possible mechanisms of action, CMX-13 did not show any 
inhibitory effects on IL-2 and IFN-γ mRNA expression, suggesting that its 
mechanism of action is different from that of cyclosporine [Zuo et al., 2000].   As 
there is strong evidence that dysregulation of apoptosis in the immune regulatory 
cells could have a role in the genesis of SLE, this chapter examined the effect of 
CMX-13 on: 
1) Cell proliferation in Jurkat cells, a human leukaemic CD4+CD8- T-cell line; 
2) Cell cycle progression in Jurkat cells, and PBMCs isolated from 20 SLE 
patients and age/sex-matched normal healthy controls;   
3) Apoptotic events in both Jurkat cells, and PBMCs derived from SLE 
patients and normal controls, using Annexin-V and DNA fragmentation 
assays.   
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4.2        RESULTS 
 
 
4.2.1  Inhibition of Jurkat Cell Proliferation by CMX-13  
 
Jurkat cells are derived from a human leukaemic CD4+CD8- T-cell line, and exhibit 
spontaneous cell proliferation without the need for mitogenic stimulation.  Jurkat 
cells were cultured with and without 0.004% v/v DMSO, the solvent for CMX-13, 
as the negative control.  CMX-13 was added in concentrations of 1, 2, 4 and 8 
µg/ml to determine the effect on cell proliferation.  Cell proliferation was measured 
by [3H]-thymidine incorporation [Morsaki et al., 1992; Morsaki et al., 1994; Covas 
et al., 1996].  Cell viability, as measured by trypan blue exclusion, was greater 
than 90% in all experiments.  
 
The effect of serial dilutions of CMX-13 on Jurkat cell proliferation is illustrated in 
Table 4.2.1.1.   CMX-13 was found to significantly inhibit Jurkat cell proliferation 
(99.5 to 99.9%) in all the dilutions tested (1, 2, 4, 8 µg/ml).  The solvent, DMSO, 
did not have any effect on Jurkat cell proliferation.  As cell viability remained 
greater than 90% for all CMX concentrations, the concentration of 4 µg/ml was 
selected to perform the subsequent experiments on Jurkat cell proliferation, cell-
cycle progression and apoptosis. 
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% Inhibition of Cell 
Proliferation 
% Cell Viability 
Jurkat cells in R10 131227 ± 5674  >90 
DMSO  128396 ± 2864 2.2 ± 0.0 >90 
8 µg/ml CMX-13 67 ± 11 99.9 ± 0.0 >90 
4 µg/ml CMX-13 811 ± 7 99.9 ± 0.0 >90 
2 µg/ml CMX-13 156 ± 84 99.9 ± 0.0 >90 
1 µg/ml CMX-13 598 ± 187 99.5 ± 0.1 >90 
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4.2.2   Effect of CMX-13 on Cell-Cycle Progression in Jurkat cells and  
  PBMCs 
 
The effect of CMX-13 on cell-cycle progression was studied in Jurkat cells and 
PBMCs isolated from both normal controls and SLE patients using flow cytometric 
analysis of the nuclear DNA contents following PI staining.  Jurkat cells were 
treated with 0.004% DMSO (solvent for CMX-13 as the negative control), 4 µg/ml 
CMX-13 and CH a known apoptosis-inducer [Davidoff et al., 1992; Gong et al., 
1993; Dhein et al., 1995] for 24 hrs in cell culture medium and analyzed by flow 
cytometry for DNA content following PI staining.  Jurkat cells treated with DMSO 
had a normal cell-cycle pattern, with the following distribution pattern: 57.0±5.5% 
in G0/G1 and 34.0±6.7% in the S phase. Cells treated with CMX-13 and CH had a 
markedly increased population in the “sub-G1” area, a distinct hypo-diploid cell 
population consisting of apoptotic cells. The cell population in the G0/G1 phase 
decreased when treated with CMX-13 (35.7±5.39%) or CH (31.6±16.9%), as 
compared to the Jurkat cells cultured in DMSO (57.0.±5.5%) (p<0.001).  An 
increase of cells in the “sub-G1” or apoptotic phase were evident in cells treated 
with CMX (33.7±4.3%) and CH (54.6±17.9%) as compared to the DMSO-treated 
cells (7.4±9.0%) (p<0.02) (Figure 4.2.2.1).  Unlike the CH-treated cells where the 
increase in the apoptotic fraction was associated with cell cycle arrest in the G0/G1 




Figure 4.2.2.1  Representative DNA distribution histograms of Jurkat cells 
incubated with DMSO, CMX-13 and CH for 24 hrs. The cells incubated with DMSO 
had a normal cell-cycle pattern with very few apoptotic cells, whereas following 

























Table 4.2.2.1 Jurkat cells incubated with DMSO, CMX-13 and CH in different phase 
of the cell-cycle.  CMX-13 and CH induced apoptosis in  Jurkat cells after 24 hours 
incubation.  
 
Treatment Apoptosis  
(Sub-G1) (%) 
G0/G1 (%) S (%) G2/M (%) 
DMSO 
(0.004%) 
7.4 ± 9.0 57.0 ± 5.5 34.0 ± 6.7 1.4 ± 1.9 
 CMX-13 
(4 µg/ml) 
33.7±  4.3* 
 
35.9 ± 5.9# 27.7 ± 8.0 2.4 ± 2.4 
  CH 
(1.4 mg/ml) 
54.6 ± 17.9* 
 
31.6 ± 16.9# 12.8 ± 10.5 
 
0.8 ± 1.5 
*Comparing to DMSO-treated cells (negative control), p<0.02 






Apoptotic G0/G1 S G2/M
CMX-13 
Apoptotic  G0/G1 S G2/M
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The effect of CMX-13 on PBMCs stimulated with 0.5 µg/ml PHA was studied after 
culture for 72 hours in the following conditions: PHA control, control with DMSO 
0.004% (solvent for CMX-13), CMX-13 at dilutions of 4.0 µg/ml and 2.0 µg/ml and 
CsA 2 µg/ml and 0.078 µg/ml.  A negative control consisting of unstimulated 
PBMCs was also included.  The cells were subsequently stained with PI for 
analysis by flow cytometry, and the percentages of cells at the G0/G1, G2/M and S 
phases were determined.  Nearly all (99.8%±0.30) of the unstimulated PBMCs 
remained in the G0/G1 phase (Figure 4.2.2.2).  Table 4.2.2.2 shows the effect of 
CMX-13 and CsA on the percentages of cells (mean±SD) in the different phases 
of the cell-cycle.  The apoptotic populations in these cell cultures were low. 
 
PHA stimulation of PBMC (DMSO control) resulted in an 18.4% decrease in the 
percentage of cells in the G0/G1 phase, with a shift to the G2/M and S phases 
(Figure 4.2.2.2).  Addition of CMX-13 in both concentrations resulted in a 
complete inhibition of cell-cycle progression, similar to CsA at 2 µg/ml (Figure 
4.2.2.3).  Hence these results suggest that the immunosuppressive effect of CMX-
13 could be related to negative regulation of cell-cycle progression. 
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Table 4.2.2.2 Effect of CMX-13 on PHA-stimulated PBMCs. Data expressed as  
percentage of cells in each cell cycle phase. 
 
Cell Culture G0/G1 (%) G2/M (%) S (%) 
PBMC 98.9 ± 0.3 0.5 ± 0.04 0.6 ± 0.3 
PBMC+PHA+ DMSO 80.5 ± 11.0* 3.5 ± 2.5* 16.0 ± 8.9* 
PBMC+PHA+ 
CMX-13 (4.0 µg/ml) 
99.5 ± 0.1* 0.3 ± 0.2* 
 
0.2 ± 0.03* 
 
PBMC+PHA+ 
CMX-13 (2.0 µg/ml) 
99.2 ± 0.20* 0.6 ± 0.2* 0.2 ± 0.07* 
PBMC+PHA+    
CsA (2.0 µg/ml) 
96.0 ± 1.5* 
 
0.8 ± 0.4* 
 
3.2 ± 1.4* 
 
PBMC+PHA+  
CsA (0.078 µg/ml) 
86.9 ± 8.8 2.8 ± 2.3 10.3 ± 6.5 




























Figure 4.2.2.2. DNA distribution histograms of cell-cycle progression in 
unstimulated and PHA-stimulated PBMCs.  Most of the unstimulated PBMCs 
remained in the G0/G1 phase, whereas PHA-stimulated PBMCs had a typical cell-































Unstimulated PBMCs  PHA stimulated 
PBMCs 
G0/G1 G0/G1    S       G2/M 
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Figure 4.2.2.3. DNA distribution histograms of cell-cycle progression in PHA- 
stimulated PBMCs with CMX-13 and CsA.  Complete inhibition of cell-cycle  


























PHA Stimulated  
PBMCs + CMX-13 
PHA Stimulated  
PBMCs + Cyclosporin A 
Apoptotic G0/G1 S   G2/M  Apoptotic  G0/G1  S   G2/M  
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4.2.3            Effect of CMX-13 on DNA Fragmentation in Jurkat cells and 
PBMCs 
 
The major biochemical hallmark of apoptotic cell death is the cleavage of 
chromosomal DNA at inter-nucleosomal sites into fragments or multiples of about 
180 bp by endonucleases [Arends et al., 1990; Cohen 1993; Bedner et al., 1999]. 
This phenomenon causes the hypodiplod peak in the DNA histograms of the cell-
cycle progression analysis.  Another method of studying DNA fragmentation is by 
extracting the fragmented DNA and subjecting it to gel electrophoresis.  
 
Jurkat cells were treated with 0.004% DMSO, 4 µg/ml CMX-13 and 1.4 mg/ml CH 
for 4, 6, and 8 hours.  DNA fragmented bands appeared after 4 hours of treatment 
with CMX-13 and CH.  This phenomenon was not observed in the DMSO cells at 
all the time points studied as shown in Figure 4.2.3.1.  The appearance of the 
DNA ladder indicated that CMX-13 induces apoptosis as early as 4 hours. 
 
Similarly PBMCs from 3 healthy individuals were incubated for 24 hrs with 0.004% 
DMSO, 4 µg/ml CMX-13 and 1.4 mg/ml CH.  DNA fragmented bands appeared 
after treatment with CMX-13 and CH as shown in Figure 4.2.3.2. This 
phenomenon was not observed in the DMSO-treated cells.  Hence CMX-13 also 
induced apoptosis in PBMCs.  
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Figure 4.2.3.1. DNA fragmentation of Jurkat cells after incubation with CH and  
CMX-13 for 0, 4, 6 and 8 hours.  Fragments in the treated cells occurred after 4  
hours incubation.   
 





   
   
   
   




   












   
   
   
   




   










   
   
   
   




   








Figure 4.2.3.2. DNA fragmentation of PBMCs after incubation with CH and CMX-13  
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4.2.4        Effect of CMX-13 on PS Exposure in Jurkat cells  
 
Jurkat cells were treated with 0.004% DMSO, 4 µg/ml CMX-13 and 1.4 mg/ml CH 
for 8 and 24 hours and stained with Annexin-V FITC and PI.  Figure 4.2.4.1 shows 
the results of the flow cytometric analysis of Jurkat cells following Annexin V-FITC 
and PI staining in a representative experiment.  The cells were gated (R1 and R2) 
as shown in the upper panel.  In the lower panel, the lower left quadrant shows 
the viable cells (mainly R1), which were FITC negative/ PI negative.  The lower 
right quadrant represents the early apoptotic cells (FITC positive/PI negative, R1 
and R2).  The upper right quadrant represents the late apoptotic cells (FITC 
positive and PI positive, mainly R2).  The percentage of total apoptotic cells was 
given by the formula: 
                  Cells in the Lower Right Quadrant + Upper Right Quadrant 
Total Gated Cells in R1 and R2 
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Figure 4.2.4.1. Apoptosis of Jurkat Cells induced by CH and CMX-13 after 24-hour 
culture (representative experiment).  Flow cytometric analysis of Jurkat cells 
following Annexin V-FITC and PI staining. The upper panels show the dot plots of 
the gated cells (R1 and R2) where the cell debris and necrotic cells were excluded 
based on FSC and SSC.  An increase of apoptotic cells occurred following 

























Figure 4.2.4.2 shows the increase in the percentage of apoptotic population after 
8 and 24 hours of treatment.  After 8 hours of incubation with 0.004% DMSO, the 
spontaneous apoptotic cell population was 21.3±2.9%, whereas treatment with 
1.4 mg/ml CH resulted in a significant shift of the apoptotic population to 
68.0±0.0% (p<0.04).  A similar population shift was caused by CMX-13 treatment 
with increase of the apoptotic population to 53.0±9.5% (p<0.05).  The apoptotic 
population increased significantly when treated for 24 hours: DMSO-treated cells 
40.1±2.1%; CMX-13-treated cells 89.3±1.2% (p<0.005); CH-treated cells 
96.0±0.0% (p<0.04).   
Figure 4.2.4.2  Percentage of apoptotic cells after 8 and 24-hour cultures, as 
determined by Annexin V-FITC and PI-staining of Jurkat cells following incubation  
with 4 µg/ml CMX-13 and 1.4 mg/ml CH.  Significant increase of apoptotic cells after  











































4.2.5 Apoptosis induced by CMX-13 in PBMC of SLE patients. 
 
PBMCs were obtained from 20 SLE patients who fulfilled the criteria for SLE as 
defined by the American College of Rheumatology [Tan et al., 1982]. Disease 
activity in these patients were scored using two clinical scoring systems, SLE-
Disease Activity Index (SLEDAI) [Bombardier et al, 1992] and Systemic Lupus 
International Collaborating Clinics (SLICC) [Gladman et al, 1996].  In this group of 
20 patients, 8 (40%) had SLEDAI scores of > 2 and 5 (25%) had SLICC scores of 
> 2.  The individualized scores are listed in Appendices 4.1 and the SLICC and 
SLEDAI score in Appendix 4.2 and 4.3, respectively.  
 
As all of the SLE patients were on prednisolone as maintenance treatment, a 
dose-response experiment was conducted to examine the apoptotic effect of DEX 
on PBMCs in culture. Freshly isolated PBMCs from 3 normal controls were 
incubated with DEX at different concentrations (1000 µg/ml, 500 µg/ml, 100 µg/ml, 
5 µg/ml, 1.0 µg/ml, 0.5 µg/ml) for 24 hours, following which the percent apoptotic 













Experiment 2 Experiment 3 Mean ± SD p value 
Untreated 13.82 12.8 17.8 14.81±2.6 .011 
CH 53.4 70.33 66.28 63.33±8.8 .172 
1000 µg/ml 
DEX 
14.9 24.16 23.79 17.8±5.0 .376 
500 µg/ml DEX 11.95 17.67 22.18 16.08±3.89 .054 
100 µg/ml DEX 20.59 15.89 25.52 17.7±4.72 .097 
5 µg/ml DEX 20.1 14.69 21.26 16.7±3.5 .165 
1 µg/ml DEX 14.0 15.21 19.37 15.5±2.55 .170 
0.5 µg/ml DEX 14.08 17.22 23.46 16.5±3.9 .889 
 0.004% 
DMSO 
9.6 10.21 22.33 14.4±7.8 .501 
 
 
The percent of apoptotic cells was increased in DEX-treated PBMCs at a 
concentration of 1000 µg/ml (17.8±5.0%).  Although this was higher than 
Untreated PBMCs cultured in media (14.8±2.6%) or DMSO-treated cells (solvent 
control) (14.4±7.8), however this did not reach statistical significance. There was 
also no difference in percent apoptotic cells induced with the varying 
concentrations of DEX.  The dose-response curve is shown in Figure 4.2.5.1. On 
the other hand, the positive control, CH, at a concentration of 1.4 mg/ml induced 
apoptosis significantly (63.3+8.8%) when compared to the Untreated and DMSO-




Figure 4.2.5.1  Effect of DEX on apoptosis in PBMCs. PBMC from 3 healthy 
individuals were treated with 1000 µg/ml, 500 µg/ml, 100 µg/ml, 5 µg/ml, 1 µg/ml, 0.5 
µg/ml. CH at a concentration of 1.4 mg/ml was used as a positive control. DMSO at 








In separate experiments to compare the effect of CMX-13 on PBMCs from normal 
controls and SLE patients, PBMCs from the SLE patients were treated with 
0.004% DMSO, 4 µg/ml CMX-13 and 1.4 mg/ml CH for 24 hours and analyzed for 
apoptosis using flow cytometric analysis following Annexin-v FITC/PI staining.  
PBMCs were also obtained from normal healthy age/sex-matched controls, and 
treated with 0.004% DMSO, 4 µg/ml CMX-13, 1.4 mg/ml CH, 0.5 mg/ml DEX  
[Seki et al., 1998; Potter et al., 1999] and a combination of: 0.5 mg/ml DEX and 4 
µg/ml CMX-13. The DEX treatment in the control groups was included in order to 
take into consideration any possible effects corticosteroids may have on 
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Figure 4.2.5.2 shows representative flow cytometric histograms of PBMCs from a 
normal control.  In the lower panel, the percentage of cells in the early and late 
apoptotic stages is shown.  A significant increase of the total apoptotic population 
occurred when the cells were treated with CH (72.1±12.3%) or CMX-13 
(51.1±14.1%) compared to the DMSO-treated cells (37.3±20.5%) (p<0.05).  The 
DEX-treated cells (38.2±16.7%) did not exhibit an increase of the apoptotic 
population compared to the DMSO group (37.3±20.5%).  The combination of 4 
µg/ml CMX-13 and 0.5mg/ml DEX did increase the apoptotic population slightly 






























Figure 4.2.5.2  Representative flow cytometric histograms of PBMCs from a normal 
control.  Percent spontaneous apoptotic cell population incubated with DMSO was 
37%. Increase of the apoptotic population was observed following treatment with 



































Figure 4.2.5.3 shows the representative flow cytometric histograms of the PBMCs 
from a SLE patient.  In the cells incubated with DMSO, the spontaneous apoptotic 
population was 31.8±15.0%, whereas following incubation with CH and CMX-13, 
the apoptotic population increased to 63.2±21.0% and 44.3±15.7% respectively 
(p<0.05).   
 
Figure 4.2.5.3  Representative flow cytometric histograms of PBMCs from a SLE  
patient.  Percent spontaneous apoptotic cell population incubated with DMSO was  
32%. Increase of the apoptotic population was observed following treatment with  





























The mean percentages of apoptotic cells following incubation with CMX-13 or 
CH comparing with DMSO, the solvent control, are summarized in Table 
4.2.5.2 
Table 4.2.5.2  Percentage of apoptotic PBMCs in 20 SLE patients and age/sex- 
matched healthy controls after treatment with  CMX-13.  Values are expressed as  









DMSO 37.3±20.5 31.8±15.0 
CMX-13 51.1±14.1* 44.3±15.7* 
CH 72.1±12.3* 63.2±21.0* 
DEX 38.2±16.7  
DEX+CMX-13 44.3±16.0  
 
 
Paired analysis of the effect of CM on apoptosis in both normal controls and 
SLE patients is depicted in Figure 4.2.5.4.  There was a significant increase in 
the percentage of apoptotic cells in both the SLE and control PBMCs following 
treatment with CMX-13 (p<0.001).  This was in coordance with our DEX dose 
response experiment. 
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Figure 4.2.5.4  Effect of CMX-13 on apoptosis in PBMCs from SLE patients and 
age-sex matched healthy controls.  Paired analysis showed a significant 
increase in apoptotic cells following 24-hour incubation with CMX-13 in both 

























































Table 4.2.5.3 outlines the SLEDAI and SLICC scores of the individual patients, 
and the percentages of apoptotic cells present before and after incubation with 
CMX-13.  In Table 4.2.5.4 the SLEDAI/SLICC scores are tabulated with the 
medication the patients were on, the activity of the disease, the status of the 
kidney. With increasing SLE activity as determined by the SLICC score, an 
increase in the percentage of spontaneous apoptotic PBMCs was seen, 
although this did not reach statistical significance (r=0.40, p=0.08) (Figure 
4.2.5.5).  
Table 4.2.5.3  Total SLICC/SLEDAI scores of SLE patients and the percentage of 




SLEDAI SLICC Percent apoptotic PBMCs 
before CMX-13 treatment 
Percent apoptotic PBMCs 
after CMX-13 treatment 
1 0 1 13.8 12.0 
2 6 0 23.0 33.0 
3 0 1 31.0 45.0 
4 0 3 24.0 42.0 
5 4 0 34.0 46.0 
6 1 1 36.0 51.0 
7 0 2 29.0 38.0 
8 16 4 38.0 36.0 
9 0 0 74.0 71.0 
10 2 2 38.0 45.0 
11 4 2 27.0 50.0 
12 20 3 42.0 47.0 
13 0 3 54.0 68.0 
14 18 2 40.0 73.0 
15 0 1 5.7 24.0 
16 0 0 20.0 40.0 
17 2 1 35.0 32.0 
18 12 1 32.0 58.0 
19 0 2 13.0 24.0 
20 10 4 38.0 50.0 
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Table 4.2.5.4 Details of Patients. Disease Activity, Anti-DNA levels, Kidney 
disease from individual patients, Proteinuria levels and Medication during the 
time of assessment. (Prednisolone = PNL; Azathioprine = AZT; Cellcept = CC; 
Cyclosporine A = CsA; Hydroxychloroquine = HDCL) 
 
 












1 0 1 Active   PNL 3 mg om 
2 6 0 Remission   PNL 12 mg om 
AZT 50 mg om 
3 0 1 Active > 100   
4 0 3 Active  > 100  CC 500 mg bd 
CSA  100 mg bd 
PNL 5 mg om 
5 4 0 Remission  Renal transplant  
6 1 1 Active  Nephritis  
Class IV (c) 
Proteinuria 
 2.12 g 
 
 7 0 2 Active   AZT 50 mg om 
HDCL 200 mg om 
8 14 4 Active   PNL 10 mg om 
HDCL 200 mg om 
9 0 0 Remission 31  PNL 10 mg om 
HDCL 200 mg om 
10 2 2 Active 32  AZT (day 1,3,5,7) 
50 mg om 
AZT (day2,4,6)25 
mg om 
11 4 2 Active    
12 20 3 Active >100 Nephritis  
Class IV (c) 
Proteinuria  
11.06 g 
PNL 13 mg om 
HDCL 200 mg om 
13 0 3 Active  Proteinuria  
0.19 g 
HDCL 200 mg om 
PNL 50 mg om 
14 18 2 Active 72 Chronic  
renal failure  
Proteinuria 3.97 g 
PNL 3 mg om 
15 0 1 Active  Proteinuria  
120 mg 
 
16 0 0 Remission   AZT 50 mg om 
PNL 30mg om  
17 2 1 Active >100 Proteinuria 3.84 g PNL  15 mg om 
18 12 1 Active 41   
19 0 2 Active    






Figure 4.2.5.5  Correlation between SLICC score and baseline percent apoptotic  







































r = 0.40 




We have previously shown that the hydrophobic extract, CMX-13, of a 
Chinese herbal decoction used in the treatment of patients with SLE, 
inhibited lymphocyte proliferation following PHA stimulation.  In this 
chapter, we have shown that this phenomenon was also demonstrated in 
Jurkat cells, which is a CD4+CD8- T-cell line.  CMX-13 significantly 
inhibited spontaneous Jurkat cell proliferation by >99% in all the 
concentrations tested (1-8 µg/ml). 
 
In order to further elucidate the immunosuppressive action of CMX-13 on 
Jurkat cells, we examined its effect on cell-cycle progression as well as the 
induction of apoptosis, and compared this to CH, a known protein synthesis 
inhibitor.  Apoptosis is intimately linked to cell stimulation and proliferation [Van 
Parijs et al., 1998], and is initiated by ligand-receptor interactions that are 
highly regulated.  It can also result from the removal of growth factors that are 
necessary for sustaining cell proliferation. In Jurkat cell cultures, the 
percentage of spontaneous apoptotic cells is low, as the cells are proliferating 
actively.  CMX-13 was able to inhibit Jurkat cell proliferation, not by inhibiting 
cell-cycle progression, but by inducing spontaneous apoptosis in cells in the 
G0/G1 phase.  This effect of CMX-13 on apoptosis in Jurkat cells was confirmed 
by DNA fragmentation analysis and Annexin-V staining.  Apoptosis was 
induced at a very early phase, as was demonstrated by the “sub-G1” or 
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apoptotic peaks appearing in the cell-cycle analysis.  This mechanism of action 
was different from drugs such as CH, which induces apoptosis related to a 
G0/G1 cell-cycle arrest.     
 
There is a close linkage between the genes that determine cell proliferation on 
the one hand, and apoptosis on the other [Evan et al., 1992].  For example, c-
myc can act as a bivalent regulator and is able to induce either cell proliferation 
or apoptosis [Mountz et al., 1994].  In addition, both extra- and intra-cellular 
stimuli can induce apoptosis by triggering a group of intracellular cysteine 
proteases known as caspases [Thornberry et al., 1998].  Caspases are also 
thought to be involved in cell-cycle progression [Los et al., 2001] and cellular 
stress-related apoptosis [Planey et al., 2000].  Two distinct pathways of 
apoptosis have been described that induce the activation of caspases and 
other pro-apoptotic activities. One of the pathways leading to apoptosis is 
activation of caspase 8 upon binding of a death ligand on the cell membrane 
[Hakem et al., 1998].  The second pathway is related to cellular stress, 
whereby mitochondria release cytochrome c which binds to Apaf-1 [Zheng et 
al., 1999; Cecconi, 1999].  This complex activates caspase-9, which 
subsequently activates downstream caspases [Yoshida et al., 1998].  
Therefore further studies are required to determine if induction of apoptosis by 
CMX-13 is related to the caspase-8 or caspase-9 pathway.  
 
Defective apoptosis has been suggested to be an important mechanism in the 
pathogenesis of various autoimmune diseases [Mountz et al., 1994; Carrichio 
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et al., 1999; Papo et al., 1998].  Apoptosis is important for the immune system 
to regulate cell growth and terminate immune responses in order to ensure that 
overall the rate of division is balanced by cell death [Lorenz et al., 2001].  In 
SLE, one of the hypothesis is that dysregulation of apoptosis might be 
responsible for the induction of anti-nuclear antibodies, pathognomonic of the 
disease. In some patients, decreased apoptosis in SLE appears to be 
associated with increased production sFas molecule that is capable of 
inhibiting apoptosis after a stimulus to proliferate [Cheng et al., 1994], whereas 
other studies reported accelerated apoptosis of lymphocytes in SLE patients 
[Emlen et al., 1992; Lorenz et al., 1997]. This increased rate of apoptosis was 
not affected by treatment with corticosteroids [Emlen et al., 1992].  Similarly, in 
our SLE patients, the percentage of apoptotic cells was increased with 
increasing activity of the disease as measured by the SLICC score (Figure 
4.2.5.5). Although all of the patients were on corticosteroid treatment, this 
should not have affected the apoptotic rate, as addition of DEX to control 
PBMCs did not induce apoptosis (Table 4.2.5.2). 
 
A high threshold for DNA damage-induced apoptosis might also explain the 
presence of DNA mutations in T cells from SLE patients [Gmelig-Myeling et al., 
1992], where such mutations could lead to T cell death and increased release 
of non-degraded DNA by necrosis instead of apoptosis, contributing to the 
production of anti-DNA antibodies seen in this disease.  Apoptosis-induced 
nucleosomes constitute a unique reservoir of potentially immunogenic nuclear 
autoantigens.  In SLE, it has been postulated that there is defective 
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macrophage clearance of early apoptotic cells.  Hence binding of nuclear 
autoantigens to follicular dendritic cells in lymph nodes may provide a signal for 
autoreactive B cells, overriding the control mechanism of B-cell tolerance 
[Baumann et al., 2002]. 
 
We have shown that CMX-13 was able to induce apoptosis in Jurkat cells, but 
to a lesser extent than CH, a known apoptosis inducer.  In addition, its effect on 
cell-cycle progression was less.  Similarly, its apoptotic effect on PHA-
stimulated PBMC was less than that of CH, although it completely inhibited 
cell-cycle progression.  Hence the immunosuppressive mechanism of CMX-13 
could be partly related to its effect on apoptosis.  However further studies are 
required to elucidate other possible mechanisms of its immunosuppressive 
action, especially in the context of suppression of SLE activity, where increased 









CHAPTER 5 EFFECT OF CMX-13 ON THE MRL-lpr/lpr SLE MOUSE 
MODEL 
 
5.1   INTRODUCTION 
 
MRL-lpr/lpr mice spontaneously develop an autoimmune disorder with similar 
pathological features to human SLE.  The symptoms are characterized by 
lupus nephritis, the production of anti-double stranded DNA (dsDNA) and anti-
IgG or rheumatoid factor-specific autoantibodies, proteinuria, skin lesions at the 
back and the ear, and distorted cytokine levels [Andrews et al., 1978; Steinberg 
et al., 1978; Jonsson et al., 1987; Bigazzi and Rose, 1996; Theofilopoulos 
,1993].  The severity of the autoimmune disease increases with the age of the 
mice, with the majority dying of renal failure at 16-24 weeks of age.  A main 
characteristic of the MRL-lpr/lpr mouse is massive lymphadenopathy, an 
exclusive feature found in mouse SLE but not in human SLE, and is caused by 
a defective Fas molecule.   
  
The MRL-lpr/lpr SLE mouse model has a recessive gene defect [Cohen and 
Eisenberg, 1991] in the apoptotic Fas gene or the lymphoproliferative (lpr) gene 
located on chromosome 19 [Watanabe et al., 1992; Watson et al., 1992].  This 
mutation is caused by an insertion of a retrotransoposon element, Etn, in the 
intron between exon 2 and exon 3 [Adachi et al., 1993; Wu et al., 1993; Chu et 
al., 1993].  The lpr mutation leads to loss of functional Fas mRNA expression, 
consequently leading to non-production of the Fas protein (CD95) [Adachi et 
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al.,1993]. The dysfunctional Fas mRNA expression in the MRL-lpr/lpr mice is 
depicted in Figure 5.1.1.  Insertion of a full-length murine Fas cDNA has been 
shown to correct the dysfunctional Fas mRNA expression resulting in 
elimination of disease manifestations [Wu et al., 1994].  A second murine SLE 
model, the MRL-lpr/lprgld mouse has been described, consisting of a point 
mutation on the Fas ligand, with similar disease manifestations. 
Figure 5.1.1  Dysfunctional Fas gene expression in the MRL-lpr/lpr mouse.   
Insertion of the transposable element, Etn, in the fas gene located on mouse  











The development of autoreactive T-cells in the MRL-lpr/lpr SLE mouse model 
was thought to be a consequence of T cells escaping negative selection 
secondary to defective apoptosis caused by the deficient Fas molecule (CD95). 
However, recent studies have shown that negative selection of T- and B-cells is 
intact in the MRL-lpr/lpr mice [Rathmell and Goodnow, 1994].  The defective 
Fas molecule in the MRL-lpr/lpr SLE mouse model leads to defective cell death 
lpr FAS 
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of peripheral αβ T cells [Singer and Abbas, 1994; Renno et al., 1996], 
consequently resulting in expansion of double negative TCRαβCD3+CD4-CD8-
B220+ T-cells [Morse et al., 1982].  The presence of TCRαβCD3+CD4-CD8-
B220+ T-cells has been identified in the lymph nodes of the MRL-lpr/lpr mice 
leading to lymphadenopathy at the age of 13-14 weeks [Theofilopoulos et al., 
1979; Lewis et al., 1981; Morse et al., 1982; Wofsy et al., 1984; Murray et al, 
1990].  The contribution of these cells to the development of SLE has been 
investigated, but no direct link to the pathogenesis of other symptoms of SLE 
has been demonstrated except lymphadenopathy in the MRL-lpr/lpr mice 
[Singer and Abbas, 1994]. Nevertheless, these cells are a distinctive 
consequence of the lpr mutation.  
 
The TCRαβCD3+CD4-CD8-B220+ T-cells have unique characteristics, for 
example, they do not proliferate in-vivo [Sobel et al., 1995] or in-vitro [Budd et 
al., 1985], and they also fail to respond to IL-2 and other agents that activate T-
cells [Wofsy et al., 1981; Altman et al., 1981].  The origin of the CD4-CD8-
B220+ T-cells has been thought to be the lpr CD4+ T-cells.  Following the 
injection of CD4+ T-cells from B6 lpr mice into nude mice, the presence of 
TCRαβCD3+CD4-CD8-B220+ T-cells was observed [Santoro et al., 1987; 
Laouar and Ezine, 1994].  Hence the lpr CD4+ T-cells could play an important 
role in the development of SLE in the MRL-lpr/lpr mouse.  There is also 
evidence suggesting that these cells are resistant to apoptosis [Bossu et al., 
1993].  
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These TCRαβCD3+CD4-CD8-B220 T-cells are a rich source of proinflammatory 
cytokines including TNF-α and IFN-γ [Murray and Martens, 1990].  Moreover, 
MRL-lpr/lpr mice also display proinflammatory alterations in the intrarenal 
cytokine network [Boswell et al., 1988a; Boswell et al., 1988b; Fan et al., 1997].  
Alterations in the cytokine network are characteristic of many immune-
mediated disorders, and the pro-inflammatory cytokines such as TNF-α and 
IFN-γ, may play a major role in the pathogenesis of autoimmune diseases. 
 
In our previous studies using the Brown Norway→Lewis (BN→LEW) rat lung 
transplant model, we showed that 25 mg/kg/day of CMX-13 was effective in 
suppressing acute allograft rejection.  CMX-13 was able to prevent vasculitis, 
necrosis and hemorrhage, which are features of an aggressive rejection 
process [Yap et al, 1998; Zuo et al, 2000].  In these studies, CMX-13 did not 
inhibit IL-2 and IFN-γ mRNA expression, suggesting that its mechanism of 
action was different from that of CsA.  We also showed, in our in-vitro studies 
discussed in Chapter 4 that CMX-13 successfully induced apoptosis in Jurkat 
cells and PBMCs of SLE patients and age-sex matched normal controls.  In the 
MRL-lpr/lpr SLE mouse model, the Fas apoptosis pathway is non-functional 
[Rose et al., 1997; van der Linden et al., 2001; Sato et al., 2000].  Current 
immunosuppressive agents that are used in the treatment of SLE have been 
shown to act in part via the induction of apoptosis [Amano et al., 2000; Dooley 
and Falk, 1998; Steinberg, 1994].  
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In this chapter, we studied the effects of CMX-13 on: 
1. Progression of autoimmune disease in the MRL-lpr/lpr lupus mouse 
model, in terms of skin lesions, joint involvement and lymphadenopathy 
2. Development of anti-DNA antibodies 
3. Development of lupus nephritis as measured clinically by the onset and 
degree of proteinuria and histological scoring of severity of the nephritis 












5.2.1     Clinical Observation on the MRL-lpr/lpr Mice 
 
MRL-lpr/lpr mice typically develop skin lesions on the back, neck and ears by 
the age of 20-24 weeks [Reininger et al., 1990; Chan et al., 2001].  To 
determine if CMX-13 had any effect on the development of clinical disease, the 
mice were treated with either DMSO (solvent control), CMX-13 or DEX as 
described in chapter 2.3.2, from the age of 12 weeks, and were observed for 
development of skin vasculitic lesions, articular hind pad swelling and 
lymphadenopathy.  The mice were examined for the development of skin 
lesions at 22 weeks.  The DMSO control group had visible vasculitic skin 
lesions on the ear (Figure 5.2.1.1) and back (Figure 5.2.1.2).  Surprisingly, the 
untreated control group did not demonstrate any skin lesions.  Both the CMX-
13 and DEX-treated mice also did not develop these features. 
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Figure 5.2.1.1   Vasculitic skin lesions in the ear in MRL-lpr/lpr mice in the  
DMSO-control group at age 22 weeks.  No skin lesions were seen in the  
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Figure  5.2.1.2 Vasculitic skin lesions on the back of DMSO control mice at age  
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Similarly, articular swelling of the hind footpads was only observed in the 
DMSO-control mice but not in the untreated controls, CMX-13-treated and 
DEX-treated groups.  These features are shown in Figure 5.2.1.3. 
 
Figure 5.2.1.3  Severe articular swelling of the hind footpads seen only in the 
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MRL-lpr/lpr mice generally develop lymphadenopathy and splenomegaly as a 
consequence of accumulation of the double negative T cells that down-regulate 
their co-receptor, primarily CD8, and up-regulate B220 with a cell phenotype 
that is TCRαβCD3+CD4-CD8-B220+ compared to conventional CD3+CD4+B220- 
or CD3+CD8+B220- cells.  Thus, we next assessed the effect of CMX-13 
treatment on the development of lymphadenopathy in these mice. 
Lymphadenopathy started to become visible from the age of 12-13 weeks in 
the untreated and DMSO control groups (Figure 5.2.1.4).  The CMX-13 and 
DEX treatment groups did not develop lymphadenopathy until at least 18 



















Figure 5.2.1.4 Lymphadenopathy visible at age 12 weeks only in the untreated 














5.2.2   Effect of CMX-13 on Proteinuria  
 
Proteinuria starts to occur by the age of 8–12 weeks in the MRL-lpr/lpr mice 
due to development of lupus nephritis [Eilat and Naparstek, 1999; Appel and 
Valeri, 1994].  This is associated with increased levels of IL-6 in the urine, 
possibly related to the glomerular inflammation [Iwano et al., 1993].  In this 
study, the development of proteinuria in the untreated controls, DMSO controls, 
CMX-13-treated and DEX-treated mice was monitored every 4 weeks from the 
age of 8 weeks up to the age of 22 weeks (Appendix 5.1).  Urinary protein 
concentration was graded semi-quantitatively by a proteinuria score raging 
from 0 to 5 scale ( 0 = Negative; 1 = Trace; 2 = 0-30 mg/dl (+); 3 = 30-100 
mg/dl (++); 4 = 100- 300 mg/dl (+++);  5 = > 300 mg/dl  (++++) ) [Ishida et al., 
1994; Yamamoto et al., 1990; Mihara et al., 1997; Aihira M, et al., 1997], using 
urine reagent strips as described in section 2.3.3.   
  
After 4 weeks of treatment at the age of 16 weeks, a reduction of proteinuria in 
the CMX-13-treated and DEX-treated mice was observed.  Compared to the 
untreated and DMSO-treated mice, CMX-13-treated mice (p<0.005 and p<0.04 
respectively) and DEX-treated mice (p<0.001 and p<0.006 respectively) had a 
significantly lower level of proteinuria (Figure 5.2.2.1). 
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Figure 5.2.2.1 Effect of CMX-13 on proteinuria score in MRL-lpr/lpr autoimmune  
mice compared to untreated controls, DMSO controls and DEX-treated mice at  




Over the 10 weeks of treatment up to the age of 22 weeks, there was an 
increase in the proteinuria score in all the groups (Figure 5.2.2.2).   However, 
there was no significant difference in the proteinuria scores between the groups 
at 22 weeks, primarily due to small numbers of mice that were still alive and 
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Figure 5.2.2.2  Changes in proteinuria score over time MRL-lpr/lpr autoimmune 
mice. 
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5.2.3    Effect of CMX-13 on Anti-dsDNA Antibodies  
 
Lupus-specific anti-dsDNA autoantibodies appear in the MRL-lpr/lpr mice at the 
age of 6-8 weeks [Andrews et al, 1978; Putterman and Naparstek, 1994].  Sera 
were collected from the untreated controls, DMSO controls, CMX-13-treated 
and DMSO-treated mice at the ages of 8, 12 and 16 weeks for analysis of IgG-
specific anti-dsDNA autoantibody levels (Appendix 5.2).  It was not possible to 
analyse the differences in the anti-dsDNA antibody levels after 16 weeks, due 
to a progressive increase in the number of mice dying, especially in the 
negative control groups.   
 
As shown in Table 5.2.3.1, at 8 weeks of age the anti-dsDNA antibody levels in 
all the groups were not significantly different, and ranged from 0.10-1.40 ηg/ml.  
At 12 weeks of age, the anti-dsDNA antibody levels increased over the 
baseline in all the groups.  Following treatment with either CMX-13 or DEX in 
two groups, the rise in anti-dsDNA antibody levels with time was decreased 
compared to the control group and the group treated with the solvent DMSO 
(p<0.05) (Figure 5.2.3.1). 
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Table 5.2.3.1 Serum anti-dsDNA antibody levels in MRL-lpr/lpr mice  
at age 8, 12 and 16 weeks. 
 
Age of mice Groups 
 8 weeks 12 weeks 16 weeks 
Untreated 0.39±0.26 0.73±0.09 1.48±0.46a,b 
DMSO control 0.36±0.35 0.53±0.31 
 
1.58±0.50a,b 
CMX-13 0.22±0.06 0.57±0.20 
 
1.03±0.43a 
DEX 0.23±0.04 0.38±0.19 0.88±0.40b 
ap<0.05, comparing CMX-13 with disease control and DMSO control. 
bp<0.03, comparing DEX with disease control and DMSO control. 
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Figure 5.2.3.1 Serial serum anti-DNA antibody levels in MRL-lpr/lpr mice at age 8,  
12 and 16 weeks.  CMX-13 and DEX treated mice had a lower elevation of anti- 
dsDNA antibody levels than untreated or DMSO-treated mice.  aComparing CMX- 
13 with disease control and DMSO control, p<0.05.  bComparing DEX with  
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5.2.4 Effect of CMX-13 on Serum Creatine level 
 
The creatinine levels in the sera of the Untreated group was lower 
(0.551±0.074 mg/ml) when compared to the DMSO (0.84±0.041 mg/ml) or the 
DEX (0.82±0.062 mg/ml) treated group. Higher creatinine levels in the samples 
Untreated mice were expected. The creatinine levels did not differ significantly 
in the Untreated group  when compared to  the DMSO and DEX group. The 
creatinine levels in the CMX-13 treated group also was not significantly 
different from the Untreated group (0.68±0.111 mg/ml). These results are 
shown in Figure 5.2.4.1 and in Table 5.2.4.1.  
Figure 5.2.4.1. Serum creatine in CMX-13 treated mice. Serum creatine levels did 
not significantly decreased in CMX-13 mice when compared to Untreated or 





Table 5.2.4.1 . Serum Creatine levels in the MRL-lpr/lpr mice after treatment with 
CMX-13 (mean+SD ).   
 
Untreated 
(n = 11) 
DMSO 
(n = 11 ) 
CMX-13 
(n =9 ) 
DEX 
(n = 12) 
0.356 0.651 0.879 0.658 
0.731 0.805 0.916 0.916 
0.768 0.842 0.104 1.1 
0.658 0.879 0.99 0.805 
0.209 0.916 0.731 0.731 
0.725 1.137 0.805 0.621 
0.135 0.879 0.916 0.584 
0.658 0.99 0.135 1.1 
0.547 0.768 0.658 0.621 
0.731 0.731  0.805 
0.5518 0.731  0.694 
   1.211 

















5.2.5    Histological Scoring of Lupus Nephritis in MRL-lpr/lpr Mice 
 
To define the effects of CMX-13 treatment on the development of 
glomeurlonephritis in MRL-lpr/lpr mice, we evaluated kidneys at the age of 23 
weeks of two mice in each group and those mice, which became moribund 
earlier according to the WHO morphologic classification of lupus nephritis 
(Peutz-Kootstra et al, 2001). The following histological characteristics were 
graded from 0 to 3+ according to severity for: 1) glomerular cell proliferation; 2) 
leucocyte exudation; 3) karyorrhexis and fibrinoid necrosis; 4) cellular 
crescents; 5) hyaline deposits; 6) interstitial inflammation as described in 
section 2.3.6, with a maximum score of 24. These histological characteristics 
are demonstrated in Figures 5.2.5.1 to 5.2.5.3, and varied from mild mesangial 
proliferation to full-blown proliferative and crescentic glomerulonephritis.      
 178
Figure  5.2.5.1  Light microscopic examination of kidney specimen in control 
MRL-lpr/lpr mouse with diffuse proliferative lupus nephritis showing fibrinoid 
necrosis, interstitial inflammation, cellular crescents and leucocyte exudation 






















Figure  5.2.5.2  Light microscopic examination of kidney specimen in control 















Figure  5.2.5.3  Light microscopic examination of kidney specimen in control 
MRL-lpr/lpr mouse with diffuse proliferative lupus nephritis showing 














An overall histological index for each kidney was obtained by a score/age ratio 
to compensate for the effect of age on the progression of disease, summarized 
in Table 5.2.5.2.  Both the CMX-13 treated (0.52±0.18) and Dex-treated groups 
(0.40±0.11) had lower histological indices than the untreated controls 
(0.66±0.18) and DMSO controls (0.62±0.20) (Figure 5.2.5.4).  However, only 
the DEX-treated group had significantly different histological index than 
untreated controls (p<0.005) and DMSO-treated group (p<0.03). 
 
 
Hyaline deposits Karyorrhexis 
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Table 5.2.5.2. Individual histological scores of the Untreated, DMSO, CMX-13 and 
DEX treated animals.  An overall histological index for each kidney was obtained 
by a score/age ratio. 
 
Untreated 
Age in weeks 
(n = 7) 
score Histological index 
(score/age) 
23 14 0.608 
23 16 0.695 
19 14 0.736 
17 9 0.529 
16 9 0.562 
18 9 0.5 
22 22 1 




Age in weeks 
(n = 11) 
Score Histological index 
(score/age) 
23 9 0.391 
22 11 0.5 
23 14 0.608 
25 12 0.48 
17 16 0.941 
22 15 0.681 
18 11 0.611 
23 9 0.391 
21 16 0.761 
21 10 0.476 
19 20 1.052 









CMX-13 treated mice 
 
Age in weeks 





23 15 0.652 
25 20 0.8 
23 16 0.695 
22 12 0.545 
24 10 0.416 
26 9 0.346 
23 10 0.434 
25 9 0.36 




DEX treated mice 
 







17 7 0.411 
23 7 0.304 
18 9 0.5 
23 7 0.304 
26 10 0.384 
26 8 0.307 
26 17 0.653 
19 8 0.421 
26 9 0.346 












Figure 5.2.5.4  Histological indices expressed as a ratio of histological score/age 
in untreated controls, DMSO controls, CMX-treated and DEX-treated groups.  
aComparing DEX-treated group with controls, p<0.005.  bComparing DEX-treated 
















0.66±0.18 0.62±0.20 0.52±0.18 0.40±0.11
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5.2.6  Effect of CMX-13 on Life Span of MRL-lpr/lpr Mice 
 
In the autoimmune MRL-lpr/lpr mice, the severity of the disease increases with 
age of the mice, with the majority dying of renal failure at 16-24 weeks of age 
[Putterman and Naparstek, 1994].  At the beginning of this study, 8-week old 
female MRL-lpr/lpr mice were divided randomly into 4 groups of 13 animals.  
Each group received by intra-peritoneal injection either 100µl PBS, 16% v/v of 
DMSO, 25 mg/kg of CMX-13, or 1 µg/kg of DEX, on alternate days, and was 
observed daily.  A Kaplan-Meier survival analysis was done on the MRL-lpr/lpr 
mice where death before the age of 22 weeks was defined as the outcome 
parameter.  Appendix 5.3 shows the life-table calculations for the different 
groups.  
 
As shown in Figure 5.2.6.1, only 2 mice of the untreated controls and 3 of the 
DMSO controls survived at 22 weeks of age. The survival of each group is 
summarized in Table 5.2.6.1 On the other hand 9 of the mice treated with CMX-
13 and 7 of DEX-treated mice were alive at 22 weeks.  Kaplan-Meier analysis 
showed that only the CMX-13-treated group had significantly increased survival 
when compared with control (p=0.005) and DMSO-treated (p=0.049) groups. 
DEX treatment did improve survival, as 7 animals were alive when the 
experiment was terminated at week 22, however it was not statistically significant 
when compared to the Untreated and DMSO treated animals. 
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Table 5.2.6.1 (I): Cumulative survival of individual mice in the Untreated group 
 
 
Case Time in 
weeks 













Pi-1 x Pi 
1 8 Surv 13 0/13 = 0 1 1 x 1 = 1 
2 12 Dead 12 1/12 = 
0.08 
0.92 1 x 0.92 = 
0.92 
3 13 Surv 12 0 1 0.92 x 1= 
0.92 
4 14 Dead 11 1/11 
=0.09 
0.90 0.92 x 0.9 = 
0.83 
5 15 Surv 11 0 1 0.83 x 1 = 
0.83 
6 16 Dead 10 1/10 = 0.1 0.90 0.83 x 0.9 = 
0.75 
7 17 Dead 7 3/7 = 0.4 0.6 0.75 x 0.6 = 
0.45 
8 18 Dead 5 2/5 = 0.4 0.6 0.45 x 0.6 = 
0.27 
9 19 Dead 3 2/3 = 0.67 0.33 0.27 x 0.33 
= 
0.09 
10 20 Dead 3 0/3 = 0 1 0.09 x 1 = 
0.09 
11 21 Surv 3 0 1 0.09 x 1 = 
0.09 





















Case Time in 
weeks 













Pi-1 x Pi 
1 8 Surv 13 0/13 = 0 1 1 
2 12 Surv 13 0 1 1 
3 13 Surv 13 0 1 1 
4 14 Surv 13 0 1 1 
5 15 Surv 13 0 1 1 
6 16 Surv 13 0 1 1 
7 17 Dead 12 1/12 = 
0.08 
0.92 0.92 
8 18 Dead 10 2/10 = 0.2 0.8 0.92 x 0.8 = 
0.74 
9 19 Dead 9 1/9 = 0.1 0.9 0.74 x 0.9 = 
0.67 
10 20 Surv 9 0 1 0.67 
11 21 Dead 6 3/9 = 0.30 0.7 0.67 x 0.7 = 
0.47 





























Case Time in 
weeks 













Pi-1 x Pi 
1 8 Surv 13 0/13 = 0 1 1 
2 12 Surv 13 0 1 1 
3 13 Surv 13 0 1 1 
4 14 Dead 12 1/12 = 
0.08 
0.92 0.92 
5 15 Surv 12 0 1 0.92 
6 16 Dead 11 1/11 = 
0.09 
0.91 0.92 x 0.91 
= 
7 17 Dead 10 1/10 = 0.1 0.9 0.83 
8 18 Surv 10 0  1 0.83 
9 19 Surv 10 0 0.9 0.83 x 0.9 = 
0.75 
10 20 Surv 10 0 1 0.75 
11 21 Surv 10  0.7 0.75 x 0.7 = 
0.53  

























Table 5.2.6.1 (IV): Cumulative survival of individual mice in the DEX treated group. 
 
Case Time in 
weeks 













Pi-1 x Pi 
1 8 Surv 13 0/13 = 0 1 1 
2 12 Surv 13 0 1 1 
3 13 Surv 12 1/12 = 
0.08 
0.92 0.92 
4 14 Dead 12  0 0.92 0.92 x 0.92 
= 0.85 
5 15 Surv 12 0 1 0.85 
6 16 Surv 12 0 0.91 0.85 x 0.91 
= 0.77 
7 17 Dead 9 3/9 = 0.3 0.7 0.77 x 0.7 = 
0.54 
8 18 Surv 8 1/8 = 0.12 0.88 0.88 x 0.54 
= 0.48  
9 19 Surv 7 1/7 = 0.14 0.86 0.48 x 0.86 
= 0.41 
10 20 Surv 7 0 1 0.41 x 1= 
0.41 
11 21 Surv 7 0 1 0.41 





Figure 5.2.6.1 Kaplan-Meier survival analysis in MRL-lpr/lpr mice following CMX-13 
or DEX treatment compared with Untreated controls and solvent (DMSO) controls. 
aComparison between CMX-13 treatment group and untreated controls, p<0.005.  
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5.3    DISCUSSION 
 
MRL-lpr/lpr mice represent an excellent model to study the pathogenesis of lupus 
nephritis [Theofilopoulos et al., 1985].  These mice spontaneously develop a 
generalized autoimmune disease, including vasculitis, generalized 
lymphadenopathy, arthritis and a severe immune complex glomerulonephrititis, 
dying of renal failure between 5 to 8 months of age [Andrews et al., 1978].  
These mice also produce autoantibodies such as anti-double-stranded DNA 
antibodies and anti-IgG (rheumatoid factor).  Defective transcription of the 
apoptosis gene encoding Fas (CD95) causes lymphoproliferation of double-
negative (TCRαβCD3+CD4-CD8-B220+) T cells and autoantibody-producing B 
cells [Watanabe et al., 1992; Adachi et al., 1993].  This leads to massive 
lymphadenopathy, elevated serum anti-dsDNA antibody levels, and progressive 
lupus nephritis, as seen in the untreated control mice and the control group 
treated with the solvent DMSO in our experiment. 
   
In the untreated and DMSO control mice, lymphadenopathy started to become 
visible from the age of 12-13 weeks (Figure 5.2.1.4), whereas development of 
significant lymphadenopathy in the CMX-13 and DEX treatment groups was 
delayed until at least 18 weeks, and was less severe than the control groups.  In 
previous studies, Morton and co-workers reported that 3% DMSO supplemented 
in the drinking water of C3H/lpr SLE mouse model decreased the severity of 
lymphadenopathy [Morton and Siegel, 1986].  On the other hand, intraperitoneal 
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injections of 50% DMSO over a period of 20 weeks, was not shown to reduce 
lymphadenopathy [Morton et al., 1983].  In our experiment, where CMX-13 and 
DEX were dissolved in 16% DMSO, it was unlikely that DMSO was responsible 
for the reduction of lymphadenopathy in these treatment groups, as the DMSO 
control group given 16% DMSO intraperitoneally, developed marked 
lymphadenopathy early, similar to the untreated controls.  The lpr CD4+ T-cells 
have been shown to be the source of the TCRαβCD3+CD4-CD8-B220 T-cells 
responsible for the massive lymphadenopathy in MRL-lpr/lpr mice [Laouar and 
Ezine, 1994], and these cells are resistant to apoptosis [Bossu et al., 1993].  As 
we have shown in chapter 4 that CMX-13 was able to induce apoptosis, studies 
on apoptosis of these cells in the lymph nodes of CMX-13 treated mice may 
provide further insight into its immunosuppressive mechanism. 
 
MRL-lpr/lpr mice typically develop skin lesions of back, neck and ears by the age 
of 20-24 weeks [Reininger et al., 1990; Chan et al., 2001].  As the surviving mice 
in our experiment were sacrificed after 22 weeks of age, development of skin 
lesions and arthritis was not universally seen in our experimental mice, with only 
some of the DMSO controls developing these lesions.  However, all our mice 
developed anti-dsDNA antibodies from the age of 8 weeks.  The untreated and 
DMSO control mice had the highest level of rise in antibody concentrations by 16 
weeks of age, whereas both the CMX-13 and DEX-treated groups had 
significantly lower anti-dsDNA antibody levels (Figure 5.2.3.1). Serum creatine 
levels were also measured at the age of 16 weeks. However, the changes in the 
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serum creatine levels were not significant (Figure 5.4.2.1).  The solvent DMSO 
had no effect on anti-dsDNA antibody levels in our studies, similar to the work by 
Milner and co-workers who showed that DMSO given intraperitoneally as a 75% 
solution did not affect the development of autoantibodies in NZB/W F1 lupus mice 
[Milner et al., 1987]. 
 
Mice homozygous for the mutation in the lpr gene develop lupus-like 
autoimmunity characterized not only by the accumulation of double negative T 
cells, but also non-malignant autoantibody-producing B cells.  Anti-dsDNA 
antibodies were first described 40 years ago, and it is well-known that the 
production of these autoantibodies is driven by hyperreactive B-cells [Kotzin, 
1996].  However, little is known about their role in the pathogenesis of tissue and 
organ injury [Eilat and Naparstek, 1999].  Anti-dsDNA antibodies have often been 
implicated in the development of glomerulonephritis [Koffler et al., 1967; Lambert 
and Dixon, 1968].  Earlier studies suggested that entrapment of anti-dsDNA 
antibodies in the glomerulus could be the cause of the proliferative lesion seen in 
lupus nephritis [Yamada et al, 1982].  Recent studies on the autoantibody 
specificities from kidney eluates in lupus mice have shown that cross-reactive 
anti-dsDNA antibodies predominate, and these antibodies also bound to 
glomerular substrate and laminin [Xie et al., 2003].  Hence development of 
glomerulonephritis and vasculitis could be due to in-situ immune complex 
formation in the glomerular and vascular sites [Vlahakos et al, 1992].  The in-situ 
formation of these immune complexes was also thought to be due to the binding 
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of anti-DNA antibodies to structural proteins found in mesangial cells and 
glomerular podocytes, such as α-actinin [Mostoslavsky et al, 2001].  Moreover, 
prevention of binding of anti-DNA antibodies to the glomeruli by low-dose heparin 
was found to inhibit the progression of glomerulonephritis in MRL-lpr/lpr mice 
[Naparstek et al., 1990].  
 
The increased mortality seen in the MRL-lpr/lpr mice is attributed in a large part 
to the development of progressive severe proliferative lupus nephritis, with the 
majority of mice dying of renal failure at 16-24 weeks of age.  In this chapter, we 
have shown that CMX-13 was able to improve survival of the MRL-lpr/lpr mice  
compared to the untreated or DMSO controls (Figure 5.2.6.1).  At 22 weeks of 
age, 9 of the mice treated with CMX-13 were still alive, whereas only 2 of the 
untreated controls and 3 of the DMSO controls survived.   
 
In the MRL-lpr/lpr mice, the severity of kidney disease increases with age and 
manifests as mesangial and endothelial cell proliferation, occasional crescent 
formation, thickening of the glomerular capillary walls and tubulointerstitial 
nephritis with vasculitis [Austin et al, 1984: Moyer et al, 1987; Appel and Valeri, 
1994; Putterman and Naparstek, 1994].  The acute glomerular inflammation 
results in proteinuria, which is usually apparent by the age of 8-12 weeks in the 
MRL-lpr/lpr mice [Eilat and Naparstek, 1999; Appel and Valeri, 1994].  In our 
experiment, CMX-13 treatment of MRL-lpr/lpr mice with progressive lupus 
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nephritis resulted in decrease in the degree of proteinuria and improvement in 
renal histological indices (Figure 5.2.5.4). 
 
In conclusion, this chapter shows that CMX-13 appeared to be effective in 
attenuating clinical and histological disease activity in the MRL-lpr/lpr mouse 
model of SLE.  The exact mechanism of the immunosuppressive action of CMX-
13 remains to be elucidated, and the next chapter will be addressing some of the 





















CHAPTER 6  EFFECT OF CMX-13 ON CYTOKINE GENE EXPRESSION 
IN THE MRL-lpr/lpr SLE MOUSE MODEL 
 
6.1           INTRODUCTION 
 
SLE is an autoimmune disease that involves increased production of IgG 
autoantibodies and immune complex deposition in the microvasculature of 
organs such as the kidney, resulting in complement activation, leucocyte 
infiltration and tissue damage.  Affinity maturation of B cells with isotype 
switching are T-cell dependent processes, hence the similarity of the anti-dsDNA 
response in murine and human SLE strongly supports the hypothesis that T 
helper cells are involved in the pathogenesis.  CD4+ T-cells act as the driving 
force for the hyperreactive B-cells through the production of cytokines [Kotzin, 
1996;Theofilopoulos et al., 1989]. The role of cytokines in providing the non-
specific help, as well as in mediating tissue injury is currently being investigated. 
 
In patients with active disease as well as in experimental murine models of SLE, 
both the serum cytokine levels and gene expression in PBMCs have been found 
to be abnormal [Prud’homme, 1995].  In fact, there have been reports of a 
relationship between abnormal cytokine mRNA levels and disease activity 
[Linker-Israeli et al., 1991].  For example, increased IL-10 and IFN-γ gene 
expressions have been described in SLE patients, and this correlated with 
disease activity [Csiszar et al., 2000].  Moreover, several studies have described 
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an imbalance of Th1 (IL-2 and IFN-γ) and Th2 (IL-6 and IL-10) cytokines in 
patients with SLE.  mRNA expression of IFN-γ has been shown to be elevated in 
MRL-lpr/lpr autoimmune mice [Murray and Martens, 199o; Prud’Homme et al., 
1995], suggesting that IFN-γmay play a role in the genesis of SLE.  In contrast, 
IL-2 mRNA expression in the MRL-lpr/lpr mice was downregulated. 
 
IFN-γ is a key cytokine that controls Th1-dependent Ab production and is crucial 
for functional immune responses.  IFN-γ is secreted by activated T-cells and 
natural killer (NK) cells and promotes inflammation.  High levels of IFN-γ mRNA 
have been found in PBMCs from SLE patients [Csiszar et al., 2000].  IFN-γ has 
also been demonstrated in the renal tissue of SLE patients with severe lupus 
nephritis, compared to individuals with milder renal disease [Akahoshi et al., 
1999; Masutani et al., 2001].  The predominant role of IFN-γ in disease 
pathogenesis has been demonstrated in murine lupus [Takahashi et al., 1996], 
where disease activity in the MRL-lpr/lpr mice was linked to the presence of IFN-γ 
[Peng et al., 1997; Haas et al., 1997].   Interestingly, transgenic expression of 
IFN-γ in the epidermis of non-autoimmune mice resulted in the development of 
inflammatory skin disease resembling lupus erythematosus [Seery et al., 1997].  
Following treatment with IFN-γ the onset of disease was aggravated in NZB X 
NZWF1 mice [Jacob et al., 1987]. Blocking or inhibition of IFN-γ  had a positive 
affect on disease symptoms, and deletion of either the IFN-γ gene or IFN-γ 
receptor gene in lupus mice reduced the severity of glomerulonephritis [Haas et 
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al., 1998].  Decreasing IFN-γ production by approximately 50% decreased both 
autoantibody production and onset of glomerulonephritis [Lawson et al., 2000; 
Ozmen et al., 1995] 
 
IL-2 mRNA expression has been shown to be downregulated in PBMCs from 
SLE patients [Crispin and Alcocer-Varela, 1998].  Moreover, in-vitro IL-2 
production by PBMCs was impaired following stimulation with antigens [Alcocer-
Varela and Alarcon-Segovia, 1982].  Other studies have shown that the defective 
production of IL-2 occurred in both CD4+ and CD8+ T-cells [Murakawa et al., 
1985].  Additionally, there was impaired IL-2-stimulated T-cell proliferation in SLE 
patients [Miyasaka et al., 1984].  This decrease in PBMC IL-2 secretion was not 
due to an intrinsic T-cell defect, as production of IL-2 returned to normal when 
the cells were isolated and allowed to rest in-vitro for a few days before antigen 
stimulation [Huang et al., 1986].  However, in the MRL-lpr/lpr murine lupus 
model, no difference was observed in the IL-2 mRNA expression when compared 
to the MRL-wt mice.  There was also no detectable increase in IL-2 gene 
expression in the TCRαβCD3+CD4-CD8-B220+ T-cells of these mice [Murray et 
al, 1990].  IL-2 is an important cytokine that determines the balance between cell 
proliferation and apoptosis [Lenardo, 1991].  IL-2 induces apoptosis in CD4+ and 
CD8+ T-cells [Lenardo, 1991] and this is mediated by the Fas-FasL-pathway 
[Refaeli et al., 1998].  As discussed in chapter 4, the Fas-FasL apoptotic pathway 
is defective in the murine MRL-lpr/lpr autoimmune model.  Hence administration 
of IL-2 could result in improvement in the disease.  Guitierrez-Ramos and co-
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workers were able to prevent autoimmune disease in MRL-lpr/lpr mice by 
transfecting them with IL -2/vaccinia recombinant virus [Gutierrez-Ramos, 1991]. 
 
The levels of Th2 cytokines IL-6 and IL-10 were found to be elevated in the 
serum of SLE patients [Grondal et al., 2000; Jones et al., 1999]. IL-6 is a 
multifunctional cytokine and is involved in the growth and differentiation of B and 
T-cells.  IL-6 is produced by a variety of different cell types upon induction by 
viral infections [Cayphas et al., 1987; van Snick, 1990] and stimulation by other 
pro-inflammatory cytokines such as IL-1 and TNF-α [Akira et al., 1993].  IL-6 has 
B-cell stimulatory activity and induces the secretion of other cytokines.  Together 
with IFN-γ it plays a significant role in inflammation and may be linked to the 
development of inflammatory lesions [Prud’homme, 1993], including proliferative 
glomerulonephritis [Horii et al, 1993].  IL-6 has been reported to be upregulated 
in the sera [Swaak et al., 1989] and renal biopsy specimens of SLE patients 
[Horii et al., 1993].  This finding was supported by studies which showed that 
treatment of lupus-prone NZB/NZW F1 mice with anti-IL-6 antibody abrogated 
the disease [Finck et al., 1994b].  Several studies have reported elevation of IL-6 
concentrations in the urine of patients with lupus nephritis, and this was a reliable 
indicator of the progression of lupus nephritis [Iwano et al., 1993].  IL-6 has been 
shown to stimulate glomerular mesangial cell proliferation [Horii et al, 1993].   
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B-cell hyperactivity in SLE patients is thought to be induced by IL-6 [Linker-Isreali 
et al., 1991].  The increased IL-6 levels were shown to be related to increased 
stability of IL-6 mRNA expression levels in these patients [Linker-Israeli et al., 
1999].  The stability of the IL-6 gene transcripts implies that there would be no 
correlation between the increased levels of IL-6 protein and mRNA expression 
during periods of active disease [Cross and Benton et al., 1999].   
 
IL-10 is a regulatory cytokine that inhibits Th1 cytokine production and 
proliferation of CD4+ T cells [Moore et al., 2001].  This anti-inflammatory cytokine 
promotes Th2 immune responses by their effect on antigen-presenting cells as 
well as a direct effect on T-cells [Moore et al., 1993].  Patients with SLE have 
been shown to have increased serum levels of IL-10 [Llorente et al., 1995], with 
enhanced gene expression in the PBMC [Csiszar et al., 2000].  The serum IL-10 
levels correlated with disease activity [Park et al., 1998; Hagiwara et al., 1996].  
The precise role of IL-10 in the pathogenesis of SLE is not well understood.  
Continuous administration of IL-10 to the NZB/NZW F1 SLE mouse accelerated 
the onset of renal disease, while treatment with anti-IL-10 monoclonal antibodies 
(mAb) delayed onset of the disease [Ishida et al., 1994].  In another study, 
significant improvement of SLE symptoms and SLEDAI scores was achieved 
when 6 patients with active SLE were treated with murine IgG1 anti-IL-10 mAb 
for 21 days [Llorente et al., 2000].  This beneficial effect was seen up to 6 months 
following cessation of treatment.  
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Studies on the MRL-lpr/lpr mice have identified various cytokine abnormalities 
[Lemay et al., 1996; Prud’Homme et al., 1995].  The following cytokine genes 
were found to be upregulated in the MRL-lpr/lpr mice with autoimmune disease: 
IFN-γ in lymph nodes, spleen and kidney, TNF-α in the spleen and kidney, IL-1β 
in lymph nodes, spleen, kidney, and liver, and IL-10 in lymph nodes of diseased 
mice (Table 6.1.1).  IL-2, IL-4, and IL-6 mRNA were not detected in these organs.   
 
Table 6.1.1   Cytokine mRNA expression in MRL-lpr/lpr (d) and MRL-wt (n) mouse 
organs by RNase protection assay.  LN = lymph nodes; SP =Spleen; KID = Kidney; 
LIV = Liver. - = no expression, +/- = Normal level, + = Detectable, ++ = heightened 
level [Lemay et al., 1996; Prud’Homme et al., 1995]. 
 
 
Cytokine LN/n LN/d SP/n SP/d KID/n KID/d LIV/n LIV/d 
IL-1β - ++ +/- ++ +/- ++ - ++ 
IL-2 - - - - - - - - 
IL-4 - - - - - - - - 
IL-6 - - - - - - - - 
IFN-γ - + - + - + - - 
TNF-α + + - + - + - - 
IL-10 + ++       
  
Hence this chapter examined the effect of CMX-13 on cytokine gene expression 
particular CD4+ and CD8+ T-cells, liver and glomeruli of the autoimmune MRL-
lpr/lpr mouse.  The mice were treated with either, DMSO (solvent control), CMX-
13 or DEX as described in chapter 2.3.2, from the age of 12 weeks.  Real-time 
RT-PCR was employed to examine IL-2, IL-6, IL-10 and IFN-γ mRNA expression 
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in tissues and lymphocyte subsets from each of the groups of MRL-lpr/lpr mice 
that were moribund during the experiment and up to the age of 23 weeks.  As a 
control for these experiments, the mRNA cytokine expression in the 










6.2  RESULTS 
 
6.2.1     IL-2 mRNA Expression in and Splenic CD4+ and CD8+ T-cells 
from MRL-lpr/lpr Mice  
 
The IL-2 mRNA expression levels in splenic CD4+ cells of MRL-lpr/lpr mice and 
MRL-wt mice at age 23 weeks prior to sacrifice of the surviving mice in all 
groups, are shown in Table 6.2.1.1.  IL-2 mRNA expression was lower in both 
untreated (0.006±0.003) and DMSO control MRL-lpr/lpr mice (0.010±0.003) as 
compared to MRL-wt mice (0.048±0.027) (p<0.04).  Treatment of the MRL-lpr/lpr 
mice with CMX-13 resulted in a significant increase in IL-2 mRNA expression in 
CD4+ cells (0.030±0.017), as compared to untreated controls (p<0.05) (Figure 
6.2.1.1).  However, when compared to DMSO controls, this did not reach 
statistical significance.  On the other hand, DEX treatment did not result in a 
significant increase in CD4+ IL-2 mRNA expression in the MRL-lpr/lpr mice 

















Table 6.2.1.1   IL-2 mRNA expression in CD4+ T-cells from MRL-lpr/lpr and MRL-wt 














0.016 0.022 0.1332 0.014 0.0234 
0.007 0.016 0.0906 0.028 0.0194 
0 0.0009 0.104 0.0031 0.102 
0.0002 0.008 0.1 0.035  











ap<0.02, comparing with MRL-wt mice 
bp<0.04, comparing with MRL-wt mice 




Figure 6.2.1.1  Quantitative analysis of IL-2 mRNA expression in splenic CD4+ T- 
cells isolated from MRL-lpr/lpr mice and MRL-wt mice at 23 weeks.  IL-2 mRNA  
transcription level was significantly lower in untreated and DMSO-control MRL- 
lpr/lpr mice, as compared to MRL-wt micea,b.  Treatment with CMX-13 resulted in  
an increase in CD4+ IL-2 mRNA expression, compared with DMSO control MRL- 











The IL-2 mRNA expression levels in splenic CD8+ T-cells were significantly lower 
in untreated MRL-lpr/lpr mice (0.005±0.002) compared to MRL-wt mice 
(0.058±0.036) (p<0.04).  Although DMSO control MRL-lpr/lpr mice also had lower 
CD8+ IL-2 mRNA expression levels (0.010.±0.003) than MRL-wt mice, however 
this did not reach statistical significance probably because of the small numbers.  
Treatment of MRL-lpr/lpr mice with CMX-13 (0.123±0.033) resulted in a 
significant increase in CD8+ IL-2 mRNA expression compared to untreated and 
DMSO control animals (p<0.005) (Figure 6.2.1.2).   
 

























Table 6.2.1.2   IL-2 mRNA expression in CD8+ T-cells from MRL-lpr/lpr and MRL-wt 













0.0062 0.0143 0.1332 0.0048 0.129 
0.004 0.0071 0.0906 0.014 0.0089 
0.0003 0.0087 0.104 0.009 0.037 
0.002 0.011 0.1 0.0067  









0.010.±0.003c 0.123±0.033b,c 0.015±0.006 0.058±0.036a 
 
ap<0.04, comparing with MRL-wt mice 
bp<0.005, comparing with untreated MRL-lpr/lpr mice 
cp<0.005, comparing with DMSO control MRL-lpr/lpr mice 
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 Figure 6.2.1.2  Quantitative analysis of IL-2 mRNA expression in splenic CD8+ T- 
cells isolated from MRL-lpr/lpr mice and MRL-wt mice at 23 weeks.  IL-2 mRNA  
transcription level was significantly lower in untreated MRL-lpr/lpr mice, as  
compared to MRL-wt micea.  Treatment with CMX-13 resulted in an increase in  
CD8+ IL-2 mRNA expression, compared with Untreatedb and DMSO controlc MRL- 












































6.2.2 IFN-γ mRNA Expression in Splenic CD4+ and CD8+ T-cells, 
Liver and Glomeruli from MRL-lpr/lpr Mice 
 
The IFN-γ mRNA expression levels in splenic CD4+ cells at age of 23 weeks prior 
to sacrifice of the surviving mice in all groups, are shown in Table 6.2.2.1.  All the 
groups of MRL-lpr/lpr mice had higher IFN-γ mRNA expression than MRL-wt 
mice, although this did not reach statistical significance probably because of the 
small numbers.  Moreover, the IL-2/IFN-γ mRNA ratio was significantly lower in 
the untreated (0.0095±0.005) and DMSO control (0.011±0.003) MRL-lpr/lpr mice, 
compared to the MRL-wt mice (0.73±0.34) (p<0.03).  Treatment with either CMX-
13 or DEX did not reduce the IFN-γ mRNA expression levels (Figure 6.2.2.1).  
However, CMX-13 treatment of the MRL-lpr/lpr mice resulted in an increase in 
the IL-2/IFN-γ mRNA ratio (0.027±0.010), compared to either the untreated or 
DMSO control mice, although this did not reach statistical significance because 




















Table 6.2.2.1  IFN-γ mRNA expression and IL-2/IFN-γ mRNA ratio in splenic CD4+  












6.798 0.925 0.204 0.322 0.0205 
0.185 1.01 0.211 3.256 0.0196 
0.16 2.398 1.74 0.554 1.925 
0.357 0.521 1.556 0.308 













0.011±0.003a 0.027±0.010 0.017±0.004 0.73±0.34 
 
ap<0.03; comparing with MRL-wt mice 
 
 
Figure 6.2.2.1  Quantitative analysis of IFN-γ mRNA expression in splenic CD4+ T- 
cells of MRL-lpr/lpr mice and MRL-wt mice at age 23 weeks.  The IFN-γ mRNA  
transcripts were higher in all the groups of MRL-lpr/lpr mice compared to the  


































The IFN-γ mRNA expression levels in splenic CD8+ cells at age of 23 weeks prior 
to sacrifice of the surviving mice in all groups, are shown in Table 6.2.2.2.  There 
was no significant difference between the IFN-γ mRNA levels in the untreated, 
DMSO control, CMX-13 and DEX-treated MRL-lpr/lpr mice, as well as the MRL-
wt mice (Figure 6.2.2.2).  However, the IL-2/IFN-γ mRNA ratio was significantly 
lower in the untreated MRL-lpr/lpr mice (0.0041±0.0011) compared to the MRL-
wt mice (0.086±0.050) (p<0.03) (Table 6.2.2.2).  Treatment with CMX-13 resulted 
in an increase in the IL-2/IFN-γ mRNA ratio (0.42±0.25) compared to the 
untreated (p<0.005) and the DMSO control MRL-lpr/lpr mice (0.018±0.005). 
Table 6.2.2.2  IFN-γ mRNA expression in splenic CD8+ T-cells from MRL-lpr/lpr and 












1.998 0.627 0.132 0.54 2.026 
1.251 0.917 0.065 2.015 0.049 
0.151 0.065 4.643 0.015 3.262 
0.04 1.778 3.76 0.046  
0.967 0.028 2.502 3.087  
IFN-γ/Cyclo 
ratio 
0.648 1.963 6.608 0.431  
Mean 
+ SEM 





0.42±0.25b 0.17±0.12 0.086±0.050 
ap<0.03; comparing with MRL-wt mice 
bp<0.005; comparing with untreated MRL-lpr/lpr mice 







Figure 6.2.2.2  Quantitative analysis of IFN-γ mRNA expression in the splenic CD8+ 
T-cells of MRL-lpr/lpr and the MRL-wt mice.  CMX-13 treatment of the MRL-lpr/lpr 











































The IFN-γ mRNA expression levels in the glomeruli isolated from the different 
treatment groups of MRL-lpr/lpr and MRL-wt mice are illustrated in Table 6.2.2.3.  
The glomerular expression of IFN-γ mRNA was significantly higher in the DMSO 
control MRL-lpr/lpr mice (0.022±0.004) compared to the MRL-wt mice 
(0.005±0.001) (p<0.02) (Figure 6.2.2.3).  Although the IFN-γ mRNA levels were 
also higher in the untreated, CMX-13 treated and DEX treated MRL-lpr/lpr mice, 
as compared to the MRL-wt mice, but because of their small numbers, no 
statistical significance was observed.   
Table 6.2.2.3  IFN-γ mRNA expression in glomeruli isolated from kidneys of MRL-












0.198 0.012 0.027 0.021 0.005 
0.043 0.03 0.002 0.003 0.003 
0.007 0.012 0.004 0.002 0.006 
0.002 0.03 0.004 0.011 
0.034 0.012 0.056 0.042 
IFN-γ/Cyclo 
ratio 




0.050±0.030 0.022±0.004a 0.037±0.02 0.019±0.07 0.005±0.001 





Figure 6.2.2.3  Quantitative analysis of IFN-γ mRNA expression in glomeruli 
isolated from the kidneys of MRL-lpr/lpr and MRL-wt mice. The MRL-lpr/lpr mice 
had higher expression of IFN-γ mRNA transcripts in the glomeruli as compared to 
the MRL-wt mice, however only the DMSO control group reached statistical 

















































Table 6.2.2.4 outlines the IFN-γ mRNA expression in the liver of MRL-lpr/lpr and 
MRL-wt mice.  The CMX-13 treated mice had higher IFN-γ mRNA expression than 
the other groups of MRL-lpr/lpr mice, and the MRL-wt mice, but this did not reach 












0.285 0.4 0.003 0.312 0.127 
0.218 0.348 0.009 0.178 0.121 
0.003 0.005 0.997 0.002 0.122 
0.003 0.149 0.495 0.005 
0.105 0.005 0.262 0.047 
IFN-γ/Cyclo 
ratio 











Figure 6.2.2.4  Quantitative analysis of IFN-γ mRNA expression in the liver of  
MRL-lpr/lpr and MRL-wt mice. The highest number of IFN-γ mRNA transcripts was  
































   
   
   
   















6.2.3    IL-6 mRNA Expression in Splenic CD4+ and CD8+ T-cells and 
Glomeruli from MRL-lpr/lpr Mice  
 
Table 6.2.3.1 outlines the IL-6 mRNA expression levels in splenic CD4+ cells of 
MRL-lpr/lpr and MRL-wt mice at the age of 23 weeks.   The untreated MRL-lpr/lpr 
mice had higher CD4+ IL-6 mRNA expression compared to MRL-wt mice, 
although this was not statistically significant, probably because of the small 
numbers in each group.  Treatment with CMX-13 and DEX both resulted in lower 
IL-6 mRNA expression, however, a solvent effect could not be excluded as the 
DMSO controls had the lowest IL-6 mRNA expression levels (Figure 6.2.3.1).    
Table 6.2.3.1  IL-6 mRNA expression in splenic CD4+ T-cells from MRL-lpr/lpr and 












0.052 0.002 0.0009 0.002 0.0057 
0.005 0.001 0.0009 0.001 0.0055 
0.002 0.009 0.002 0.024 0.0012 
0.001 0.001 0.001 0.0009  
0.2 0.0005 0.004 0.018  
IL-6/Cyclo 
ratio 
0.005 0.005 0.123 0.023  
Mean 
+ SEM 










Figure 6.2.3.1  Quantitative analysis of IL-6 mRNA expression in splenic CD4+ T- 
cells of MRL-lpr/lpr mice and MRL-wt mice at age 23 weeks.  The IL-6 mRNA  
transcripts were highest in the CD4+ T-cells of the untreated MRL-lpr/lpr mice,  
compared to the MRL-wt mice.  Treatment with CMX-13 and DEX resulted in a  
decrease in IL-6 mRNA transcripts, similar to that seen in the DMSO control MRL- 













Table 6.2.3.2 shows the IL-6 mRNA expression levels in the splenic CD8+ cells 
isolated from the different groups of MRL-lpr/lpr and MRL-wt type mice at age 23 
weeks.  The untreated (0.020±0.014) and DMSO control (0.014±0.004) MRL-
lpr/lpr mice had low CD8+ IL-6 mRNA expression, similar to the MRL-wt mice 
(0.043±0.020).  Treatment with CMX-13 resulted in a significant increase in the 
IL-6 mRNA levels (0.121±0.039) when compared to the DMSO control MRL-
lpr/lpr mice (p<0.005) (Figure 6.2.3.2). 









   
   
   















Table 6.2.3.2 IL-6 mRNA expression in splenic CD8+ T-cells from MRL-lpr/lpr and  













0.0048 0.0017 0.185 0.006 0.082 
0.0018 0.0015 0.035 0.0036 0.02 
0.025 0.013 0.167 0.031 0.027 
0.0013 0.017 0.033 0.038 
0.085 0.022 0.05 0.08 
IL-6/Cyclo 
ratio 




0.020±0.014 0.014±0.004 0.121±0.039a,b,c 0.030±0.011 0.043±0.020 
ap<0.02; compared to untreated MRL-lpr/lpr mice 
bp<0.005; compared to DMSO controls 
cp<0.04; compared to DEX-treated mice 
 
Figure 6.2.3.2 Quantitative analysis of IL-6 mRNA expression in splenic CD8+ T- 
cells of MRL-lpr/lpr mice and MRL-wt mice at age 23 weeks.  Treatment with CMX- 
13 resulted in a significant increase in the IL-6 mRNA transcripts.  Note:  ap<0.02,  
compared to untreated MRL-lpr/lpr mice; bp<0.005, compared to DMSO controls;  






















   
   
   















Table 6.2.3.3 summarizes the IL-6 mRNA expression in the glomeruli isolated 
from kidneys of MRL-lpr/lpr and MRL-wt mice at age 23 weeks.   The IL-6 mRNA 
expression was very low in the glomeruli of MRL-wt mice (0.067±0.062).  On the 
other hand, the untreated (0.579±0.309) and DMSO control (0.716±0.407) MRL-
lpr/lpr mice had higher IL-6 mRNA expression in their glomeruli (0.656±0.369).  
CMX-13 treatment did not reduced the IL-mRNA expression in the glomeruli of 
these mice, however, DEX treatment resulted in lower IL-6 mRNA glomerular 
expression (0.281±0.118), although this did not reach statistical significance 
(Figure 6.2.3.3).  
Table 6.2.3.3   IL-6 mRNA expression in glomeruli isolated from kidneys of MRL-












0.081 0.006 0.523 0.838 0.007 
0.002 0.046 0.175 0.037 0.004 
0.758 0.309 0.036 0.152 0.190 
0.169 5.071 0.054 0.152 
2.017 0.141 2.412 0.183 
IL-6/Cyclo 
ratio 








Figure 6.2.3.3 Quantitative analysis of IL-6 mRNA expression in glomeruli isolated 
from the kidneys of MRL-lpr/lpr and MRL-wt mice. The untreated and DMSO 
control MRL-lpr/lpr mice had higher IL-6 mRNA transcripts in the glomeruli as 
compared to the MRL-wt mice.  Treatment with DEX resulted in lower IL-6 mRNA 









































   















6.2.4    IL-10 mRNA Expression in Splenic CD4+ and CD8+ T-cells and 
Glomeruli from MRL-lpr/lpr Mice 
 
 
Table 6.2.4.1 outlines the IL-10 mRNA expression in CD4+ T cells isolated from 
the spleens of the different groups of MRL-lpr/lpr mice and MRL-wt mice.  The 
DMSO control MRL-lpr/lpr mice had significantly higher IL-10 mRNA expression 
(0.78±0.11) compared to the MRL-wt mice (0.080±0.005) (p<0.04).  Treatment 
with CMX-13 resulted in a significant decrease in the IL-10 mRNA expression 
level in MRL-lpr/lpr mice (0.28±0.029), compared to the DMSO controls (p<0.02) 
(Figure 6.2.4.1).  DEX treatment did not influence the IL-10 mRNA levels 
(0.86±0.32) in the MRL-lpr/lpr mice. 
 
Table 6.2.4.1   IL-10 mRNA expression in splenic CD4+ T-cells from MRL-lpr/lpr and  













0.408 0.742 0.368 0.841 0.0787 
0.188 0.658 0.242 1.61 0.0756 
0.188 0.631 0.226 0.0613 0.085 
IL-10/Cyclo 
ratio 
0.919 1.1 0.325 0.943  
Mean 
+ SEM 
0.43±0.17 0.78±0.11 0.28±0.029a 0.86±0.32 0.080±0.005b 
 
ap<0.02; compared with DMSO controls 




Untreated DMSO CMX-13 DEX MRL-wt 
Figure 6.2.4.1 Quantitative analysis of IL-10 mRNA expression in splenic CD4+ T-
cells of MRL-lpr/lpr mice and MRL-wt mice at age 23 weeks.  The IL-10 mRNA 
transcripts were higher in the DMSO control MRL-lpr/lpr mice compared to the 
MLR-wt mice (p<0.04)a. Treatment with CMX-13 resulted in a significant decrease 
in IL-10 mRNA transcripts compared to the DMSO control MRL-lpr/lpr mice 



















   
   















As shown in Table 6.2.4.2, the glomerular IL-10 mRNA expression was low, 
especially in the MRL-wt mice (0.003±0.000).  The IL-10 mRNA expression was 
only slightly higher in the untreated (0.046±0.023) and DMSO control 
(0.045±0.021) MRL-lpr/lpr mice, and treatment with either CMX-13 (0.072±0.036) 
or DEX (0.037±0.016) did not significantly upregulate its expression (Figure 
6.2.4.2).   
Table 6.2.4.2 IL-10 mRNA expression in glomeruli isolated from kidneys of MRL- 













0.030 0.030 0.027 0.007 0.003 
0.008 0.008 0.027 0.014 0.003 
0.114 0.114 0.056 0.076 0.003 
IL-10/Cyclo 
Ratio 
0.030 0.030 0.180 0.052  
Mean 
+ SEM 























Figure 6.2.4.2 Quantitative analysis of IL-10 mRNA expression in glomeruli 
isolated from the kidneys of MRL-lpr/lpr and MRL-wt mice.  The IL-10 mRNA 
transcripts in the glomeruli were very low in MRL-wt mice compared to the MRL-




















   














6.3   DISCUSSION 
 
Studies on the MRL-lpr/lpr autoimmune mice have identified various cytokine 
abnormalities [Lemay et al., 1996; Prud’Homme et al., 1995].  Data from such 
studies in the literature are conflicting, due to the different methodologies utilized 
(mRNA expression versus cytokine excretion), different sources (cells vs serum) 
and different experimental approaches (in-vitro versus in-vivo with or without 
various stimuli).  In our study, quantitative real-time RT-PCR was utilized to study 
the changes in the number of mRNA cytokine transcripts upon treatment of MRL-
lpr/lpr mice with CMX-13 and DEX, as compared to the untreated or DMSO 
control MRL-lpr/lpr mice, and MRL-wt mice.  The abnormalities in cytokine mRNA 
expression in MRL-lpr/lpr mice as compared to MRL-wt mice in our study, and 
the effect of CMX-13 on these abnormalities are outlined in Table 6.3.1.   
Table 6.3.1 Effect of CMX-13 on cytokine mRNA expression in MRL-lpr/lpr mice.  
N=no difference from MRL-wt mice; D=decreased; I=increased; ND=not done. 
*Changes in MRL-lpr/lpr mice following CMX-13 treatment, NC=no change; 
D=decreased; I=increased. 
 











































We used the quantitative real-time RT-PCR to study the changes in the number 
of mRNA cytokine transcripts following treatment of MRL-lpr/lpr mice with CMX-
13 and DEX, as compared to DMSO controls or untreated MRL-lpr/lpr mice.  In 
order to define the cytokine gene expression abnormalities in MRL-lpr/lpr mice, 
MRL-wt mice were used as controls.  As the numbers in this section of the study 
were small, due to the fact that the diseased mice tended to die early limiting the 
numbers available for cytokine gene studies after 23 weeks of treatment.  
Nevertheless, there was a trend showing that in the CD4+ and CD8+ cells, IL-2 
mRNA transcripts at 23 weeks of age were decreased, whereas IL-6 mRNA 
expression was increased in CD8+ cells from MRL-lpr/lpr mice compared to 
MRL-wt mice.  Treatment with CMX-13 resulted in a significant correction of 
these abnormalities in the MRL-lpr/lpr mice. On the other hand, there was an 
increase in the glomerular mRNA expression of IFN-γ, IL-6 and IL-10 in MRL-
lpr/lpr mice, but treatment with CMX-13 did not show any changes in cytokine 
gene expression.  Treatment with CMX-13 also increased IFN-γ mRNA 
expression in the liver of MRL-lpr/lpr mice. 
 
Our data showing a decrease in IL-2 mRNA transcripts in CD4+ and CD8+ cells 
were consistent with the studies on PBMCs in human SLE, where IL-2 mRNA 
expression has been shown to be downregulated [Crispin and Alcocer-Varela, 
1998].  Moreover, in-vitro IL-2 production by PBMCs was impaired following 
stimulation with antigens [Alcocer-Varela and Alarcon-Segovia, 1982].  Other 
studies have shown that the defective production of IL-2 occurred in both CD4+ 
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and CD8+ T-cells [Murakawa et al., 1985]. Moreover, these studies demonstrated 
that IL-2 production was not defective in vivo, but suppressed [Alcocer-Varela 
and Alarcon-Segovia, 1982; Murakawa et al., 1985; Huang et al., 1986], and 
induction of IL-2 production by an IL-2/vaccinia recombinant virus was effective in 
correcting the immunological abnormalities in the MRL-lpr/lpr mice [Gutierrez-
Ramos, 1991].  The authors speculated that the dramatic reduction in the 
abnormally expanded CD3+CD4-CD8- (double negative) T-cell population 
following IL-2 therapy might be directly related to the amelioration and/or 
prevention of autoimmune disease in these mice.  Our studies also showed that 
treatment of MRL-lpr/lpr mice with CMX-13 was associated with an increase in 
IL-2 mRNA expression as compared to the untreated mice, and this finding could 
have therapeutic significance, as we have previously shown in chapter 5 that 
CMX-13 appeared to be effective in attenuating the clinical and histological 
disease activity in the MRL-lpr/lpr mouse.  
 
A possible causal relationship has been shown between the development of SLE 
and IFN-γ up-regulation in human and mice [Haas et al, 1997; Prud’Homme et 
al., 1995].  Increased levels of IFN-γ mRNA transcipts have been demonstrated 
in PBMCs, kidney, lymph nodes, and spleen of diseased MRL-lpr/lpr mice 
[Prud’Homme et al., 1995].  Additionally, suppression of IFN-γ has been shown to 
improve disease activity.  Treatment of autoimmune prone NZB/NZW F1 mice 
with exogenous IFN-γ treatment accelerated the autoimmune response and renal 
disease, while blocking of IFN-γ with anti-IFN-γ monoclonal antibodies or soluble 
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IFN-γ receptor inhibitor inhibited the onset of glomerulonephritis [Ozmen et al., 
1995].  Moreover, MRL-lpr/lpr mice lacking the IFN-γ receptor did not develop 
glomerulonephritis.   
 
In our study, we could only demonstrate an increase in the IFN-γ mRNA 
expression in the glomeruli of untreated and DMSO control MRL-lpr/lpr mice, 
similar to the results from other groups [Lemay et al., 1996].  CMX-13 did not 
affect the IFN-γ gene expression in the glomeruli, but it resulted in an increase in 
the number of IFN-γ mRNA transcripts in the liver, although this did not reach 
statistical significance due to the small numbers studied.  However, as shown in 
Table 6.2.2.2 and 6.2.2.3, the IL-2/IFN-γ mRNA ratio in CD4+ and CD8+ T-cells 
was significantly lower in untreated MRL-lpr/lpr mice.  Treatment with CMX-13 
resulted in improvement in the IL-2/IFN-γ mRNA ratio in CD4+ and CD8+ T-cells 
from MRL-lpr/lpr mice. 
  
IL-6 has been shown to promote B-cell hyperactivity in SLE patients [Linker-
Isreali et al., 1991] and lupus in NZB/NZW F1 mice.  Additionally, IL-6 was found 
to be upregulated in the sera [Swaak et al., 1989] and renal biopsy tissue of SLE 
patients [Horii et al., 1993].  Treatment of lupus-prone mice with anti-IL-6 
antibody abrogated the disease [Finck et al., 1994b].  Our study also 
demonstrated an increase in IL-6 mRNA expression in the glomeruli of MRL-
lpr/lpr mice compared to MRL-wt mice.  Unfortunately, CMX-13 had no effect on 
glomerular IL-6 gene expression.  Only treatment with DEX down-regulated IL-6 
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gene expression.  On the other hand, treatment with CMX-13 resulted in 
upregulation of CD8+ IL-6 gene expression.  As auto-aggressive CD4+CD8- αβT-
cells have been postulated to be the driving force for autoreactive B-cells in the 
development of SLE, upregulation of suppressor CD8+ cells which secrete the 
Th2 cytokine IL-6, may be important in modulating B-cell hyperreactivity, 
suppressing the disease.   
 
IL-10 is produced by several cell types and is also a potent stimulator of B-cells.  
Hence it may play an important role in B lymphocyte hyperreactivity associated 
with SLE [Mosmann, 1994; Cross and Benton, 1999]. In fact, IL-10 induced the 
secretion of IgG1 and IgG3 [Briere et al., 1994].  PBMCs from SLE patients 
spontaneously expressed higher levels of the IL-10 gene and released large 
amounts of the IL-10 protein.  Several studies have attempted to define the role 
of IL-10 in autoantibody production by hyperactive B-cells.  Inhibition of IL-10 with 
anti-IL-10 monoclonal antibodies in lupus-prone mice significantly reduced 
autoantibody production [Llorente et al., 1995], and delayed onset of the disease 
[Ishida et al., 1994].   
 
Previous studies employing the RNase protection assay technique have shown 
that IL-10 was only detectable in the lymph nodes of MRL-wt mice, but was 
significantly upregulated in diseased MRL-lpr/lpr mice [Prud’homme et al., 1995].   
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In our study, we showed that IL-10 mRNA expression was increased in splenic 
CD4+ cells, as well as glomeruli of untreated MRL-lpr/lpr mice.  Unfortunately, we 
could not demonstrate any downregulation of IL-10 gene expression following 
treatment with CMX-13 or DEX, although these mice had better clinical and 
histopathological outcomes than the untreated or DMSO-control MRL-lpr/lpr 
mice.  
 
In conclusion, our studies showed that diseased MRL-lpr/lpr mice which did not 
receive any treatment had decreased CD4+ and CD8+ IL-2/IFN-γ mRNA ratio at 
the age of 23 weeks, as well as upregulation of CD4+ IL-10 mRNA expression, 
similar to other reports in the literature.  In addition, glomerular mRNA expression 
of IFN-γ, IL-6 and IL-10 were also upregulated.  On the other hand, the CMX-13 
treated group showed significantly higher CD4+ and CD8+ IL-2/IFN-γ mRNA ratio, 
and this was associated with improved clinical, serological and histopathological 
parameters, including survival.  However, CMX-13 treatment did not improve the 










CHAPTER 7  CONCLUSION 
 
 
Our research group’s interest in the “Ming Decoction of 21 Tonics for Kidney” 
arose from treatment in a patient with lupus nephritis and chronic nephritic 
syndrome, in whom clinical remission started after ingestion of this Chinese 
herbal decoction (CM).  Preliminary studies have demonstrated the 
immunosuppressive potency of both the crude decoction CM, as well as the 
active fraction CMX-13, a derivative of the herb RC, on in-vitro T-lymphocyte 
proliferation, as well as B-cell secretion of immunoglobulins in both normal 
individuals as well as patients with SLE.  In addition, we have shown the efficacy 
of CMX-13 on preventing acute rejection in a rat lung transplant model of 
hyperacute allograft rejection.  This thesis utilizes the MRL-lpr/lpr murine model 
of lupus nephritis to study the mechanism of the immunosuppressive action of 












7.1  CHARACTERIZATION OF CMX-13 
 
In the first part of this thesis, work was performed to characterize CMX-13, which 
is the fraction which contains the active component(s) of the herb RC, following 
separation by liquid chromatography using spectroscopic and chemical methods.  
RP-HPLC revealed that CMX-13 contained a mixture of possibly 8 or more 
compounds. Two RP-HPLC fractions of CMX-13, namely CMX-13-1 and CMX-
13-5 had 100% immunosuppressive properties.  The RP-HPLC fraction CMX-13-
5 contained fewer impurities than CMX-13-1 as shown in the RP-HPLC profiles 
of CMX-13-1 and CMX-13-5 (Figures 3.2.5.2 and 3.2.5.7 respectively). Therefore 
we attempted to elucidate the structure of CMX-13-5 by 1H-NMR and LC-Mass 
spectrometry.  The LC chromatogram of CMX-13-5 showed a single peak, 
suggesting either a single molecule with a weight of 807.5 or two molecules with 
a weight of 270 and 537.5.  1H-NMR spectrum of CMX-13-5 was shown to 
resemble the 1H-NMR spectra of a bicyclic hexapeptide isolated by the group of 
Itokawa and co-workers [Itokawa et al., 1992; Itokawa et al., 1993].  Subsequent 
to our work, our collaborators were able to analyze the structure of the purified 
bioactive compound in CMX-13’ (using material from the same source) and 
showed that the bioactive compound in CMX-13’ was identical to a compound 




7.2 MOLECULAR BASIS FOR IMMUNOSUPPRESSIVE 
EFFECTS OF CMX-13 
 
We have previously shown that CMX-13 was able to suppress mitogen-
stimulated lymphoproliferative responses and PBMC immunoglobulin production, 
as well as inhibit T-cell colony formation.  In our earlier studies on the possible 
mechanisms of action, CMX-13 did not show any inhibitory effects on IL-2 and 
IFN-γ mRNA expression, suggesting that its mechanism of action was different 
from that of CsA [Zuo et al., 2000].  As there is strong evidence that 
dysregulation of apoptosis in the immune regulatory cells could have a role in the 
genesis of SLE, the second part of the thesis examined the effect of CMX-13 on: 
1) Cell cycle progression in PBMCs isolated from normal controls and 
patients with SLE, as well as Jurkat cells, a human T-cell line  
2) Apoptotic events.   
 
In addition to its effect on PBMC, CMX-13 was also shown to significantly inhibit 
spontaneous Jurkat cell proliferation by >99% even at low concentrations of 1 
µg/ml.  The inhibitory effect of CMX-13 on Jurkat cell proliferation was not due to 
inhibition of cell-cycle progression, but rather by the induction of spontaneous 
apoptosis in cells in the G0/G1 phase.  This effect of CMX-13 on apoptosis in 
Jurkat cells was confirmed by DNA fragmentation analysis and Annexin-V 
staining.  Apoptosis was induced at a very early phase, as was demonstrated by 
the “sub-G1” or apoptotic peaks appearing in the cell-cycle analysis.  This 
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mechanism of action was different from drugs such as cyclohexmide, which 
induces apoptosis related to a G0/G1 cell-cycle arrest.   
 
Defective apoptosis has been suggested to be an important mechanism in the 
pathogenesis of various autoimmune diseases [Mountz et al., 1994; Carrichio et 
al., 1999; Papo et al., 1998].  Apoptosis is important for the immune system to 
regulate cell growth and terminate immune responses in order to ensure that 
overall the rate of division is balanced by cell death [Lorenz et al., 2001].  In SLE, 
one of the hypothesis is that dysregulation of apoptosis might be responsible for 
the induction of anti-nuclear antibodies, pathognomonic of the disease.  In some 
patients, decreased apoptosis in SLE appears to be associated with increased 
production sFas molecule that is capable of inhibiting apoptosis after a stimulus 
to proliferate [Cheng et al., 1994], whereas other studies reported accelerated 
apoptosis of lymphocytes in SLE patients [Emlen et al., 1994; Lorenz et al., 
1998].  Similarly, in our SLE patients, the percentage of apoptotic cells was 
increased with increasing activity of the disease as measured by the SLICC 
score.   
 
Hence the immunosuppressive mechanism of CMX-13 could be partly related to 
its effect on apoptosis, especially in the context of suppression of SLE activity, 
where increased apoptosis has been demonstrated.  Two distinct pathways of 
apoptosis have been described that induce the activation of caspases and other 
pro-apoptotic activities. One of the pathways leading to apoptosis is activation of 
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caspase 8 upon binding of a death ligand on the cell membrane [Hakem et al., 
1998], whereas the second pathway is related to cellular stress, whereby 
mitochondria release cytochrome c which binds to an apoptotic protease 
activating factor (Apaf-1), activating caspase-9 [Zheng et al., 1999; Cecconi, 
1999].  Therefore further studies are required to determine if induction of 



















7.3 EFFECT OF CMX-13 ON MRL-lpr/lpr AUTOIMMUNE 
MOUSE MODEL 
 
MRL-lpr/lpr mice spontaneously develop an autoimmune disorder with 
pathological features similar to human SLE, including vasculitis, generalized 
lymphadenopathy, arthritis and a severe immune complex glomerulonephritis, 
[Andrews et al., 1978].  These clinical features, accompanied by elevation of 
serum anti-dsDNA antibody levels, were seen in the untreated control mice and 
the control group treated with the solvent DMSO in our experiments.  The 
severity of the autoimmune disease increased with the age of the mice, with the 
majority dying of renal failure at 16-24 weeks of age. 
 
Treatment of the MRL-lpr/lpr mice with CMX-13 and DEX resulted in delay by at 
least 4 weeks in the development of lymphadenopathy, which was also less 
severe than in the control groups.  All of the mice developed anti-dsDNA 
antibodies from the age of 8 weeks, with the untreated and DMSO control mice 
having the highest level of rise in antibody concentrations by 16 weeks of age, 
whereas both the CMX-13 and DEX-treated groups had significantly lower anti-
dsDNA antibody levels.   
 
Anti-dsDNA antibodies have often been implicated in the development of 
glomerulonephritis [Koffler et al., 1967; Lambert and Dixon, 1968], where 
deposition of anti-dsDNA antibodies in the glomerulus resulted in a proliferative 
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glomerulonephritis [Yamada et al, 1982].  Recent studies on the autoantibody 
specificities from kidney eluates in lupus mice have shown that cross-reactive 
anti-dsDNA antibodies predominate, and these antibodies also bound to 
glomerular substrate and laminin [Xie et al., 2003].  Hence development of 
glomerulonephritis and vasculitis could be due to in-situ immune complex 
formation in the glomerular and vascular sites [Vlahakos et al, 1992].  The 
increased mortality seen in the MRL-lpr/lpr mice is attributed in a large part to the 
development of progressive severe proliferative lupus nephritis, with the majority 
of mice dying of renal failure at 16-24 weeks of age.   
 
This thesis has shown that CMX-13 was able to improve survival of the MRL-
lpr/lpr mice compared to the untreated or DMSO controls, where 9 of the mice 
treated with CMX-13 were still alive at 22 weeks of age, whereas only 2 of the 
untreated controls and 3 of the DMSO controls survived.  This was despite the 
fact that in the MRL-lpr/lpr mice, the severity of kidney disease increases with 
age due to progressive mesangial and endothelial cell proliferation, crescent 
formation, thickening of the glomerular capillary walls and tubulointerstitial 
nephritis with vasculitis [Austin et al, 1984: Moyer et al, 1987; Appel and Valeri, 
1994; Putterman and Naparstek, 1994].   In our experiment, CMX-13 treatment of 
MRL-lpr/lpr mice with progressive lupus nephritis resulted in decrease in the 
degree of proteinuria and improvement in renal histological indices.   Hence 
CMX-13 appeared to be effective in attenuating the clinical and histological 
disease activity in the MRL-lpr/lpr mouse model of SLE. 
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In patients with active disease as well as in experimental murine models of SLE, 
both the serum cytokine levels and gene expression in PBMCs have been found 
to be abnormal [Prud’homme, 1993].  In fact, there have been reports of a 
relationship between abnormal cytokine mRNA levels and disease activity 
[Linker-Israeli et al., 1996].  Hence we examined the effect of CMX-13 on 
cytokine gene expression in particular CD4+ and CD8+ T-cells, liver and glomeruli 
of the autoimmune MRL-lpr/lpr mouse.  The mice were treated with either  DMSO 
(solvent control), CMX-13 or DEX as described in chapter 2.3.2, from the age of 
12 weeks, and real-time RT-PCR was employed to examine IL-2, IL-6, IL-10 and 
IFN-γ mRNA expression levels in tissues and lymphocyte subsets from each of 
the groups of MRL-lpr/lpr mice that were sacrificed at 23 weeks.  Our studies 
showed that diseased MRL-lpr/lpr mice which did not receive any treatment had 
decreased CD4+ and CD8+ IL-2/IFN-γ mRNA ratio at the age of 23 weeks, as well 
as upregulation of CD4+ IL-10 mRNA expression, similar to other reports in the 
literature.  In addition, glomerular mRNA expression of IFN- γ, IL-6 and IL-10 
were also increased.  On the other hand, the CMX-13 treated group showed 
significantly higher CD4+ and CD8+ IL-2/IFN- γ mRNA ratio, and this was 
associated with improved clinical, serological and histopathological parameters, 
including survival.  However, CMX-13 treatment did not improve the abnormality 
in glomerular IFN- γ, IL-6 and IL-10 gene expression.   
 
Our data showing a decrease in IL-2 mRNA transcripts in CD4+ and CD8+ cells 
were consistent with the studies on PBMCs in human SLE, where IL-2 mRNA 
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expression has been shown to be downregulated [Crispin and Alcocer-Varela, 
1998].  Other studies have shown that induction of IL-2 production by an IL-
2/vaccinia recombinant virus was effective in correcting the immunological 
abnormalities in the MRL-lpr/lpr mice [Gutierrez-Ramos, 1991].  A possible 
causal relationship has been shown between the development of SLE and IFN-γ 
up-regulation in human and mice [Haas et al, 1997; Prud’Homme et al., 1995].  
Additionally, suppression of IFN-γ has been shown to improve disease activity.  
In our study, we could only demonstrate an increase in the IFN-γ mRNA 
expression in the glomeruli of untreated and DMSO control MRL-lpr/lpr mice, 
similar to the results from other groups [Lemay et al., 1996].  CMX-13 did not 
affect the IFN-γ gene expression in the glomeruli, but it resulted in an increase in 
the number of IFN-γ mRNA transcripts in the liver, although this did not reach 
statistical significance due to the small numbers studied.  However, the IL-2/IFN-γ 
mRNA ratio in CD4+ and CD8+ T-cells was significantly lower in untreated MRL-
lpr/lpr mice.  Treatment with CMX-13 resulted in improvement in the IL-2/IFN-γ 
mRNA ratio in CD4+ and CD8+ T-cells from MRL-lpr/lpr mice.     
 
IL-6 has been shown to promote B-cell hyperactivity in SLE patients [Linker-
Isreali et al., 1991] and lupus in NZB/NZW F1 mice.  Treatment of lupus-prone 
mice with anti-IL-6 antibody abrogated the disease [Finck et al., 1994b].  Our 
study also demonstrated an increase in IL-6 mRNA expression in the glomeruli of 
MRL-lpr/lpr mice compared to MRL-wt mice.  Unfortunately, CMX-13 had no 
effect on glomerular IL-6 gene expression.  Treatment with CMX-13 resulted in 
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upregulation of CD8+ IL-6 gene expression.  As auto-aggressive CD4+CD8- αβT-
cells have been postulated to be the driving force for autoreactive B-cells in the 
development of SLE, upregulation of suppressor CD8+ cells which secrete the 
Th2 cytokine IL-6, may be important in modulating B-cell hyperreactivity, 
suppressing the disease.   
 
IL-10 has been postulated to play an important role in B lymphocyte 
hyperreactivity associated with SLE [Mosmann, 1994; Cross and Benton, 1999].  
Inhibition of IL-10 with anti-IL-10 monoclonal antibodies in lupus-prone mice 
significantly reduced autoantibody production [Llorente et al., 1995], and delayed 
onset of the disease [Ishida et al., 1994].  Previous studies have also shown that 
IL-10 was was significantly upregulated in diseased MRL-lpr/lpr mice 
[Prud’homme et al., 1995].  In our study, we showed that IL-10 mRNA expression 
was increased in splenic CD4+ cells, as well as glomeruli of untreated MRL-
lpr/lpr mice, however, CMX-13 did not appear to have any effect on its 
expression.   
 
In conclusion, one possible mechanism by which CMX-13 acts an 
immunosuppressive agent in the treatment of lupus nephritis in the autoimmune 
MRL-lpr/lpr mouse model is through the induction of apoptosis of autoreactive 
lymphocytes, as illustrated in Figure 7.1.  Auto-aggressive CD4+CD8- αβT-cells 
have been postulated to be the driving force for autoreactive B-cells in SLE 
resulting in abnormalities in cytokine production, and suppression of these 
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autoreactive lymphocytes could result in inhibition of autoantibody production, 
thus retarding the progression of lupus nephritis.   
 
Further investigations into the apoptotic mechanisms are required to examine the 
transcription of apoptotic and cell-cycle genes, so that the exact molecular 



















Figure 7.1 Hypothetical model for the therapeutic effect of CMX-13 on Human and 
Mouse SLE. CMX-13 induces apoptosis in CD4+ T-cells and autoreactive B-cells. 
Consequently no production of autoantibodies occurs and no autoantibody 
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Appendix 4.1  The individual SLEDAI and SLICC scores of the SLE patients. 
 
 
No SLEDAI SLICC SEX APOPTOTIC 
Cells after  
CMX-13 
treatment 
1 0 1 F 12 
2 6 0 F 33 
3 0 1 F 45 
4 0 3 M 42 
5 4 0 F 46 
6 1 1 M 51 
7 0 2 F 38 
8 14 4 F 36 
9 0 0 F 71 
10 2 2 M 45 
11 4 2 F 50 
12 20 3 F 47 
13 0 3 F 68 
14 18 2 M 73 
15 0 1 F 24 
16 0 0 M 40 
17 2 1 F 32 
18 12 1 F 58 
19 0 2 M 24 
























Ocular Neuropsychiatry Renal Pulmonary Cardiovascular Peripheral 
Vascular 
1 0 0 0 0 0 0 
2 0 0 0 0 0 0 
3 0 0 0 0 0 0 
4 0 0 3 0 0 0 
5 1 0 2 0 0 0 
6 0 0 0 0 0 0 
7 0 0 0 1 0 0 
8 0 0 0 0 0 0 
9 1 0 0 1 0 0 
10 1 0 0 0 0 0 
11 0 0 1 0 2 0 
12 0 0 0 0 0 0 
13 0 0 1 0 1 0 
14 1 0 0 0 0 0 
15 0 0 0 0 1 0 
16 0 0 1 0 0 0 
17 0 1 0 0 0 0 
18 0 0 0 0 0 0 
19 0 0 0 0 0 0 
20 0 0 0 0 0 0 
 















1 0 0 1 0 0 0 
2 0 0 0 0 0 0 
3 0 0 0 0 0 0 
4 0 0 0 0 0 0 
5 0 0 0 0 0 0 
6 0 0 0 0 0 0 
7 0 0 1 0 0 0 
8 0 0 0 0 0 0 
9 0 0 0 0 0 0 
10 0 0 0 0 0 0 
11 0 0 0 0 0 0 
12 0 0 0 0 0 0 
13 0 0 0 0 1 0 
14 0 0 0 0 0 0 
15 0 0 0 0 0 0 
16 0 0 0 0 0 0 
17 0 0 0 0 1 0 
18 0 0 0 0 0 0 
19 0 0 0 0 0 0 
20 0 0 0 0 0 0 
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APPENDIX 4.3.1.  SLEDAI Score Of SLE Patients (I) 
Patient 
No. 








1 0 0 0 0 0 
2 0 0 0 0 0 
3 0 0 0 0 0 
4 0 0 0 0 0 
5 0 0 0 0 0 
6 0 0 0 0 0 
7 0 0 0 0 0 
8 0 0 0 0 0 
9 0 0 0 0 0 
10 0 0 0 0 0 
11 0 0 0 0 0 
12 0 0 0 0 0 
13 0 0 0 0 0 
14 0 0 0 0 0 
15 0 0 0 0 0 
16 0 0 0 0 0 
17 0 8 8 0 0 
18 0 0 0 0 0 
19 0 0 0 0 0 
20 0 0 0 0 0 
 
 APPENDIX 4.3.2  SLEDAI Score Of SLE Patients (II) 
Patient 
No. 
Lupus headache CVA Vasculitis Arthritis Myositis 
1 0 0 0 0 0 
2 0 0 0 0 0 
3 0 0 0 0 0 
4 0 0 0 0 0 
5 0 0 0 0 0 
6 0 0 0 0 0 
7 0 0 0 0 0 
8 0 0 0 0 0 
9 0 0 0 0 0 
10 0 0 0 0 0 
11 0 0 0 0 0 
12 0 0 0 0 0 
13 0 0 0 0 0 
14 0 0 0 0 0 
15 0 0 0 0 0 
16 0 0 0 0 0 
17 0 0 0 0 0 
18 0 0 0 0 0 
19 0 0 0 0 0 
20 0 0 0 0 0 
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Urinary casts Hematuria Proteinuria Pyuria New rash 
1 0 0 0 0 0 
2 0 4 0 0 0 
3 0 0 0 0 0 
4 0 0 0 0 0 
5 0 0 0 0 0 
6 0 0 0 0 0 
7 0 0 0 0 0 
8 0 0 0 0 2 
9 0 0 0 0 0 
10 0 0 0 0 0 
11 0 4 4 4 0 
12 0 0 0 0 0 
13 0 4 4 4 0 
14 0 0 0 0 0 
15 0 0 0 0 0 
16 0 0 0 0 0 
17 0 0 0 0 0 
18 0 0 0 0 0 
19 0 0 0 0 0 
20 0 0 0 0 0 
 
APPENDIX 4.3.4 SLEDAI Score Of SLE Patients (IV) 
Patient 
No. 
Alopecia Mucosal ulcers Pleurisy Pericarditis Low 
complement 
1 0 0 0 0 0 
2 0 0 0 0 0 
3 0 0 0 0 2 
4 0 0 0 0 0 
5 0 0 0 0 0 
6 0 0 0 0 0 
7 0 0 0 0 0 
8 0 0 0 0 0 
9 0 0 0 0 0 
10 0 0 0 0 0 
11 0 0 0 0 2 
12 0 0 0 0 0 
13 0 0 2 2 2 
14 0 0 0 0 0 
15 0 0 0 0 0 
16 0 0 0 0 0 
17 0 0 0 0 0 
18 0 0 0 0 0 
19 0 0 0 0 0 
20 0 0 0 0 0 
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Fever Thrombocytopenia Leukopenia 
1 0 0 0 0 
2 2 0 0 0 
3 2 0 0 0 
4 0 0 0 0 
5 0 0 0 0 
6 0 0 0 0 
7 0 0 0 0 
8 2 0 0 0 
9 2 0 0 0 
10 0 0 0 0 
11 2 0 0 0 
12 0 0 0 0 
13 2 0 0 0 
14 0 0 1 0 
15 0 0 0 0 
16 2 0 0 0 
17 2 0 0 0 
18 0 0 0 0 
19 0 0 0 0 





























APPENDIX 5.1 Urine proteinuria score. Urine protein levels were assessed using 
Urine reagent strips (TECO Diagnostics URS-2P) and graded the 
semiquantitatively : 0 = Negative; 1 = Trace; 2 = 0-30 mg/dl (+); 3 = 30-100 mg/dl 
(++); 4 = 100-300 mg/dl (+++) ;5 =  > 300 mg/dl  (++++) 
 
 
















mg/dl   
CONTROL 1 6 6    
DMSO  8 4 1   
CMX-13 1 5 5 2   
DEX 1 9 3    
 
WK 12 0 1 2 3 4 5 
CONTROL  3 8 2   
DMSO 2 5 3 2   
CMX-13 1 4 7 1   
DEX  2 10 1   
 
WK16 0 1 2 3 4 5 
CONTROL   7 4  1 
DMSO 2  5 5  1 
CMX-13 4 2 4 1   
DEX 7 3 1 1   
 
WK18 0 1 2 3 4 5 
CONTROL    4 1  
DMSO  2 3 2 3  
CMX-13 1 3 4 1 1  
DEX 3 2 1 2   
 
WK19 0 1 2 3 4 5 
CONTROL   1 2 1  
DMSO   4 3 2  
CMX-13 1 3 3 1 2  
DEX 2 3 2    
 
WK 20 0 1 2 3 4 5 
CONTROL   1 2   
DMSO  3 3 2 1  
CMX-13 3 1 1 2   







APPENDIX 5.2  IgG-specific anti-ds DNA autoanitbody levels. Anti-dsDNA 
antibody in serum of  MRL-lpr/lpr mice at 8, 12 and 16 weeks of age. 
 
 
8 weeks old mice 
 
Control DMSO CMX-13 DEX 
0.17 0.17 0.27 0.21 
0.18 0.24 0.10 0.24 
0.21 0.16 0.20 0.25 
0.27 0.20 0.32 0.24 
0.24 0.22 0.29 0.28 
0.41 0.25 0.17 0.18 
0.96 0.47 0.19 0.27 
0.45 0.21 0.16 0.22 
0.24 1.40 0.17 0.20 
0.17 0.17 0.23 0.28 
0.70 0.59 0.28 0.20 




12 weeks old mice 
 
Control DMSO CMX-13 DEX 
0.82 0.47 0.80 0.30 
0.63 0.26 0.49 0.73 
0.78 0.42 0.24 0.26 
0.68 0.98 0.80 0.27 
  0.52 0.24 
  0.67 0.45 




16 weeks old mice 
 
Control DMSO CMX-13 DEX 
1.02 1.33 1.15 0.23 
1.35 2.00 0.57 1.17 
1.39 0.79 0.74 1.29 
1.25 1.14 1.32 0.51 
1.27 1.81 0.74 0.65 
1.60 1.78 0.76 0.54 
2.45 2.21 1.12 1.06 
  1.88 1.04 
   1.39 
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8 0  13 
12 1 Found dead 12 
13 0  12 
14 1 Found dead 11 
15 0  11 
16 1 Found dead 10 
17 3 3 Moribund 7 
18 2 2 Moribund 5 
19 2 1 Moribund 
1 Found dead 
3 
20 0  3 
21 0  3 
22 1 1 Found dead 2 












8 0   
12 0   
13 0   
14 0   
15 0   
16 0   
17 1 1 Moribund 12 
18 2 2 Moribund 10 
19 1 1 Moribund 9 
20 0  9 
21 3 3 Moribund 6 
22 3 3 Moribund 3 


















8 0  13 
12 0  13 
13 0  13 
14 1 1 Found dead 12 
15 0  12 
16 1 1 Found dead 11 
17 1 1 Found dead 10 
18 0  10 
19 0  10 
20 0  10 
21 0  10 
22 1 1 Found dead 9 













8 0  13 
12 0  13 
13 1 1 Found dead 12 
14 0  12 
15 0  12 
16 0  12 
17 3 1 Found dead 
2 Moribund 
9 
18 1 1 Moribund 8 
19 1 1 Moribund 7 
20 0  7 
21 0  7 
22 0   
23 7 7 Sacrificed 0 
 
